Synthesis of the acylpyridones : natural and unnatural products by Choudhury, Abdul K
Loughborough University
Institutional Repository
Synthesis of the
acylpyridones: natural and
unnatural products
This item was submitted to Loughborough University's Institutional Repository
by the/an author.
Additional Information:
• A Doctoral Thesis. Submitted in partial fulﬁllment of the requirements
for the award of Doctor of Philosophy of Loughborough University.
Metadata Record: https://dspace.lboro.ac.uk/2134/6310
Publisher: c© Abdul Kasem Choudhury
Please cite the published version.
 
 
 
This item was submitted to Loughborough’s Institutional Repository 
(https://dspace.lboro.ac.uk/) by the author and is made available under the 
following Creative Commons Licence conditions. 
 
 
 
 
 
For the full text of this licence, please go to: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ 
 
 1
 
 
 
 
 
Synthesis of the Acylpyridones: Natural 
and Unnatural Products 
 
by 
Abdul Kasem Choudhury 
Doctoral Thesis 
 
 
 
 
 
 
 
 
 
 
Submitted in partial fulfillment of the requirements for the award of 
Doctor of Philosophy of Loughborough University 
January 2010 
 
 
 
© A K Choudhury 2010  
 2
Abstract 
 
The 3-acyl-4-hydroxy-pyridin-2-one core is a common feature observed in a number of 
natural products. This thesis describes the design and the development of an 
isoxazolopyridone as a masked form of this core and elaboration at the sites C-3’ (Me), 
C-7 and N-5 of the related isoxazolopyridone. The polar nature of the heterocyclic trione 
makes these compounds difficult to work with, particularly with regards to purification 
and handling. A strategy is applied to disguise this polar nature, by masking the 4-
hydroxy and 3-acyl functions as an isoxazole.  
 
The isoxazolopyridone building block is available from diaminopropionic acid or β-
alanine. A 1,3-dipolar cycloaddition of a nitrile oxide with a pyrrolidine enamine resulted 
in an isoxazole. In the case of the β-alanine series, a photolytic dehydrochlorination 
reaction was employed to introduce the C6-C7 unsaturation. The isoxazolopyridone 
building block was then elaborated at the sites, C-3’ (Me), N-5 and C-7 to work towards 
the development of natural products and non-natural analogues. The use of anion-type 
aldol reaction was applied to construct a number of side chains at C-3’ (Me). The use of 
Suzuki cross-coupling reactions, with a palladium-based catalyst for C-C coupling with a 
7-iodoisoxazolopyridone was developed. The construction of the hydroxamic acid 
functionality at N-5 was investigated with little success. The unmasking of the 
isoxazolopyridone revealed the heterocyclic trione in the final step of the synthesis, by 
cleavage of the N-O bond followed by diazotization to prove its validity as a synthetic 
strategy. 
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Ad    adenylation domain     
ATP    adenosine triphosphate 
n-BuLi   n-butyllithium 
13C    carbon-13 
CHCl3   chloroform 
DCM    dichloromethane 
DIBAL-H   diisobutylaluminium hydride 
DMDO   dimethyldioxirane 
DMF    N,N-dimethylformamide 
Et    ethyl 
GC-MS                            gas chromatography-mass spectrometry 
1H    proton 
HMDS            hexamethydisilazane 
HPLC   high performance liquid chromatography 
IR    infra red 
LDA    lithium diisopropylamide 
LC-MS   liquid chromatography mass spectrometry 
m-CPBA   meta-chloroperoxybenzoic acid 
MeOH   methanol 
NADPH   nicotinamide adenine dinucleotide phosphate 
NMR    nuclear magnetic resonance 
Ph    phenyl 
SAM    S-adenosyl methionine 
TFA    trifluoroacetic acid 
THF    tetrahydrofuran 
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TIPSCl   triisopropylsilyl chloride 
TLC    thin layer chromatography 
TMSCl   trimethylsilyl chloride 
TsOH    para-toluenesulfonic acid 
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Introduction 
1.1 The 3-acyl-4-hydroxypyridone unit 
 
N O
R
ON
7
6
N
OH
O
R2
R3
O
R1
 
                Isoxazolopyridone as masked version          Acylpyridone unit 
                                    1                                                           2 
 
A range of fungi have been found to produce compounds with the core 3-acyl-4-hydroxy-
pyridone nucleus as in 2, which constitutes a structurally diverse group of biologically 
active natural products.1 Isoxazolopyridone 1 is a simplified masked version of the highly 
polar acylpyridone 2 that is central to the synthetic strategy employed in this thesis. 
Interest in the acylpyridones has been due to their wide spectrum of biological activity, 
which includes antifungal, antibiotic and antiviral.1 As a result, these compounds have 
become the subject of biosynthetic studies and total synthesis. Examples of natural 
products with such activity include tenellin 3, bassianin 4, ilicicolin 5 and funiculosin 6.1 
Tenellin 3 is a 2-pyridone isolated from the imperfect fungus Beauveria bassiana as a 
yellow pigment; it is structurally related to other 2-pyridones and 3-acyltetramic acids. 
The fungus was originally isolated by an Italian microbiologist Agostino Bassi2 and was 
demonstrated to show insect pathogenic properties causing white muscardine disease in 
domestic silkworm. It was later found to be effective towards the Colorado potato beetle. 
It is also used in a number of commercial products such as the insecticide Mycotrol.  
 
New synthetic methodology will be described in this thesis towards the synthesis of 
tenellin and its analogues. Synthetic interest arises not only due to its biological activity, 
but also because of the number of diverse functionalities it contains. Other key members 
of the tenellin family of secondary metabolites will also be discussed along with their 
biosynthetic origins. 
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The synthetic strategy applied in this thesis towards tenellin could also be implemented to 
allow direct access to a number of 2-pyridones isolated from other insect pathogenic 
fungi. The polar nature of the acylpyridone unit 2 makes these compounds difficult to 
work with, particularly with regards to purification and handling. A strategy was devised 
to disguise this polar nature, by masking the acylpyridone unit in the form of 
isoxazolo[4,3-c]pyridone 1, which is then used as the building block. The R1 position in 
the acylpyridone 2 is normally occupied by an aryl group, such as 4-hydroxyphenyl in 
tenellin 3. The R3 position frequently consists of sequences of alternating double and 
single C-C bonds known as polyenes. The R2 position is often simple; methyl, hydrogen 
or even hydroxyl.  
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1.2 Biosynthesis of the 3-acyl-4-hydroxypyridone natural products        
                       
Bassianin 4 and tenellin 3 have been isolated from the imperfect fungi Beauveria 
bassiana and Beauveria tenella as yellow pigments. 3 They contain the 5-(4-
hydroxyphenyl)-pyridin-2-one ring system with the acylated moiety at C-3. The proposed 
biosynthetic pathway suggests that tenellin 3 is assembled from three key precursors, 
polyketide 9, phenylalanine 7, and methionine 10 (Scheme 1).3 
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Scheme 1. Proposed biosynthesis of tenellin 3 by Leete et al. 
 
The biosynthetic route for tenellin 3 shows the presence of a possible intermediate α-
formylphenylacetyl coenzyme A 8, which undergoes a condensation reaction with 
polyketide 9 to form the key carbon skeleton.3 The migration of the carboxylic group of 
phenylalanine 7 leads to its eventual position at C-4 in tenellin 3, and the additional 
methyl groups required are provided by methionine 10.  
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During 1975 Leete et al. showed interest in the rearrangement of the carboxylic group of 
phenylalanine in the biosynthesis of tenellin and they proved that the rearrangement of 
the carboxylic group of phenylalanine in this case is intramolecular;4 a similar type of 
rearrangement was observed in the biosynthesis of tropic acid 11.5 This was confirmed 
through numerous feeding experiments using [1,3-13C2]phenylalanine, wherein the 
majority of the labeled molecules contained two 13C atoms. Administration of DL-[1,3-
13C2]phenylalanine into cultures of B. bassiana for 7 days afforded tenellin 3, and after  
purification 13C NMR spectroscopy revealed coupling between the two adjacent C4 and 
C5 signals due to spin spin coupling, suggesting these are derived from C1 and C3 
carbons of phenylalanine, therefore supporting the type of rearrangement to be 
intramolecular.  
 
During 1977 Wright et al. proposed a hypothesis for the biosynthesis of tenellin 3 using 
an aromatic amino acid L-phenylalanine and polyketide derived chains (Scheme 2).6 It 
was also suggested, with evidence from the feeding experiments that tyrosine does not 
contribute towards the aryl ring although phenylalanine does.  
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Scheme 2. Wright et al. proposed hypothesis for the biosynthesis of tenellin 3 
 
The hypothesis suggests phenylalanine 7 is fused with a polyketide chain 12 to form the 
acyltetramic acid 13, which then undergoes oxidation at the para position of the aryl ring 
to construct a quinoid intermediate 14.6 Rearrangement of this intermediate directs the 
formation of the pyridone ring and ultimately furnishes the target natural product tenellin 
3. This hypothesis was later tested by Moore and co workers,1 who prepared the 
acyltetramic acid intermediate 13 (Scheme 3), and conducted feeding experiments using 
isotopically labeled 13 with 13C. The feeding experiments conducted include the addition 
of [4-13C]-acyltetramic acid 13 at a concentration of 2.0 mM and in a minimum volume 
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of ethanol to B. bassiana. Together with the HPLC and 13C NMR results clearly 
indicating no observable isotope enrichment at C-4 of tenellin, it was concluded that the 
feeding experiments demonstrated the acyltetramic acid 13 was not an intermediate in the 
biosynthesis of tenellin 3 and therefore does not support the hypothesis.   
 
Although this acyltetramic acid intermediate 13 was not identified from the cultures of B. 
bassiana, a minor metabolite 17 was isolated after HPLC analysis to be a precursor of 
tenellin, which lacks the hydroxylamine moiety.1  
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The acyltetramic acid intermediate 13 was prepared via a condensation reaction between 
the protected L-phenylalanine methyl ester 15 and complementary side chain 16 under 
acidic conditions followed by a Dieckmann cyclisation (Scheme 3).1  
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Scheme 3. Preparation of the acyltetramic acid intermediate 13 
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The amine protection in compound 15 was necessary for the successful Dieckmann 
cyclisation. Deprotection of the amine followed to yield the acyltetramic acid 
intermediate 13.  
 
A similar hypothesis was proposed for the biosynthesis of ilicicolin by Wright et al. 
(Scheme 4).6 The biosynthetic proposal involves phenylalanine 7 interacting with the 
bicyclic carbocycle 18 to afford an acyltetramic acid intermediate 19. The bicyclic 
carbocycle 18 is formed through cyclisation of a linear polyketide chain. The proposed 
biosynthetic pathway from here continues similarly to the proposed tenellin 3 
biosynthesis. A number of feeding experiments were carried out by Tanabe and co-
workers using 13C-labeled phenylalanine, 15N-labeled phenylalanine and 13C-labeled 
acetates in Cylindrocladium ilicicola. 7  The results of these experiments suggest 
phenylalanine as a possible intermediate in the biosynthesis of ilicicolin 5.                   
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Scheme 4. Biosynthesis of ilicicolin 5 proposed by Wright et al.  
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The role of tyrosine in the biosynthesis of tenellin 3 was later reinvestigated, as DL-[3-
13C]-tyrosine 21 was introduced to a culture of B. bassiana at a concentration of 3.0 mM.1 
Tenellin was successfully isolated and purified by HPLC, and 13C NMR spectroscopy 
was used to show 13C enrichment at the C-5 position of tenellin 3. Following the success 
of this, DL-[1-13C]-phenylalanine 7 was also introduced to a culture of B. bassiana at a 
concentration of 3.5 mM. 13C NMR spectroscopy illustrated 13C enrichment at the C-4 
position of tenellin 3. It seems in this case phenylalanine is converted into tyrosine due to 
the presence of the enzyme phenylalanine hydroxylase (PAH) in B. bassiana before 
forming the natural product tenellin 3 (Scheme 5).1           
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                                                           Scheme 5 
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Both phenylalanine and tyrosine have thus been incorporated into cultures of B.bassiana 
to produce tenellin 3. It seems that phenylalanine is incorporated 20% more efficiently 
than tyrosine.1 This could be due to many factors, one of which may be the different 
transport rates of the amino acids across membranes. The new evidence from the tyrosine 
feeding experiments may suggest a para-hydroxyphenyl acyltetramic acid pretenellin A 
27 (Scheme 7), to be a more suitable intermediate than the acyltetramic acid intermediate 
13 proposed this far in the biosynthesis of tenellin 3. It is likely the phenolic hydroxyl is 
introduced by tyrosine rather than a late stage oxidation of the aryl ring in the 
biosynthesis.            
 
In previous discussions, the biosynthesis of tenellin has been considered to be derived 
from a polyketide pathway, and evidence from the isotope feeding experiments has 
shown amino acids such as phenylalanine and tyrosine to be suitable co-precursors, and 
demonstrated that the amino acids undergo a late stage rearrangement.1 Recent 
biosynthetic studies during 2007 have shown that the polyketide synthase and 
nonribosomal peptide synthetase (PKS-NRPS) are involved in the biosynthesis of the 2-
pyridone natural products.8 The NRPS are large multifunctional proteins, which work in 
conjunction with the PKS synthetase. These are also large multi-enzyme complexes with 
active sites that consist of modular units (modules). Each protein contains one or more 
modules. Each module contains multiple domains (active sites) with defined functions. 
The modules determine the length of carbon backbone of complex polyketides. The large 
multifunctional proteins assemble acyl units in a programmed fashion to build natural 
products. The functionality of the natural products is controlled by each individual 
functional domain. The PKS-NRPS allows identification of various domains for a given 
peptide sequence and predicts the starter and extender precursors at each domain. In 
general acetyl-CoA and malonyl-CoA are the starter and extender in the fungal 
polyketide pathway. For example, in the modular polyketide synthases of 6-
deoxyerythronolide B, 9 , 10  each protein contains a module with multiple domains 
(Scheme 6). The modules are responsible for growing a chain of carbon-carbon bond. 
Module one contains a loading module as a starter unit, and towards the end there is a 
termination module, which is to release the product. In this example, the starter group, 
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propionyl CoA is loaded onto the ACP domain catalysed by the AT domain. There 
follows a condensation reaction with the extender, methylmalonyl bound also to an ACP 
domain, to release CO2 and HS-ACP in module one. The KR domain is responsible for 
the reduction of the carbonyl group to an alcohol. A similar sequence follows in modules 
2-6, however in module 4, dehydration (DH domain) and further reduction (ER domain) 
reactions take place to leave the saturated bond. Finally, in the last step the polyketide 
chain is released to cyclise to the 6-deoxyerythronolide B.9          
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S-CoA
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HO
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Methylmalonyl CoA
Propionyl CoA
 
 
 
 
 
 
 
 
 
Definition of the domains;  
AT: acyl-transferases - loading of starter, extender and intermediate acyl units 
ACP: acyl carrier proteins - holds the growing chain as a thioester  
KS: β-keto-acyl synthases - catalyses the polyketide chain extension  
KR: β-keto reductases - responsible for the reduction to an alcohol 
DH: dehydratases - eliminates water to give an unsaturated thioester  
ER: enoyl reductases - catalyses the final reduction to full saturation 
TE: thiolesterase – release of the polyketide chain  
Scheme 6. Modular polyketide synthases (PKSs)9  
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Previous studies have identified some PKS-NRPS genes responsible for the biosynthesis 
of a number of pyridones.11, 12 Further studies are in search for similar PKS-NRPS genes  
involved in tenellin biosynthesis.13 Cox et al have proposed the biosynthesis of 
pretenellin A 27 (Scheme 7) to be the product of the tenS gene encoding tenellin 
synthetase (TENS) PKS-NRPS protein.13 The pathway is followed as the desired amino 
acid is chosen by the NRPS section (adenylation domain) and is believed to be tyrosine 
21, which is then adenylated to an active ester 22 followed by transfer onto the T 
(thiolation) domain. The amine bound to the T domain 23 and the polyketide bound to the 
ACP (acyl carrier protein) domain 24 undergo condensation (catalysed by the C domain) 
to afford the N-β-ketoacyl amino thioester 25 (bound to the T domain). The polyketide 
backbone is formed from acetates and malonates from the PKS portion of the synthetase. 
The reduction domain could release the T domain to afford the peptide aldehyde 26, 
which would be followed by cyclisation to the acyltetramic acid pretenellin A 27.   
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Scheme 7. Proposed biosynthesis of pretenellin A 27 
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The timing of the cyclisation step to pretenellin A remains unclear, i.e. whether it takes 
place before or after the release from the synthetase, and the mechanistic aspects of this 
step are yet to be fully understood.8 The proposed mechanistic pathway (Scheme 8) 
suggests the peptide aldehyde 26 could cyclise readily to the intermediate 28 by a 
dehydration reaction. Previously, a similar pathway to the acyltetramic acids has been 
reported in the case of fusarin.8 In the case of fusarin biosynthesis, the cyclic intermediate 
28 is proposed to undergo an epoxidation reaction catalysed by cytochrome P450 to 29. 
Such compounds can undergo hydrolysis to the 1,2 diol intermediate 30, and dehydration 
of the diol would lead to the acyltetramic acid core 31. Eventually tautomerisation of the 
keto form would afford compound 27. Following this pathway, it is possible a series of 
cyclodehydration, oxidation, hydration and dehydrations reactions could explain the 
cyclisation step to afford pretenellin A 27.    
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Scheme 8 Proposed mechanism for the ring closure to pretenellin 
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Further studies by Cox and co-workers during 2008 focused their attention on the role of 
TENS PKS-NRPS in tenellin biosynthesis.13 The authors identified three new precursors 
of tenellin synthesised from the large multi-enzyme protein complexes, as TENS PKS-
NRPS from B.bassiana was expressed in Aspergillus oryzae. Previous reports have used 
Aspergillus oryzae to identify roles of PKS genes.14  Prototenellin A 32 and B 33 were 
isolated as the major metabolites and identified without great difficulty, whilst 
prototenellin C 34 proved difficult to isolate due to instability during purification. These 
are all structurally related and differ in the polyketide side chain. The structures of 
prototenellin A 32 and B 33 were confirmed by LCMS and NMR analysis, however 
prototenellin C 34 has not been fully characterised but is suggested to be the illustrated 
structure. Prototenellin C 34 was confirmed to contain a more oxygenated side chain than 
tenellin, and these compounds show 1H NMR signals corresponding to the presence of 
the para-hydroxyphenyl substituent. In a second experiment the reaction conditions were 
altered by the addition of a biosynthetic gene cluster of TENS PKS-NRPS since the 
previous experiment failed to produce the tenellin side chain, and in this case pretenellin 
A 27 was isolated as the major metabolite.13 These experimental data have revealed key 
aspects for the programming for fungal PKS-NRPS proteins in the biosynthesis of 
tenellin 3.      
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Biosynthetic studies towards tenellin 3 by Cox and co-workers have focused their 
attention on the possible routes to tenellin 3 and analogues from pretenellin A 27.15,  16 
Strains of B.bassiana were grown in liquid culture for 10 days followed by extraction 
using suitable solvent. The organic extracts were analysed using liquid chromatography 
mass spectrometry (LCMS) and structures elucidated by 1H and 13C NMR spectroscopy, 
which revealed the presence of a number of metabolites (Scheme 9).15 The major 
metabolite isolated was tenellin 3, and others include pretenellin A 27, prototenellin D 35 
and 15-hydroxy tenellin 38. The minor metabolites include the isolation of pretenellin B 
17, pyridovericin 36 and 13-hydroxy tenellin 37, demonstrating the late stage side chain 
oxidations. Further experiments were conducted in cell free extracts of B.bassiana 
containing TENS PKS-NRPS with purified pretenellin A and prototenellin D.15 These 
extracts were grown for 10 days and are incapable of tenellin 3 biosynthesis but contain 
the cytochrome P450 proteins. The purified pretenellin A 27 and prototenellin D 35 were 
incubated in separate batches of the cell free extracts and then isolated through extraction 
with ethyl acetate. The metabolites isolated were purified by HPLC and in the case of 
pretenellin A 27, pyridovericin 36 and 13-hydroxy tenellin 37 were both observed.15 
However in the case of prototenellin D no metabolites were detected and the cell free 
extract was unstable.     
 
 23
HO
OH
N O
OH
N
H
HO HO
O
HO
OH
N O
H
O
N
H
HO HO
O
OH
O
HO
OH
N O
H
O
15
13
O
O
O
O
O
OH
HO
OH
N O
OH
15
O
OH
HO
OH
N O
H
O OH
pretenellin A 27 prototenellin D 35
pretenellin B 17
tenellin 3 15-hydroxy tenellin 38
13-hydroxy tenellin  37
pyridovericin 36
 
 
Scheme 9. Proposed biosynthetic relationship of compounds isolated 
 
Previous hypotheses of tenellin biosynthesis ‘evolved’ around the acyltetramic acid 
intermediates, which undergo an oxidation reaction at the para position of the aryl ring to 
construct a quinoid intermediate, followed by a rearrangement to tenellin 3. However in 
this case two possible steps from the pretenellin A 27 are considered, ring expansion 
followed by N-hydroxylation catalysed by cytochrome P450 oxidases (Scheme 9).15 From 
the experimental results obtained it appears the ring expansion of the pretenellin A 27 is 
catalysed by the cytochrome P450 oxidases to produce tenellin 3 and derivatives. A 
second oxidative step must follow to yield the 15-hydroxytenellin 38 suggesting the 
presence of an additional P450 enzyme in the B.bassiana. The presence of excess P450 
enzyme would also account for the selective hydroxylation of the polyketide side chain 
 24
and would explain the presence of the other hydroxylated pyridones. From the 
experimental results, protenellin D 35 formed from pretenellin A 27 may be a possible 
precursor of tenellin 3, however current experimental data to support this remains weak. 
It is currently described as a “shunt” compound as it failed to produce any 2-pyridones 
whilst incubated with the cell free extracts of B.bassiana.15 
 
There have been several possible mechanisms suggested for the ring expansion of 
acyltetramic acid intermediates to 2-pyridones.8 The first proposed oxidative ring 
expansion follows path A (Scheme 10),15 which has been discussed previously to follow 
the quinomethide mechanism. Path B follows a radical route, which involves a hydrogen 
atom abstraction at the benzylic position forming intermediate 43, followed by the 
addition of a hydroxyl radical to give the alcohol 44. Ring expansion then follows to 
leave the imine 41 as in path A, followed by tautomerisation to the 2-pyridone 42. Path C 
again follows a radical route, and similarly a hydrogen atom is abstracted from the 
benzylic position forming intermediate 43; cytochromes P450 are known to be 
responsible for such hydrogen atom abstraction.15 A radical-induced ring expansion 
follows via a short lived radical intermediate 45. Ring expansion follows to a possible 
radical intermediate 46, which can either pick up a hydroxyl radical leading to the alcohol 
47 and elimination of water to leave the 2-pyridone 42, or in one step to yield the 2-
pyridone 42 through the loss of another hydrogen atom. A similar mechanism has been 
proposed for aspyridone.17  
 
The possible ring expansion of the acyltetramic acid intermediates to 2-pyridones is 
proposed by Cox et al to most likely to follow path C.15 It is unlikely that path A would 
be followed, as this could not account for compounds which lack the para-substituted 
phenol, as observed in other 2-pyridones such as leporin B. It would not be possible to 
form the quinomethide 40 in the absence of the para-substituted phenol. If Path B is 
likely then it would suggest protenellin D as a true intermediate, but this is currently 
described as a “shunt” compound. Therefore Path C seems in favour for the ring 
expansion to 2-pyridones, and it is also known that cytochrome P450 hydroxylation 
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proceeds by H-atom abstraction, which also supports this route. Nevertheless further 
investigation is required to prove the proposed hypothesis.               
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Scheme 10. Proposed ring expansions of the acyltetramic acid to 2-pyridones 
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From the mycelium extract of the insect pathogenic fungus Paecilomyces militaris, was 
isolated the novel bioactive natural product militarinone A 48.18 This pyridone alkaloid 
contains similar structural features to tenellin 3, consisting of the polyene side chain, 
hydroxamic acid functionality, and in addition the cis-(1,4-substituted cyclohexyl) moiety.  
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The discovery was made by Schmidt and co-workers after pursuing their interest in 
secondary metabolites of imperfect fungi.18 Their findings demonstrated that a mycelium 
extract of Paecilomyces militaris strain RCEF 0095 exhibited neuritogenic activity on 
PC-12 cells and no cytotoxicity in PC-12 cells, and the bioassay revealed fractions to 
contain the natural product. PC-12 cells are isolated from a rat medulla, which has the 
ability to respond to nerve growth factors and therefore it is commonly used as a model 
for neuronal differentiation.  
 
Further investigation into Paecilomyces militaris strain RCEF 0097, led to the discovery 
of the novel pyridone alkaloid (+)-N-deoxymilitarinone A 49.19 This compound is almost 
structurally identical to militarinone A 48, differing by a single oxygen atom. This 
compound also exhibited neuritogenic activity on PC-12 cells.  
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Further novel alkaloids were isolated in 2002 by Schmidt and co-workers from the 
mycelium extract of the pathogenic fungus Paecilomyces militaris, three yellow pigments 
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identified as militarinone B 50, C 51 and D 52.20  The structure of militarinone D 52 is 
almost identical to tenellin 3 and other pyridone fungal metabolites; it consists of the 5-
(4-hydroxyphenyl)pyridine-2-one ring system, and the extended acylated moiety at C-3. 
Militarinone B 50 and C 51 are structurally almost identical, both containing the 
acyltetramic acid functionality, the 4-hydroxyphenyl moiety, the polyene side chain and 
the stereochemistry is unknown at the centres. The two differ by the presence of the extra 
benzylic hydroxyl group in militarinone B 50. Militarinones 50 and 51 both contain the 
pyrrolidine-2,4-dione (tetramic acid) ring, which has been reported in other microbial 
natural products as antibiotics and antiviral agents.21  Militarinones B-D were tested for 
neuritogenic properties in PC-12 cells and test results were negligible, however 
militarinones D 52 confirmed evidence of cytotoxicity in PC-12 cells.20 
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The biosynthetic pathway proposed for militarinones A-D is similar to the tenellin 3 
biosynthetic pathway, and is suggested to proceed via an acyltetramic acid intermediate 
(Scheme 11).20 The hypothesis illustrates tyrosine 21 fused with a polyketide derived 
chain 53 to form the acyltetramic acid intermediate militarinone C 51, followed by 
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oxidation to provide the corresponding 6-hydroxy derivative militarinone B 50. This is 
suggested to undergo dehydration and tautomerisation to construct a possible quinoid 
intermediate 55. Rearrangement of the intermediate directs the formation of the pyridone 
ring in militarinone D 52. The interesting conversion of the aromatic substituent to 
produce the 1,4-disubstituted cyclohexane is accompanied by  further reactions, such as 
N-oxidation, as well as oxidative and reductive steps to complete the biosynthetic 
pathway to furnish militarinone A 48. It may be that the radical ring expansion sequence 
proposed for tenellin (Scheme 10, Path C)15 also operates here, as the militarinone 
proposal is based not on experimental evidence but on metabolite co-occurrence.20  
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Scheme 11. Proposed biosynthesis for the militarinone alkaloids. 
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Two new pyridone alkaloids have been reported by Hamburger and co-workers, 
farinosones A 56 and B 57.22 A third compound farinosone C 58 was also isolated, which 
is possibly involved in the pyridone biosynthesis (Scheme 12).22 These were isolated 
from the mycelium extracts of the fungus Paecilomyces farinosus as yellow pigments (A 
and B) and their structures were confirmed through extensive NMR and MS studies. The 
structures of 56 and 57 are almost identical to that of tenellin, the difference being that 
these have an extended polyene side chain. Previously tenellin 3 and pretenellin B 17, 
were reported to have the hydroxylamine group and simple NH respectively. Here we 
have the same case with farinosones A 56 and B 57. The only difference in structure is 
the hydroxylamine group in 56 and simple NH in 57.         
 
The presence of the tyrosine-like moiety in structure C 58 supports a biosynthetic 
pathway that could be similar to other members of the related pyridone family. The 
presence of tyrosine in the biosynthetic pathway of the tenellin and militarinone series 
was discussed previously. Again it is possible the sequence proposed for tenellin also 
operates here, for instance tyrosine fused with a poly-β-keto acid could lead to such 
metabolites.  
 
Interests in these metabolites arise due to their bioactivity, such as in cancer treatment 
and as antibiotics. These compounds are of great interest to the medicinal field, in this 
case towards neurodegenerative disorders.22 These disorders are often caused by 
misfolding of proteins and more commonly known as Alzheimer’s disease (AD). Cells of 
the brain are lost and eventually lead to CNS related dysfunction. Clinical studies of AD 
are aimed at neurotrophic factors such as nerve growth factors, however success to date 
has been limited.22 Natural products are often screened for neurotrophic properties and 
entomopathogenic imperfect fungi are known to have shown CNS bioactivity, and often 
produce metabolites which are responsible for the interaction with their host insect, 
causing behavioural changes and even death. The farinosone family was tested for 
neurotrophic activity towards PC-12 cells, and compound A 56 and C 58 showed some 
activity, whilst compound 57 was inactive.  
 
 31
 
HO
OH
N O
OH
O
 
                                                
                                              Farinosone A 56  
 
HO
OH
N O
H
O
 
  
                                                Farinosone B 57 
 
HO
OH
HN
O
CO2H
 
 
                                                Farinosone C 58 
 
Scheme 12 
 
From extracts of the fungus Aspergillus nidulans were isolated the natural products 
aspyridones A 59 and B 60.17 The structures of these compounds are similar to that of 
other 2-pyridones such as tenellin 3 but not identical. Similarities arise through the 4-
hydroxyphenyl group and the 3-acyl aliphatic side chain with notable differences: the 
hydroxylamine group is absent, as was also observed in pretenellin B 17, and the 3-acyl 
side chain is saturated. The structures of these compounds were confirmed through 
extensive NMR and MS studies. This demonstrated aspyridone B 60 to have an extra 
quaternary carbon, absence of an aromatic H and increase in mass which confirmed its 
structure to be the 3,4-dihydroxyphenyl analogue of aspyridone A 59. These compounds 
were screened for bioactivity and results showed moderate cytotoxicity.17         
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The proposed biosynthetic pathway for the aspyridones (Scheme 13)17 suggests the key 
backbone is assembled from a polyketide pathway from the PKS–NRPS hybrid to afford 
an aldehyde 61, which would readily undergo an intramolecular Knoevenagel 
condensation reaction, with the loss of water to the pyrrolinone intermediate 62. This 
must be followed by several oxidation reactions, catalysed by cytochrome P450 to the 
tetramic acid intermediate 63. Further oxidation of this intermediate leads to the 6-
hydroxy tetramic acid 64. In the next step of this pathway, rearrangement follows with 
the loss of the hydroxyl group to the aspyridones. Comparing this biosynthetic proposal 
to that of related 2-pyridones the difference arises in this ring expansion step. Here the 
acyltetramic acid intermediate is proposed to undergo dehydration and tautomerisation to 
an intermediate, which then proceeds via rearrangement to the natural product. In contrast, 
the evidence for tenellin 3 suggested a radical route (Scheme 10).15 To date, the exact 
mechanisms and the pathways to the 2-pyridones have been studied extensively but still 
remain uncertain. Once again it seems that the sequence proposed for tenellin may also 
operate here since these are only rationalised deductions of the hypothetical biosynthetic 
pathway.  
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Scheme 13. Hypothetical biosynthetic pathway for aspyridones A and B 
 
From the acetone extracts of the fungus Aspergillus fumigatus was isolated the toxic 
metabolite fischerin 65, which is known to cause severe peritonitis in mice followed by 
death.23 Its structure was solved by extensive 1H and 13C NMR analysis to consist of a 
hydroxamic acid group, 1,4-dihydroxycyclohexane derivative (stereochemistry not 
known at the centres) and a decalin ring system. The signals observed in the 13C NMR 
spectrum of fischerin at the C1 and C2 positions suggests a cis-decalin, and the proton 
configurations between C6 and C5, C6 and C1 are trans diaxial. A similar decalin ring 
system has been observed in other natural products such as ilicicolin 5.  
 
 34
N
OH
O
O
HO
O
H
H
CH3
OH
OH
1
2
3
45
6
 
    Fischerin 65 
 
The proposed biosynthesis (Scheme 14)23 is imagined to proceed similarly to that of other 
fungal metabolites such as tenellin 3.  Again the sequence for the biosynthetic pathway 
follows a polyketide pathway with phenylalanine fused with the poly-β-keto acid and 
significant modification to form the acyltetramic acid intermediate 67, followed by 
oxidation reactions and ring rearrangement to afford the natural product 65.  
 
 
 35
NH2
CO2H
O
CO2H
O O O
CH3
O O
N
H
O
O
O
H3C
H
N
H
O
O
HO
H3C
O
O
7 66
67
68
65  
Scheme 14 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 36
Summary 
The isolation of natural products with the core 3-acyl-4-hydroxypyridone moiety and its 
acyltetramic acid analogues has been discussed in this section and the key natural 
products are summarised in Table 1. These structurally diverse groups of natural products 
display a range of biological activity, including antibiotic and antiviral. For instance they 
have been screened for CNS-related bioactivities and some have shown neuritogenic 
activity and cytotoxicity in PC-12 cells.    
 
The fungus Beauveria bassiana was first to undergo biosynthetic study due to its insect 
pathogenic properties which cause white muscardine disease in domestic silkworms.2 
This fungus has been shown to produce yellow pigments such as the 2-pyridone tenellin 
3,1 and surprisingly a number of other natural products similar in structure have been 
isolated from other fungi such as the farinosones A 56 and B 57, isolated from the 
mycelium extracts of the fungus Paecilomyces farinosus as yellow pigments.24   
 
Structural similarities arise though the core 3-acyl-4-hydroxypyridone and differences 
show in the side chains, for instance bassianin 4 has an extended polyene side chain 
compared to tenellin 3. In the case of the natural product ilicicolin 5,7 the polyene side 
chain is replaced by a trans-decalin ring system while the 4-hydroxyphenyl functionality 
remains intact. In the case of the 2-pyridone fischerin 65 the 4-hydroxyphenyl 
functionality is absent and replaced by a 1,4-dihydroxycyclohexane moiety.  
 
Early biosynthetic studies suggested the condensation of a possible intermediate α-
formylphenylacetyl CoA with a poly-β-keto acid to form the key carbon skeleton for 
tenellin 3 (Scheme 1). Over the years, as the interest in the biosynthetic pathway of 2-
pyridones developed, much of the research was focused on isotope-labeling methods in 
polyketides. Through a number of feeding experiments the first hypothesis for tenellin 3 
was developed by Wright et al. to show that they are derived from amino acids and 
polyketide precursors, and the amino acid undergoes a late stage rearrangement (Scheme 
2).6 The hypothesis initially derived from tenellin 3 biosynthetic studies illustrated the 
use of an aromatic amino acid, phenylalanine fused with a polyketide chain to form a 5-
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membered acyltetramic acid ring, which then undergoes oxidative ring expansion 
followed by rearrangement to tenellin 3. A similar hypothesis was proposed for the 
biosynthesis of ilicicolin by Wright et al. 6 Again, the biosynthetic proposal starts with 
the interaction of a ployketide and phenylalanine precursors to follow the tenellin 3 
sequence. It seems the proposed biosynthetic pathway for tenellin and related compounds 
have in common a polyketide pathway consisting of an aromatic amino acid such as 
phenylalanine or tyrosine and polyketides derived from acetates and malonates. The 
proposed biosynthetic pathway for other 2-pyridones such as the militarinone family is 
based around acyltetramic acid intermediates and oxidation and reduction reactions. 
These hypothesis are based on co-occurrences and not on actual experimental data, 
therefore it may be that the sequence proposed for tenellin also operates in the 
biosynthesis of other fungal 2-pyridones.  
 
Recent advances in the biosynthetic studies of 2-pyridones use the more modern 
technology of gene encoding, which has led to the identification of gene clusters in fungi 
that encode for the proteins governing the biosynthesis of 2-pyridones. Cox et al. have 
shown for the first time that PKS-NRPS are involved in the biosynthesis of the 2-
pyridone natural products.8 These large multifunctional proteins assemble acyl units in a 
programmed method to build natural products. The functionality of the natural products 
is controlled by each individual functional domain. They prepared PKS-NRPS genes and 
conducted several experiments to suggest possible precursors in tenellin biosynthesis. 
The studies have reported both the pretenellin A 27 and pretenellin B 17 to be possible 
intermediates in the biosynthesis, and programmed a number of domains to develop 
specific functionality (Scheme 9). The mechanistic aspect of the ring expansion from the 
acyltetramic acid pretenellin A to pretenellin B is yet to be fully understood, and 
currently a radical route via the formation of a benzylic radical intermediate in path C of 
Scheme 1015 seems to be in favour. However, a major challenge remains in 
understanding the key aspects of the programming of the PKS proteins. Controlling the 
domains to determine the chain length and the starter/extender selection, degree of 
methylation and reduction, all remain uncertain. The existing studies have revealed the 
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functions of each domain, which it is believed are the key to understanding the 
fundamental aspects of programming.         
 
In this section we have discussed the biosynthetic origin of the natural products and in the 
next part of the thesis will concentrate on the synthesis of some of these natural products 
and of other 2-pyridones.  
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Table 1. Summary of natural products  
  
 
 Natural Product          Structure                                                                  Isolation 
 
    
   Aspyridone A                                                                                            Aspergillus    
         59                                                                                                          nidulans 
  
 
 
 
 
   Aspyridone B                                                                                            Aspergillus    
           60                                                                                                        nidulans 
  
 
 
 
 Prototenellin B                                                                                            Beauveria              
          33                                                                                                        bassiana 
 
 
 
 
 
 Prototenellin A                                                                                             Beauveria              
          32                                                                                                          bassiana 
 
 
 
 
 
 
 Pretenellin A                                                                                                Beauveria              
          27                                                                                                          bassiana 
 
 
 
 Pretenellin B                                                                                                 Beauveria              
         17                                                                                                           bassiana 
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 Natural Product          Structure                                                                  Isolation 
 
    
 Tenellin                   Beauveria              
      3                                                                                                               bassiana 
 
 
 
 
 Pyridovercin                                                                                                Beauveria              
        36                                                                                                           bassiana 
 
  
 
 
 13-Hydroxy-       
  tenellin                                                                                                        Beauveria              
         37                                                                                                          bassiana 
 
 
 
 
 15-Hydroxy-                                                                                                 Beauveria              
 tenellin                                                                                                          bassiana 
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 Fischerin                                                               Aspergillus 
      65                                                                                                            fumigatus 
                  
 
 
 
 
 
 Ilicicolin                                                                                                    Cylindrocladium   
      5                                                                                                                ilicicola 
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 Militarinone A                                                                                              Paecilomyces   
          48                                                                                                            militaris 
  
 
 
 
  
 (+)-N-Deoxy                               Paecilomyces   
 militarinone A                                militaris 
          49                                                                                                                         
 
 
 
 
 
 Militarinone B                                                                                              Paecilomyces   
         50                                                                                                              militaris 
 
 
 
 
 
 Militarinone C                                                                                              Paecilomyces   
          51                                                                                                            militaris 
 
 
 
 
 
 Militarinone D                                                                                              Paecilomyces   
         52                                                                                                              militaris 
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 Farinosone A                                                                                              Paecilomyces  
          56                                                                                                           farinosus 
  
                                                                                                                       
 
 
 
 Farinosone B                                                                                              Paecilomyces  
          57                                                                                                           farinosus 
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1.3 Synthesis of the 3-acyl-4-hydroxypyridone natural products                
 
The total synthesis of tenellin 3 was reported by Williams and co-workers during 1982.25 
They prepared the hydroxamic acid derivate 70 in four steps from methyl 2-[4-
(benzyloxy)phenyl]acetate 69 (Scheme 15), which was then subjected to saponification 
of the methyl ester by treatment with lithium hydroxide in THF, followed by treatment 
with 1,1’-carbonyldiimidazole in a separate step to yield the imidazolide 72. Addition of 
sodium hydride triggered cyclisation to afford 73. Oxidation with chloranil yielded 74, 
and removal of benzyl protection yielded 75, which was reported as the bis-THP 
derivative 76. Tenellin 3 was finally furnished by the use of an aldol condensation 
reaction, which was achieved upon treating 76 with lithium diisopropylamide (LDA) in 
THF with corresponding aldehyde 77 followed by dehydration to leave 78  in 56% yield. 
Finally deprotection followed under acidic conditions to furnish racemic tenellin in 86 % 
yield. 
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Scheme 15. Total synthesis of tenellin 3 reported by Williams and co-workers 
 
Rigby and coworkers considered an alternative approach to achieve the total synthesis of 
tenellin.26 They had much interest in the cyclocondensation of vinyl isocyanates to form 
pyridone derivatives. The strategy involved treating the vinyl isocyanate 82 with 
cyclocondensation partner β-keto ester salt 81 (Scheme 16). The vinyl isocyanate 82 was 
prepared in two steps from the commercially available 4-hydroxybenzaldehyde 80 in 
90% yield. The β-keto ester was obtained upon treating (E)-2,4-dimethyl-2-hexanal 7725 
with a β-keto ester phosphine oxide 79 in the presence of the base n-BuLi. Treating the 
sodium salt of the ester 81 with the vinyl isocyanate 82 afforded the pyridone 83 in 70% 
yield as a yellow solid. The next step of the synthesis was to introduce the hydroxamic 
acid functionality. It was necessary to remove the MEM protection group before the N-
oxidation step, as this step was found to cleave the N-OH bond. The N-oxidation was 
accomplished by O-silylating the amide using hexamethydisilazane (HMDS) and a 
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catalytic amount of trimethylsilyl chloride (TMSCl). The extremely moisture sensitive 
silyl intermediate was not isolated or characterized. This was immediately treated with 
oxodiperoxymolybdenum(pyridine)(HMPA) complex27 to afford tenellin 3 in 42% yield.   
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Scheme 16. Synthesis of tenellin 3 reported by Rigby and Qabar 
 
Williams and coworkers were the first to report the total synthesis of the natural product 
ilicicolin 5 with a unique intramolecular Diels-Alder step in a late stage of the synthesis 
(Scheme 17). 28  Ilicicolin with antifungal and antibiotic activity is isolated from the 
imperfect fungus Cylindrocladium ilicicola, and contains interesting structural features. It 
has the 5-(4-hydroxyphenyl)-2-pyridone as in tenellin 3, and it has a distinctive trans-
decalin system. Having previously synthesised the benzyl protected pyridine 74,25 which 
is a good starting point for this synthesis, the pyridone was treated with the α,β-
unsaturated aldehyde 84 to afford the tetraene intermediate 85. This reaction preceded via 
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an aldol condensation between the aldehyde 84 and the dianion of the pyridone 74 using 
potassium tert-butoxide. An intramolecular Diels-Alder reaction followed upon applying 
heat to a solution of tetraene 85 in o-dichlorobenzene to construct the trans-decalin 
system. Removal of the N-1 benzyloxy function was carried out by elimination of 
benzaldehyde using strong a base, and the remaining phenolic benzyl ether was cleaved 
using boron trichloride to afford the racemic natural product 5  
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Scheme 17. Total synthesis of ilicicolin 7 
 
During 1998 Nakagawa and co-workers reported the isolation of two novel natural 
products, pyridovericin 36 and pyridomacrolidin 86 from the entomopathogenic fungus 
Beauveria bassiana.29 These compounds have been shown to inhibit protein tyrosine 
kinase (PTK), and therefore are useful as therapeutic agents against inflammatory 
diseases. A number of compounds which inhibit protein tyrosine kinase (PTK) have in 
common the p-hydroxyphenyl functionality, which is assumed to mimic tyrosine.     
 
 47
N O
HO
H
OH O
OH N O
HO
O
OH O
OH
O
O
O
OH
 
                      36                                                                   86 
 
With the obvious biological interest, the biosynthetic pathway of pyridomacrolidin 86 has 
yet to be studied, while the biosynthesis of pyridovericin 36 is assumed to follow the 
pathway of previously reported pyridone alkaloids such as tenellin 3. The total synthesis 
of pyridovericin 36 has been reported by Baldwin and co-workers (Scheme 18).30 They 
prepared pyridine 88 from the commercially available 2,4-dihydroxypyridine 87 in two 
steps, which was then treated with the boronic acid 89 under Suzuki conditions to afford 
4-benzyloxypyridone 90 as the major product, from a mixture of mono- and bis-coupled 
adducts. To construct the polyene side chain, treatment with t-BuLi in a metal-halogen 
exchange of the bromopyridine, and then with the aldehyde 91 afforded an alcohol adduct. 
Subsequent oxidation gave 92 and deprotection furnished the target natural product 36 in 
total of thirteen steps.  
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Scheme 18. Synthesis of pyridovericin 36 
 
Nageswara and co-workers have proposed a possible biosynthetic formation of 
pyridomacrolidin 86 from pyridovericin 36 (Scheme 19).31 - 32   The first step of the 
pathway involves the N-oxidation of pyridovericin 36 to yield the hydroxamic acid 
functionality as in 38. This is followed by further oxidation to the acyl nitrone 
intermediate 93, which undergoes a 1,3-dipolar cycloaddition reaction with 
cephalosporolide B 94, and finally rearomatisation takes place to furnish 
pyridomacrolidin 86. 
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Scheme 19. Proposed biomimetic pathway of pyridomacrolidin 86 
 
A biomimetic retrosynthesis, based on the proposal of scheme 19, was devised for the 
synthesis of pyridomacrolidin analogue 95. The pyridone 98 and boronic acid 99 in a 
Suzuki-cross coupling reaction would provide the 5-(4-hydroxyphenyl)pyridone 96 
(Scheme 20). The reactivity of the phenolic group in 96 is blocked by using sterically 
hindered tert-butyl groups, as previous attempts failed to trap the quinonoid intermediate 
93 shown in the biosynthetic proposal (Scheme 19), due to competing additions to this 
highly electron deficient system. The polyene side chain as in pyridovericin 36, was 
omitted in this synthesis, and replaced with an acetyl group to allow the synthesis to 
proceed without further complexity. The target compound 96 would oxidise to the 
nitrone/quinonoid intermediate, and proceed in a 1,3-dipolar cycloaddition reaction with 
a simplified cycloaddition partner 97 to furnish 95.   
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Scheme 20. Retrosynthesis of pyridomacrolidin analogue 95 
 
Bromide 98 was prepared using similar methods to those developed previously by 
Williams and co-workers.33 The boronic acid 99 was prepared from the commercially 
available 4-bromo-2,6-di-tert-butylphenol in one step. Treating bromide 98 and boronic 
acid 99, under Suzuki conditions, followed by deprotection of the benzyl group with 
hydrogen and 10% palladium on carbon presented the pyridone 96 in good yield (Scheme 
21). Oxidation of pyridone 96 in the presence of the cycloaddition partner 97 led to [3+2] 
cycloaddition via nitrone 100 to give a mixture of two products, phenol 95 and quinone 
methide 101 in 60% combined yield with a cis ring junction, in a 1:1.4 ratio respectively. 
The structures of these two tautomers were confirmed by single-crystal X-ray 
crystallography,  
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Scheme 21 
 
Many attempts were made to equilibrate the two products 95 and 101, however this 
proved to be unsuccessful. The formation of both these compounds was rationalised by 
the formation of the exo 101 and the endo 102 quinone methide adducts: under the 
cycloaddition conditions a mixture of endo and exo adducts was obtained (Scheme 22). 
The endo adduct 102 can undergo facile tautomerisation to yield phenol 95, whereas 
tautomerisation was not observed in the case of the exo adduct 101.  In conclusion a [3+2] 
cycloaddition via a nitrone intermediate has been investigated to form analogues of 
pyridomacrolidin and supports the proposed biosynthetic route.  
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Scheme 22 
 
Apiosporamide 105, an anti fungal agent, was isolated in 1994 by Gloer and co-workers 
from the fungus Apiospora montagnei.34  Like the other natural products mentioned this 
also contains the core 3-acyl-4-hydroxy-2-pyridone unit, in this particular case displaying 
a range of activity including; antifungal activity against the coprophilous fungus 
Ascobolus furfuraceus, antibacterial characteristics against the Gram-positive bacteria 
Bacillus subtilis and the human pathogen Staphylococcus aureus.  
 
Williams and co-workers have achieved the total synthesis of (+)-apiosporamide 105 and 
the corresponding ketone 106. 35  They prepared two precursors in a stereocontrolled 
manner, the left side of 105 as an epoxydiol 103 and the right side as a trans-decalin 
system 104 (Scheme 23). Preparation of the epoxydiol 103 involved nucleophilic attack 
of a β-lactam hydroxamic acid derivative on a cyclohexanone derivative. The trans-
decalin system 104 was achieved via intramolecular Diels-Alder reaction of an α,β-
unsaturated aldehyde similar to 84. Fusing the two precursors together afforded 
apiosporamide 105.   
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Scheme 23. Total synthesis of (+)-apiosporamide 
 
 
1.4 Other natural products with the core 4-hydroxypyridone unit 
 
The isolation of the natural product (+)-sambutoxin 107 was first reported by Lee and co-
workers from wheat cultures of Fusarium sambucinum PZF-4. 36 (+)-Sambutoxin 107 in 
feed sources has been found to cause hemorrhagic lesions of the gastrointestinal tract of 
livestock. Structural features of 107 include the pyridone core, 4-hydroxyphenyl 
substituent and the tetrahydropyran ring. Structural determination was able to identify the 
absolute stereochemistry of the tetrahydropyran ring, however at this stage the absolute 
stereochemistry remained uncertain. Further studies by Williams and Turske led to the 
total synthesis of (+)-sambutoxin and definition of the absolute stereochemistry.37  
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Other natural products belonging to the family of funiculosin 6 include TMC-69(6H) 108 
and its saturated analogue TMC-69 109 and these have been isolated from the fungus 
Chrysosporium. 38 These compounds are known to show antitumour activity, cytotoxic 
activity and 109 has shown significant activity towards P388 murine leukaemia in vivo.     
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Like tenellin 3, these compounds have the core pyridone nucleus, but the 4-
hydroxyphenyl substituent is replaced with just a phenyl group on the left hand side of 
the natural products. The right hand side of the compound consists of a tetrahydropyran 
system with saturated or unsaturated side chains.   
 
The structural interest combined with the potential biological activity led to the total 
synthesis of TMC-69 109. Previously Furstner and co-workers reported the Pd-C 
catalysed reaction of 108 to the saturated analogue compound 109, 39  however the 
absolute configuration at C-17 was not confirmed. Sugawara and co-workers have 
prepared compound 109 along with its stereoisomer 113.38 They treated the protected 
pyridone 110 with the tetrahydropyran moiety 111, which underwent a condensation 
reaction and cyclisation to afford (17S)-TMC-69 109 and its stereoisomer 113 (Scheme 
24).      
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Scheme 24. Synthesis of TMC-69  
 
During 2007 Surup and coworkers proposed the biosynthesis of a new family of natural 
products, the iromycins 115, isolated from a soil sample of Streptomyces bottropensis and 
having the core N-hydroxy-2-pyridone nucleus.40 The structures of these natural products 
are of interest due to the presence of the two distinctive alkyl chains. The feeding 
experiments in biosynthetic studies suggested a possible polyketide pathway, which 
includes acetate, propionate, pentanoate and isobutyrate, however the source of nitrogen 
is still unknown.  
 
This group of natural products shows useful activity: they can selectively inhibit the 
production of endothelial nitric oxide synthase (NOS) over neuronal NOS. The NOS can 
be split into three isoforms, neuronal NOS, endothelial NOS and inducible NOS, all of 
which trigger the production of nitric oxide (NO). Too much NO build up in cells can be 
harmful and can lead to conditions such as chronic inflammatory disease. These studies 
can be useful in the medicinal field to aid therapeutic advances.    
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                                            115 
From the entomopathogenic fungus Akanthomyces gracilic the natural product 
akanthomycin 116 was isolated.41 The structure was confirmed by X-ray crystallographic 
study, to contain the N-hydroxypyridone moiety linked via a single bond to an unusual 
cycloheptane ring. The X-ray studies revealed the two rings to be approximately 
perpendicular to each other in the solid state, with the C-5 hydroxyl group on the same 
side as the C-14 methyl group in the cycloheptane ring. Like other 2-pyridones, this 
compound was also tested for bioactivity and assay studies of akanthomycin 116 revealed 
antibiotic activity against Staphylococcus aureus.  
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A number of fungi produce 4-hydroxypyridone antibiotics such as tenellin 3 and ilicicolin 
5.1 Other related naturally occurring compounds which demonstrate this include PF1140 
117, pyridoxatin 118, fusaricide 119 and leporin 120.42   
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The structure of 117 has been reported but the absolute configuration was uncertain.  
Fujita and co-workers have clarified the absolute configuration via numerous feeding 
experiments and have proposed the biosynthesis of PF1140 117.42 
 
In the initial feeding experiment sodium [1-13C]acetate was incorporated into cultures of 
Eupenicillium sp. PF1140, which were extracted with acetone to isolate 117 and also 
uncovered a new compound 121. After extensive analysis, the 13C NMR spectrum clearly 
illustrated sites of incorporation at C-13, C-11, C-9, C-7 and C-2 compared to the 
unlabeled sample. Results from a further feeding experiment with sodium [1,2-
13C2]acetate provided evidence to suggest that five intact acetate units were involved in a 
head to tail fashion to form a pentaketide building block. Experiments with L-[Me-
13C]methionine confirmed the three branching methyl groups, at carbon positions 12, 10 
and 8 originate from the S-methyl group of L-methionine. To verify the role of amino 
acids in the biosynthesis of PF1140 117, L-[1-13C]serine was introduced to the feeding 
experiments and an enhanced signal in the 13C NMR spectrum was confirmed to occur at 
C4. Based on these positive results, L-[1,3-13C2]serine was introduced into the feeding 
experiments and 13C NMR spectroscopy revealed coupling between the adjacent C4 and 
C5, suggesting a possible intramolecular rearrangement of the carbon skeleton. A 
possible rearrangement has been discussed earlier in this thesis for biosynthesis of 
tenellin 3.4        
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Following the results of the feeding experiments, a biosynthetic pathway was proposed 
for PF1140 117 (Scheme 25). With verification from the feeding experiments, L-serine 
122 was integral to the pyridone framework, and therefore the proposal began with this 
the amino acid. The amino acid comes together with a polyketide chain 123 to form the 
acyltetramic acid intermediate 124, which rearranges to give the 4-hydroxy-2-pyridinone 
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125 framework by the loss of the hydroxyl group and aromatisation. After a reduction, 
there are two possible routes suggested for the last step to compose the PF1140 117 unit, 
either path A, which is a stepwise cyclisation or path B, which is a hetero-Diels-Alder 
reaction.   
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                                                      Scheme 25 
 
The acyltetramic acids as intermediates in tenellin 3 biosynthetic pathway have been the 
subject of biological studies for several years and such intermediates are also considered 
to appear in other 2-pyridone biosynthesis as discussed earlier. There are several 
naturally occurring tetramic acids which have been found to be of medicinal importance 
and isolated from marine sponges and fungi.43  Two novel tetramic acid derivatives, 
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epicoccarine A 131 and B 132, and a new pyridone alkaloid epipyridone 133, were 
reported by Hilaire and co-workers, isolated from the fungus Epicoccum sp.44 
  
Epipyridone 133 was isolated as a red oil, and the structure was determined by HR-EIMS 
and extensive NMR analysis. Structural similarities with other natural products are 
evident: like tenellin this natural product contains the 4-hydroxyphenyl substituent, and 
the atypical tricyclic ring system similar to leporin B 120, with additional methyl groups. 
Epicoccarine A 131 and B 132 are almost structurally identical; both embrace the 
tetramic acid functionality, unsaturated aliphatic side chain and the p-hydroxyphenyl ring. 
The only difference arises as epicoccarine B 132 contains the hydroxymethylene group in 
the C-6 position.   
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The structural similarities of these compounds suggest the possibility of their being 
derived from the same biosynthetic pathway. Since as previously discussed, biosynthetic 
pathways normally involve an aromatic amino acid and a polyketide chain through 
condensation reactions, a similar concept is also adopted here to follow the tenellin 3 
sequence. The polyketide synthase non-ribosomal peptide synthetase (PKS–NRPS) 
hybrid assembles the polyketide-amino acid backbone 134. Ring closure followed by 
further oxidation reactions catalysed by the enzyme P450 could lead to the tetramic acid 
with the tricarbonyl moiety 132. This undergoes rearrangement as seen in other 2-
pyridone biosyntheses to form the tenellin like pyridone alkaloid 136. Finally it is thought 
the natural product 133 is formed via an intramolecular cyclisation in a hetero Diels-
Alder reaction (Scheme 26).  
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Epipyridone 133 and epicoccarine B 132 were found to show only moderate activity 
against Gram positive bacteria. Epicoccarine A 131 on the other hand exhibited 
antibacterial activity against the Gram positive bacterium Mycobacterium vaccae. 
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Scheme 26.  Proposed biosynthetic pathway for epipyridone  
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Results and Discussion 
 
2. 1 The 3-acyl-4-hydroxypyridone 
 
2.1.1 Synthetic strategy  
 
After the review presented in chapter one of the natural products containing the 
acylpyridone motif 141, we sought original and flexible ways to access and elaborate the 
3-acyl-4-hydroxypyridone unit via the isoxazolopyridone 1 as the masked form (Scheme 
27). In a strategy to develop a building block with the 3-acyl-4-hydroxypyridone core, we 
planned to disguise the highly polar functionality of the heterocyclic triones 2, by 
masking them in the form of an isoxazolopyridone 1, as a more amenable building block. 
The polar nature makes them challenging to work with, particularly with regards to 
handling and purification. The isoxazolopyridone 1 would then be elaborated at the sites, 
C-3’ (Me), N-5 and C-7 to allow the development of natural products and non-natural 
analogues with potential biological activity. The unmasking of the elaborated 
isoxazolopyridone 141 to reveal the heterocyclic trione would follow in the final step of 
the synthesis, by cleavage of the N-O bond.  
 
The proposed synthetic strategy to develop the isoxazolopyridone 1 commences with an 
amino acid (Scheme 27). The protected amino acid would be converted to the stable 
oxime via the corresponding aldehyde. The oxime would undergo a 1,3-dipolar 
cycloaddition of the nitrile oxide formed in situ with a cycloaddition partner to form the 
isoxazole. A spontaneous cyclisation of the isoxazole would yield the isoxazolopyridone. 
Other amino acids, such as 2,3-diaminopropionic acid could also be employed in this 
strategy to afford the isoxazolopyridone building block 1.     
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Scheme 27 
 
 
2.1.2 Synthesis of the isoxazolopyridone building block 
 
 
The preparation of the isoxazolopyridone 1 building block was achieved in seven steps 
from the commercially available 2,3-diaminopropionic acid monohydrochloride 142 
(Scheme 28). Esterification of 2,3-diaminopropionic acid monohydrochloride was 
followed by  N-protection to the ester 144, and reduction of the ester to an aldehyde 145, 
which was transformed directly to diamino-oxime 146. The nitrile oxide of the oxime 146 
took part in a 1,3-diopolar cycloaddition reaction (Scheme 29), followed by spontaneous 
cyclisation at the β-amine to yield a bicyclic ring 151. The unsaturated bond was 
introduced by diazotization of the α-amine to yield the isoxazolopyridone 1 (Scheme 30).    
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Scheme 28 
 
a) Esterification 
 
The commercially available 2,3-diaminopropionic acid monohydrochloride 142 was 
treated with freshly distilled methanol and acetyl chloride, which was heated at reflux 
under nitrogen for four days. The resulting white precipitate was filtered to leave a 
mixture of the starting material and the methyl ester. The alpha proton signal of the 
amino acid was present in the 1H NMR spectrum suggesting the presence of the starting 
material, therefore a second treatment with acetyl chloride and methanol was required to 
ensure complete conversion to the methyl ester 143. At that time it was found that the 
filtrate contained starting material, and as a result, a third treatment was required. The 1H 
NMR spectrum of the methyl ester revealed double doublets for the beta protons, as they 
are diastereotopic, with a chiral centre in the molecule.  
 
b) Amine Protection 
 
The amine protection was readily achieve by addition of di-tert-butyl dicarbonate 
((Boc)2O) to a suspension of the ester dihydrochloride 143 in dichloromethane (DCM) 
was followed by dropwise addition of triethylamine at 0°C to afford the Boc protected 
methyl ester 144 in yield of 94%.  The excess ((Boc)2O) could be removed by 
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purification using silica column chromatography, however this was not required since we 
later discovered that this did not cause any complications in the following steps of the 
synthesis.   
 
c) Oxime Formation   
 
The Boc-protected methyl ester 144 was treated with diisobutylaluminium hydride 
(DIBAL-H) in toluene at -78 °C, to afford the aldehyde 145, which was used 
immediately without further purification to prevent any decomposition from occurring. 
The presence of the aldehyde proton was observed in the 1H NMR spectrum by a signal 
at 9.7 ppm as a singlet. Treating the aldehyde with hydroxylamine hydrochloride and 
sodium acetate, afforded the desired oxime 146 as a colourless oil (70-87 %). Often the 
oxime precipitated out as a solid if it was dissolved in the minimum amount of ethanol 
and left in the fridge overnight, otherwise, the oxime was extracted with ethyl acetate. 
The oxime 146 was isolated as diastereoisomers, both syn and anti oximes being 
observed, which is consistent with the literature report.45   
 
d) 1,3-Dipolar cycloaddition and nitrile oxides 
 
1,3-Dipolar cycloaddition reactions are used to make five-membered rings, with one or 
more heteroatom. These are considered to be concerted reactions, whereby two new 
bonds are formed and one is broken. They require a 1,3-dipole, which consists of three 
atoms with a four π electron system, and a dipolarophile which can be a simple alkene 
consisting of a two π electron system. Two new σ-bonds are made at the expense of two 
π-bonds.   
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The electrons in the dipole are delocalised over the three atoms. An important feature of 
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the 1,3-dipole is that it has both nucleophilic and electrophilic ends, as shown by the 
example resonance structures below.    
 
                                              Nitrile oxide 
NC O NC OR R  
                                             
This thesis focuses on nitrile oxide dipoles. Nitrile oxide species are very reactive and 
often are short-lived. In the absence of reactants, or if the concentration of the nitrile 
oxides at any one time is high, they will react with themselves. We employed the 
cycloaddition of a nitrile oxide with an olefin to develop an isoxazole as a key step in our 
synthetic strategy.   
  
Formation of the isoxazole 149 proved to be difficult at first, followed by a second 
challenge, which was to improve the yield of the isoxazole 149 (Scheme 29). In order to 
obtain a reasonable yield of the cycloaddition product, it was necessary for the oxime 146 
to be dry prior to use. This was achieved by drying the oxime 146 in a vacuum desiccator 
over phosphorus pentoxide, followed by drying in a vacuum oven. The dry oxime 146 
was then treated with freshly distilled DCM under a nitrogen atmosphere, followed by 
addition of N-chlorosuccinimide (NCS), and the mixture was heated at reflux for 2 h 
(Scheme 29). The progress of the reaction was monitored by TLC analysis and as a 
result, a further portion of NCS was added, and the reaction mixture was heated at reflux 
overnight. The formation of a blue/green solution indicated the formation of the chloro-
oxime 147. The isolation of the chloro-oxime 147 proved optional, it could either be 
isolated by simple extraction with ethyl acetate to remove any impurities, or it was 
possible to carry out the next reaction in situ. The cycloaddition partner, the enamine 148, 
previously prepared from ethyl acetoacetate and pyrrolidine in toluene under Dean-Stark 
conditions, was added in excess to the chloro-oxime 147. Triethylamine was then added 
dropwise to the reaction mixture to form the reactive nitrile oxide species. The nitrile 
oxides are very reactive so it could react with various species present, including itself; 
therefore the concentration of the nitrile oxide was kept at a minimum, which should 
increase the likelihood of reacting with the cycloaddition partner 148 via a 1,3-dipolar 
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cycloaddition reaction. Finally a spontaneous elimination of pyrrolidine followed to form 
the isoxazole 149, the yield varying between 40-50 % after purification by column 
chromatography.  
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e) Deprotection of the amines 
 
The deprotection was necessary in order to free the amine to allow the formation of the 
bicyclic pyridone 151 (Scheme 30). Removal of the amine protection was achieved 
readily by the addition of trifluoroacetic acid to the isoxazole 149, followed by treatment 
with hydrochloric acid (HCl, 2M) to afford the less hygroscopic dihydrochloride salt 150 
in excess of 85 % yield.  
                    
f) Formation of the isoxazolopyridone building block  
 
The dihydrochloride salt 150 was treated with aqueous sodium carbonate solution, and 
stirred overnight to yield the bicyclic pyridone 151 (Scheme 30). Sodium carbonate 
removes the hydrochloride salt releasing the amines, which activates spontaneous ring 
cyclisation by condensation with the ester group to form a six-membered ring. The 
formation of the five-membered ring is not observed, these are difficult to synthesise due 
to the ring strain. It has been previously shown in the tetramic acid series, the formation 
of the five-membered ring does not readily occur in a simple ring closure between the α-
amino substituent and the C-4 ester of the isoxazole.71,46  In a more complex procedure, 
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peptide coupling was employed to form an active ester, which then proceeded on to form 
a five-membered ring. Thus, in our case the α-amine does not take part in the cyclisation 
step to form a five-membered ring, whereas the β-amine is more readily involved to 
afford the six-membered ring, with the reduced ring strain provided by the extra sp3 
carbon, when compared to the alternative five-membered ring.  
 
Finally to introduce the C6-C-7 unsaturated bond in the isoxazolopyridone, the free 
amine 151 was treated with sodium nitrite and 2M HCl in water for 1 h at 0 ºC and then 
at 50 °C for another hour.  Upon treating the free amine 151 with a solution of sodium 
nitrite in HCl (2M), nitrous acid forms, which then undergoes dehydration forming a 
nitrosonium cation. The nitrosonium cation interacts with the amine forming a diazonium 
salt at 0 °C and as heat is applied, the stable dinitrogen molecule is lost readily leaving a 
cation intermediate, which undergoes spontaneous elimination of a proton to provide 
extra conjugation to furnish the desired isoxazolopyridone 1. This diazotisation reaction 
has proven to be very successful and yield of the isoxazolopyridone has reached 80 %.   
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Following the synthetic strategy, the isoxazolopyridone 1 has been synthesised in seven 
steps from the commercially available 2,3-diaminopropionic acid monohydrochloride. 
However due to the high cost of the 2,3-diaminopropionic acid monohydrochloride, we 
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investigated the use of other amino acids, such as β-alanine as a cheaper alternative. In 
addition, the inexpensive β-alanine ethyl ester hydrochloride is commercially available; 
therefore the esterification step of the acid is avoided, which can take up to a week to 
ensure full conversion to the corresponding acid.     
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2.2 β-Alanine route 
 
2.2.1 Synthesis of the bicyclic lactam 
 
An alternative route to the isoxazolopyridone 1 was the use of other amino acids, in this 
particular case a cheaper alternative to the 2,3-diaminopropionic acid monohydrochloride 
was the β-alanine ethyl ester 152. A similar synthetic route was employed in the β-
alanine series to develop the bicyclic lactam 157 (Scheme 31). The bicyclic lactam was 
synthesised in five steps following the same sequence employed previously with the 2,3-
diaminopropionic acid monohydrochloride 142. 
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a) Amine Protection 
 
The β-alanine ethyl ester 152 is commercially available, therefore the esterification step 
is avoided. We were able to employ the N-protection of the amine immediately. The N-
protection of the β-alanine ethyl ester 152 was achieved readily, by adding triethylamine 
to a solution of β-alanine ethyl ester 152 in DCM at 0 °C, followed by the addition of di-
tert-butyl dicarbonate. The reaction mixture was stirred at 23 ºC for 24 h and after an 
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aqueous workup the N-Boc-β-alanine ethyl ester 153 was formed in quantitative yield 
(Scheme 31).  
 
b) Oxime Formation   
 
The next step involved the preparation of the oxime 154 via the corresponding aldehyde. 
The N-Boc-β-alanine ethyl ester 153 was treated with diisobutylaluminium hydride 
(DIBAL-H) in toluene at -78 °C over a period of 1 h, to afford an aldehyde, which was 
used without further purification. We were concerned about the stability of the aldehyde 
to a possible β-elimination, we therefore treated this immediately with an aqueous 
solution of hydroxylamine hydrochloride and sodium acetate, followed by a workup, 
which afforded the desired oxime 154 as a colourless oil in 85 % yield. The oxime was 
isolated as diastereoisomers, both syn and anti oximes being observed.  
 
c) Formation of the isoxazolopyridone via 1,3 dipolar cycloaddition  
 
The 1,3-dipolar cycloaddition reaction was pursued to develop the isoxazole 155. The 
oxime 154 prepared previously was dried in a vacuum desiccator over phosphorus 
pentoxide, followed by drying in a vacuum oven. The oxime 154 was then dissolved in 
dry DCM and NCS was added under a nitrogen atmosphere. The reaction was monitored 
by TLC analysis and as a result a second batch of NCS was required. The resulting 
mixture was heated at reflux for 24 h. The reaction mixture was cooled to 23 °C and the 
cycloaddition partner, the enamine 148 was added in excess to the chloro-oxime, 
followed by the dropwise addition of triethylamine over a period of 1 h to form the 
reactive nitrile oxide species. The mixture was heated at reflux for a further 24 h, to 
follow a spontaneous elimination of pyrrolidine to form the isoxazole 155 in 65 % yield. 
This is an improved yield compared to the isoxazole 149 (50 % yield) from the 2,3-
diaminopropionic acid monohydrochloride route.   
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d) Deprotection of the amine 
 
Removal of the amine protection was readily achieved by the addition of excess 
trifluoroacetic acid to the isoxazole 155, followed by treatment with hydrochloric acid 
(2M), to afford the less hygroscopic hydrochloride salt 156 in 99 % yield.  
 
e) Lactam formation 
 
The bicyclic lactam 157 was formed from a base-promoted cyclisation of the 
hydrochloride salt 156. The hydrochloride salt 156 was dissolved in water and treated 
with sodium carbonate. The resulting mixture was stirred for 24 h at 23 ºC. The reaction 
mixture was extracted with ethyl acetate, dried and the solvent was removed under 
reduced pressure to leave an off white solid in 80 % yield, which did not require further 
purification. As mentioned previously, the cyclisation favours the formation of the six-
membered ring compared to the analogous five-membered ring due to the reduced ring 
strain provided by the extra sp3 carbon in the six-membered ring.  
 
Further investigation could be conducted to improve the yield of the isoxazole 149 and in 
particular isoxazole 155. A recent publication has reported the oxidation of oximes to 
nitrile oxides with hypervalent iodine (Scheme 32).47 Methanol and a catalytic amount of 
TFA were used as the solvent, which provided the best yields. These reaction conditions 
are to be considered in the future for further investigation to increase the yield of the 
isoxazoles, but due to time constraints this was not pursued at present.     
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2.2.2 Development of the C6-C7 unsaturation 
 
Following the β-alanine route has its consequence: the α-amine is no longer available as 
seen in the 2,3-diaminopropionic acid route, and therefore diazotisation is no longer an 
option to introduce the C6-C7 unsaturation.   
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There have been a number of strategies previously attempted to develop the C6-C7 
unsaturation, including dehydrogenation using Pd/C and 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ).48, 49 But these were unsuccessful, instead we planned to generate 
an N-chlorolactam and investigate dehydrochlorination.  
 
a) N-chlorination 
 
To introduce the unsaturated bond, we pursued the N-chlorination strategy. This involved 
chlorination at the N-5(H) of the bicyclic lactam 157 to yield the N-chlorolactam 158 
(Scheme 33), which would take part in a photolytic dehydrochlorination to yield the 
desired isoxazolopyridone 1 (Scheme 36). Simple base mediated dehydrochlorination had 
proved unsuccessful for a previous worker.99  
 
The N-chlorination was achieved using tert-butyl hypochlorite (Scheme 33), a reagent 
described by Mintz and Walling.50 This was prepared by treating tert-butanol and glacial 
acetic acid in commercial bleach (250 ml). Although best used freshly prepared, it was 
found to be possible to store this reagent at 0 °C in the absence of light to avoid 
decomposition. Without any significant decomposition the tert-butyl hypochlorite was 
added to a solution of the bicyclic lactam 157 in methanol to yield the N-chlorolactam 
158 as a white solid in 82% yield. The 1H NMR spectrum of this compound 158 
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demonstrated a downfield shift of the C-6/7 protons due to the presence of the 
electronegative chlorine, and the absence of a broad N-H signal verified that the N-
chlorination had taken place.      
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N-chloro compounds have received attention in organic synthesis, in industry and the 
medicinal field, and more recent studies have described simple methods of preparing N-
chloro compounds.51 Here the authors have reported a clean and efficient method of 
synthesis under mild conditions using trichloroisocyanuric acid (TCCA) (Scheme 34). 
The use of this reagent is growing rapidly and is finding its way into commercial 
products, such as detergents and disinfectants. It is hoped that this method might be 
employed successfully in our sequesnce to enhance our current yield.      
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Scheme 34 
 
 
b) Photolytic dehydrochlorination 
 
Next step in the preparation of the unsaturated pyridone 1 was by using a UV light source 
in a photolytic dehydrochlorination reaction, which would initiate radical cascade 
reactions to eventually form the unsaturated pyridone precursor 1. A reasonable pathway 
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(Scheme 35)52  would involve the homolysis of the N-Cl bond (Eq 1), followed by 
hydrogen abstraction from C-6 of the N-chlorolactam 158 to leave the radical 160 (Eq 2). 
This radical 160 would undergo β-scission to afford the acyl imine 161 and regenerate the 
chlorine atom (Eq 3), and then tautomerise to yield the favourable acyl enamine 
tautomer, i.e. the isoxazolopyridone 1 (Eq 4).  
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Scheme 35 
 
The N-chlorolactam 158 in freshly distilled methanol was degassed for 10 minutes under 
a constant nitrogen flow in the presence of two home Solaria UV lamps. The reaction was 
monitored using TLC analysis: no change was observed for the first 2 h, but after 4 h a 
yellow solution developed, and the TLC analysis revealed a second spot. The reaction 
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was allowed to proceed for an additional 1 h, after which point the solvent was 
concentrated and the residue purified by column chromatography to yield the 
isoxazolopyridone 1 in 40 % yield, or 60% yield based on the recovery of the starting 
material. However, the results were not consistent when repeat reactions were carried out 
with this light source.  
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Scheme 36 
 
Further investigation followed using a medium-pressure Hg Hanovia lamp in a water-
cooled quartz vessel. The N-chlorolactam 158 in methanol was purged with nitrogen for 
15 minutes before irradiation with the lamp for 1 h, to yield the isoxazolopyridone 1 in 
80 % yield as our best procedure. The starting bicyclic lactam 157 was also recovered, 
which can be re-used.  
 
The regeneration of the bicyclic lactam 157 is proposed via two possible mechanisms in 
competing processes by chlorination of the solvent (Scheme 37, Eq 5).52 The chlorine 
atom is terminated as HCl is formed (Eq 6). Under acidic conditions, the N-chlorolactam 
158 is converted to the bicyclic lactam 157 (Eq 7) as the by-product chlorine forms.  
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Scheme 37 
 
 
During a placement period at Syngenta, an alternative light source was used as the 
medium-pressure Hg Hanovia lamp was unavailable, and as a substitute a tungsten UV 
lamp was utilised. The N-chlorolactam 158 in methanol was degassed for 10 minutes 
under a constant nitrogen flow, before being irradiated with the light source. The reaction 
was constantly monitored by TLC analysis, which showed all the starting material had 
been consumed after 5 h. Following work up and purification, the desired 
isoxazolopyridone 1 was obtained in a low yield and often in repeat reactions this was 
only observed in trace amounts. The unexpected 7-chloroisoxazolopyridone 162 was 
isolated as the major product up to 40 % yield (Scheme 38), which was obtained in a 
mixture with the 6,7-dichlorodihydroisoxazolopyridone 163. It was possible to heat this 
mixture at 50 ºC under basic conditions, to ensure complete conversion to the 7-
chloroisoxazolopyridone 162. This elimination reaction confirms the presence of the 6,7-
dichloroisoxazolopyridone 163. The reactions were repeated several times, the reaction 
conditions were altered, and even the use of different glassware was also investigated to 
give only the same result.  
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Scheme 38 
 
To account for the formation of the chlorinated species, a possible mechanistic proposal 
via an electrophilic addition reaction is shown below (Scheme 39), which would follow on 
from formation of the unsaturated compound 1 as shown previously. The reaction 
between the unsaturated pyridone 1 and a chlorine molecule results in the imine 164 (Eq 
9), which undergoes addition with a chloride ion to give the di-chloro adduct 163. Finally 
elimination of hydrogen chloride follows, to leave the 7-chloroisoxazolopyridone 162.    
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Scheme 39 
 
 
The 7-chloroisoxazolopyridone 162 seems to be the major product other than the 
recovery of the saturated bicyclic lactam 157; the new light source could be advantageous 
if the reaction conditions could be optimised to afford a higher yield of this compound. 
Our interest lies in such halides, since we wish to pursue Suzuki cross coupling reactions 
between such alkenyl halides and boronic acids, to develop new C-C bonds at C-7. From 
a mechanistic aspect, we are chlorinating the C-6 and C-7 of the isoxazolopyridone, 
therefore we thought we might be able to increase the yield of the 7-
chloroisoxazolopyridone 162 by introducing a chlorine source. We introduced NCS to the 
reaction mixture during the photolytic dehydrochlorination step, and monitored the 
reaction progress by TLC analysis, but upon reaction completion and purification of the 
crude material, the same results were obtained as in the previous case and no change in 
the yield was observed (Scheme 40).    
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c) Alternative radical approach 
 
An alternative route to introduce the double bond in the C-6 and C-7 position of the 
bicyclic lactam 157, was to investigate the use of radical H-atom abstraction methods. 
Radical reactions are very useful, since radicals can be used as intermediates in reactions, 
which may be difficult to achieve via other routes. They are formed by homolysis, by 
either applying light or heat, or radical initiators are used to form reactive radical species, 
examples including AIBN and ACCN.    
 
To pursue our interest in this new strategy, the bicyclic lactam 157 was treated with the 
initiator 1,1-azobis(cyclohexanecarbonitrile) (ACCN) in the presence of N-
bromosuccinimide (NBS) under anhydrous conditions (Scheme 41). NBS is a good 
source of bromine atoms, “Br•”, and releases molecular bromine slowly during the 
reaction and as a result, keeps its concentration low. This is important to prevent any side 
reactions from occurring. The reaction was carried out in cyclohexane, which was 
degassed for 10-15 minutes prior to use. In the early stages of the reaction, cyclohexane 
was selected as a suitable solvent due to its high boiling point, as the initiator ACCN 
undergoes thermal homolysis at 60-70°C to generate the reactive radical species. A 
possible mechanism for this reaction would proceed through a series of radical chain 
reactions. Initially, the homolysis of the initiator forms the stabilised cyclohexane nitrile 
radicals (Eq 12), followed by the formation of the N-succinimide radical (Eq 13), which 
could abstract a hydrogen atom from the bicyclic lactam 157 (Eq 14). In the next step (eq 
15), the radical formed 165 should be able to abstract the bromine atoms from NBS, 
which is known to be a good source of bromine. Finally re-aromatization of the ring 
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would take place with the loss of hydrogen bromide to yield the unsaturated pyridone 1 
(Eq 1). Similar mechanisms have been reported by Wohl-Zeigler.53   
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In the first attempt, 8% of the initiator ACCN and 1.2 equivalents of NBS were used. The 
initiator ACCN, the bicyclic lactam 157 and NBS freshly recrystallised (from water) in 
cyclohexane were heated at refluxed overnight. Following analysis, the 1H NMR 
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spectrum revealed signals corresponding to the starting material, however TLC analysis 
revealed 3 spots with distinguishable Rf values. Purification by column chromatography 
resulted in recovery of the bicyclic lactam 157, and a trace amount of the 7-bromo-3-
methyl-5H-isoxazolo[4,3-c]pyridin-4-one 167.   
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The 7-unsubstituted isoxazolopyridone 1 was not observed, and to account for the 
formation of the 7-bromoisoxazolopyridone 167, it is possible that after a first 
bromination, a second bromination via hydrogen abstraction took place at the same 
position, C-7 (Scheme 42, Eq 17/18). A radical formation at this position 168 is favored 
due to the extra stability offered by the electron withdrawing bromine substituent. The 
reaction proceeds with the elimination of hydrogen bromide from 169, to yield the 7-
bromoisoxazolopyridone 167 (Eq 19).  
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Scheme 42 
 
Despite no trace of the 7-unsubstituted isoxazolopyridone 1, this route provided access 
the 7-bromoisoxazolopyridone 167 in one step from the bicyclic lactam 157, therefore it 
might be possible to carry out a Suzuki cross-coupling reaction with this compound and 
thus avoid the halogenation reaction of the isoxazolopyridone 1 (see later). However, it 
was necessary to obtain a good yield of 7-bromoisoxazolopyridone 167 in order to 
continue with the Suzuki cross-coupling reactions.  
 
Many attempts were made to increase the yield of the 7-bromo compound 167 by altering 
the reaction conditions. The ACCN initiator was substituted by azobisisobutylonitrile 
(AIBN), since there have been many reports of successful radical brominations using this 
initiator.54 The thermal decomposition of AIBN begins at 60 °C to form the radical 
species as the stabilised nitrile intermediate (Scheme 43).  
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A range of solvents were investigated in these reactions and it was discovered that the 
bicyclic lactam 157 had limited solubility in cyclohexane and toluene. Carbon 
tetrachloride is widely used in radical reactions, and after exploiting this solvent under 
the current reaction conditions, it provided a 30 % yield of the 7-bromo 
isoxazolopyridone 167, and also there was no observation of the non-halogenated 
isoxazolopyridone. The use of other solvents such as cyclohexane and toluene provided 
poor results and the majority of the starting material was recovered. The experimental 
procedure was then slightly adjusted due to the reactive nature of radicals: the initiator, 
AIBN was added in small portions every hour for 5 h under nitrogen, and the mixture 
was heated at reflux overnight. Conducting the reaction in tert-butanol, provided an 
improved yield of the 7-bromoisoxazolopyridone 167 of 30-35 % based on the recovery 
of the starting material.   
 
Further investigation into the 7-bromoisoxazolopyridone 167 via radical reactions led to 
pursuing similar reactions in the presence of tributyltin. The reaction did not prove 
successful and only a trace of 7-bromoisoxazolopyridone 167 was observed.  
 
The radical reactions were investigated further using N-iodosuccinimide (NIS) as an 
alternative source of halogen. The Suzuki cross coupling reactions between a halide and 
organoboron compounds often proceeds more efficiently as the reactivity increases with 
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R-X, X = I > Br > Cl. NIS is a good source of iodine atoms and iodine, and a well known 
iodination reagent. The electrophilic iodine allows good stereoselective reactions on a 
range of functional groups. The radical reaction described previously was employed once 
again, but using the electropositive iodine source. Unfortunately, only trace amounts of 7-
iodoisoxazolopyridone 170 was observed and the starting material 157 was recovered. 
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                                                                    170 
Another approach to the unsaturated isoxazolopyridone 1 was investigated using an 
alternative radical approach with the highly reactive triethylborane reagent (Scheme 44). 
The proposed reaction mechanism requires dioxygen, itself a radical, to attack the borane, 
thereby producing the ethyl radical. The ethyl radical abstracts a labile hydrogen atom 
from C-6 of the isoxazolopyridone 157, producing ethane as the by-product, which would 
be followed by further H-atom loss from the ring to yield the desired isoxazolopyridone 
1. 
 
Triethylborane ignites spontaneously in air therefore care needs to be taken while 
handling this reagent. The procedure applied was as follows; to a round bottomed flask 
was added the bicyclic lactam 157 and freshly distilled dry DCM. The flask was purged 
with nitrogen to ensure it was oxygen free, and fitted with a rubber septum. 
Triethylborane in excess was added via a syringe directly into the solution avoiding the 
walls of the flask. Whilst the solution was being constantly stirred, a small needle was 
inserted into the rubber septum to allow a slow flow of oxygen. The mixture was stirred 
overnight, followed by TLC analysis, which confirmed only one spot corresponding to 
the starting material. A second treatment with triethylborane in the same manner was 
applied, however following another day of stirring and TLC analysis, only the starting 
material was recovered.     
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Thus the best yield obtained for the 7-bromoisoxazolopyridone 167 from the saturated 
bicyclic lactam 157 was 35 %. This compares to the preparation of the unsubstituted 
isoxazolopyridone 1 by N-chlorination (82 %) and photolytic dehydrochlorination 
(80 %). Subsequent halogenation of 1 is discussed in the next section.    
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2.3 Elaboration at the C-7 of the isoxazolopyridone 
 
2.3.1 Methodology  
 
Having constructed the isoxazolopyridone building block, we require to elaborate at the 
sites C-3’ (Me), C-7, and N-5 (Figure 1). By accessing these sites we will be able to work 
towards the family of natural products containing the 3-acyl-4-hydroxypyridone core. A 
number of strategies are proposed to achieve elaboration at these sites, which will allow 
the development of natural and unnatural analogues.   
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                                                                  1 
                                                             Figure 1 
 
We investigated anion-type chemistry to construct a polyene side chain at C-3’, Suzuki 
cross-coupling reactions, with a palladium-based catalyst for C-C coupling to develop 
aryl substituents such as the 4-hydroxyphenyl group at C-7, and N-oxidation to develop 
hydroxamic acid functionality at N-5. 
 
After the successful synthesis of the isoxazolopyridone precursor 1, we required to 
elaborate and functionalise at the C-7 position. The methodologies developed are based 
around a 7-iodo compound, and its participation in a Suzuki cross coupling reaction with 
an organoboron compound to develop aryl substituents. The iodine substituent at the C-7 
position would lead to an electrophilic isoxazolopyridone, which can be used in Suzuki 
cross-coupling reactions in the presence of a Pd(0) catalyst to introduce aryl groups. The 
methodology to develop such a 7-iodo compound utilises iodine monochloride (ICl). This 
reagent serves as good iodinating agent, since chlorine is more electronegative than 
iodine, and this ICl acts as a good source of “I+”.  
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The isoxazolopyridone 1 was treated with ICl and stirred at 23 °C for 72 h, when the 
resulting precipitate was filtered to yield the 7-iodo-3-methyl-5H-isoxazolo[4,3-
c]pyridin-4-one 170 in a 60-70 % yield (Scheme 45).  
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2.3.2 Suzuki cross-coupling reactions 
 
With the 7-iodo-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 170 in hand, we continued 
the synthesis towards the natural product tenellin 3. The natural product has a phenolic 
aryl ring at the C-7 position. To achieve this, we investigated the Suzuki cross-coupling 
reaction, with a palladium-based catalyst for C-C coupling. There have been many 
advances in palladium-catalysed C-C coupling. The Suzuki palladium-catalysed cross-
coupling reactions of organoboron55 compounds with organohalides have been found to 
be extremely efficient, and an important tool in the synthesis of biaryls.56, 57 This method 
of synthesising biaryls has many advantages; 
 
¾ Relatively experimental conditions  
¾ Tolerant to many functional groups, weak nucleophilic characteristic of boronic 
acids tolerates reactants containing groups such as aldehydes, ketones and nitriles  
¾ Stability of boron reagents in air and moisture  
¾ Boron reagents usually non toxic 
¾ Easy removal of side products from mixture  
¾ Accessibility of a wide range of commercially available boronic acids 
 
A range of C-C coupling reactions have been reported previously; the cross coupling 
reactions are accessible using a variety of organometallic reagents, as reported by 
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Tamaoin 1972. 58 A number of palladium-catalysed reactions for Grignard reagents were 
first reported by Murahashi.59 The use of organoboron compounds has been extensively 
studied by Miyaura and Suzuki. Organoboron compounds are extremely electrophilic, 
and the organic groups attached to the boron are weakly nucleophilic, therefore limiting 
the use of these compounds. However, with the addition of a base to generate a boronate, 
the nucleophilicity is enhanced.  
 
The mechanistic cycle for the palladium-catalysed cross-coupling reaction, between aryl 
halide and an organoboron reagent involves 3 stages, oxidative addition, transmetallation 
and reductive elimination (Scheme 46). The oxidative addition step to the aryl halide is 
the rate determining step, and the reactivity decreases with R-X, X = I > Br > Cl. In the 
first step, oxidative addition proceeds smoothly between the Pd(0) and Ar-X to form a 
stable trans-σ-Pd(II) complex. For the transmetallation step to proceed with an 
organoboron compound, it is crucial to use precise reaction conditions and reagents. 
Organoboron compounds have been previously reported to be inert to organopalladium 
halides, and do not take part in the transmetallation step under neutral conditions, as the 
organoboron compounds are electrophilic and the attached organic groups are weakly 
nucleophilic. Under neutral conditions, the cross-coupling reaction between Ar-I and 
Ar’B(OH)2 at pH = 7.5-8.5 is hindered, however the reaction proceeds smoothly in 
aqueous solution with a negatively charged base, such as sodium carbonate at pH = 9.5-
11. 60 , 61  The pKa values of phenylboronic acid  and carbonate are 8.8 and 10.3 
respectively, therefore it is assumed the transmetallation step proceeds via the boronate 
anion RB(OH)3- , which is formed upon addition of the base to enhance the 
nucleophilicity as pH > pKa. The formation of the boronate anion RB(OH)3- at pH = 11-
12 has been previously reported.62 After transmetallation the reductive elimination step 
regenerates the palladium(0) catalyst and releases the Ar-Ar’ complex. The reaction 
proceeds as the cis-complex is formed via a cis-trans isomerisation. The order of 
reactivity for the reductive elimination step decreases with; diaryl- > (alkyl)aryl- > 
dipropyl- > diethyl- > dimethylpalladium(2). This is due to the possible interaction of the 
π-orbital of the aryl groups as the cis complex is formed (Scheme 47).  
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There are various Pd(0)-based catalysts used in Suzuki-type reactions, common ones 
include tetrakis(triphenylphosphine)palladium Pd(PPh3)4, or the Pd(II) species, palladium 
acetate Pd(OAc)2 and palladium chloride PdCl2(PPh3)2 that are reduced to Pd(0) in situ. 
In our first attempt, the Suzuki reaction was followed using the catalyst Pd(PPh3)4 
(Scheme 48). The procedure applied was as follows: to a degassed solution of 1,4-
dioxane were added 7-iodo-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 170 and 
Pd(PPh3)4 (8 mol%). The resulting solution was degassed again for another 10 minutes. 
To this solution, 4-hydroxyphenylboronic acid in degassed ethanol and aqueous sodium 
carbonate (2M), in degassed water were added sequentially. The resulting solution was 
heated at reflux for 18 h. Following work up, the crude residue was purified by column 
chromatography to leave the 7-(4-hydroxyphenyl)isoxazolopyridone 172 in 80-85 % 
yield.  
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In order to further optimise the reaction, we explored the use of alternative solvents and 
catalyst (Table 2). The reactions were repeated with Pd(OAc)2 (20%) and 
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triphenylphosphine to create  Pd(0) in situ, however only the starting material was 
recovered. Reactions with Pd(OAc)2 were monitored by TLC, and there were only two 
spots throughout the reaction corresponding to the starting materials, and no product was 
isolated in these reactions. Altering the reaction conditions, by varying the solvent and 
the base also resulted in recovery of the starting material. We therefore utilised the 
method described in Scheme 48 to develop the aryl substituents. 
Table 2 
Solvent Base Catalyst Result 
1,4-dioxane Sodium carbonate Pd(PPh3)4 80-85 % product 
1,4-dioxane Potassium carbonate Pd(OAc)2  SM 
1,4-dioxane Sodium carbonate Pd(OAc)2  SM 
Dimethoxy ethane Potassium carbonate Pd(OAc)2  SM 
 
Earlier the unexpected 7-bromoisoxazolopyridone 167 was reported, and our radical 
route allowed us to acquire the 7-bromoisoxazolopyridone 167 directly from the bicyclic 
lactam 157. Therefore, we felt it might be possible to carry out a Suzuki cross-coupling 
reaction with this compound, and thus avoid the halogenation reaction of the 
isoxazolopyridone 1. However, it was necessary to obtain a good yield of the 7-
bromoisoxazolopyridone 167, and our investigation achieved a 35 % yield (Scheme 49). 
We investigated a Suzuki cross-coupling reaction of the 7-bromoisoxazolopyridone 167 
with 4-hydroxyphenylboronic acid using the procedure developed previously. The 
reaction was indeed successful but only 35 % of the desired 7-(4-
hydroxyphenyl)isoxazolopyridone adduct 172 was isolated. Thus overall the approach via 
iodination of the isoxazolopyridone 1 was felt to be more practical.   
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After establishing a suitable method of synthesis of biaryls by means of a Suzuki cross-
coupling reaction with the catalyst Pd(PPh3)4, we explored the use of other organoboron 
reagents as a substitute for the 4-hydroxyphenylboronic acid. It is possible the 4-
hydroxyphenyl group might interfere with the aldol chemistry at the isoxazolopyridone 
C-3’(Me) during the construction of the C-3 side chains, therefore 4-
benzyloxyphenylboronic acid was explored as an alternative. In this case, with the benzyl 
protection we could rule out the possibility of the anion formation at this position in the 
presence of a strong base such as n-BuLi.   
 
The same procedure was applied using 1,4-dioxane, Pd(PPh3)4, 4-
benzyloxyphenylboronic acid and sodium carbonate solution (Scheme 50). However, this 
particular coupling product was difficult to isolate due to several spots on the TLC plate 
with similar Rf values. Following further purification, only a trace amount of the coupled 
product 173 was isolated. Changing the reaction conditions by varying the solvent and 
the catalyst to dimethoxyethane (DME) and Pd(OAc)2, afforded the desired coupled 
compound  173 in just 30% yield, which also proved to be difficult to purify.  
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We continued the Suzuki cross-coupling reaction with the commercially available 
phenylboronic acid. The original procedure was utilised using phenylboronic acid, 1,4-
dioxane, Pd(PPh3)4 and sodium carbonate solution. Following work up, the crude 
material was purified by column chromatography to leave the 7-
(phenyl)isoxazolopyridone 174 in 67 % yield (Scheme 51).  
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Scheme 51 
 
It has recently been demonstrated that an aryl halide with Pd(0) catalyst can take part in 
direct arylation via an electrophilic aromatic substitution mechanism of a nucleophilic 
partner, for example the 2-substituted thiazoles in water (Scheme 52).63 The reactions 
also work in a similar manner in acetonitrile and silver carbonate, which could act as a 
silver source or a base but the exact role of this remains unclear.   
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The reaction conditions were then exploited in the next reaction with the 
isoxazolopyridone 1 in which C-7 can be regarded as a nucleophilic ‘enamine’ centre. 
The palladium catalyst, Pd(PPh3)4,  isoxazolopyridone, iodobenzene and silver carbonate 
in water were heated 60 ºC to afford the 7-(phenyl)isoxazolopyridone 174 in 12 % yield 
(Scheme 53). Although the yield is low, we have demonstrated the cross coupling 
reaction can be carried out in water as a green solvent. To optimise the reaction 
conditions, acetonitrile may well serve as a better solvent, and both the catalyst loading 
and the reaction temperature could be increased. However no further experimentation 
was conducted and this approach remains to be optimised.       
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We have successfully developed the aryl ring at the C-7 position of the 
isoxazolopyridone. The Suzuki cross-coupling reaction of an organoboron compound and 
the 7-iodoisoxazolopyridone 170 led to the development of the 7-substituted phenyl 174, 
4-hydroxyphenyl 172, and 4-benzyloxyphenyl 173 isoxazolopyridones. The 7-
(phenyl)isoxazolopyridone 174 has also been synthesised via the electrophilic aromatic 
substitution of the isoxazolopyridone by an organopalladium halide, however our 
preferred method to date of synthesising these compounds follows the Suzuki cross-
coupling reaction between the organoboron compound and the halopyridone.   
 
 
The Suzuki cross coupling reactions using the 7-iodo and 7-bromo compounds were 
successful in the development of the 7-(phenyl)isoxazolopyridones and analogues. 
Having developed a suitable procedure, we continued this by attempting to use the 7-
chloroisoxazolopyridone 162 to construct the 7-(phenyl)isoxazolopyridone  according to 
the procedure developed previously. The 7-chloroisoxazolopyridone 162 was treated with 
its coupling partner, phenylboronic acid in the presence of Pd(PPh3)4, to only afford the 
starting material. It was therefore concluded that the conditions developed previously are 
not suitable for the cross-coupling reaction with aryl chlorides. The cross coupling 
reactions with chlorides are generally known to be difficult. The mechanism for the 
palladium catalysed cross-coupling reaction suggests the oxidative addition step is the 
rate determining step, and the reactivity decreases with R-X, X = I > Br > Cl. The 
chlorides are generally inactive and due to their high bond dissociation energy, for 
instance Ph-X: Cl 96, Br 81 and I 65 kcal mol-1, they are slow during the oxidative step to 
add to the Pd(0) centre.64  
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We nevertheless found several reports of successful cross-couplings of inactivated aryl 
chlorides and bromides by Buchwald and co-workers.65 They reported the use of general 
catalysts in Suzuki-Miyaura coupling reactions of aryl chlorides in water. Reactions 
conducted in water are environmentally friendly since water is non-toxic, non-flammable 
and its low cost. Much of the report focused on electron poor aryl chlorides, which are 
activated towards the oxidative addition step.   
      
Using the catalysts reported, we investigated the coupling reaction between the 7-
chloroisoxazolopyridone 162 and phenylboronic acid (Scheme 54). In the first instance, 
the alkenyl chloride was not protected as several reports have debated the need to protect 
functional groups, such as amines and alcohols prior to the coupling reactions.66 These 
reactions often depend on the basicity of the heteroaryl chlorides, and strong basicity 
could increase the chance to coordinate to the palladium, and as a result terminate the 
catalytic cycle. The selection of ligands is also crucial, especially with inactivated aryl 
chlorides, and the correct choice of ligand would aid the oxidative addition and reductive 
elimination steps. The use of a bulky ligand would increase the electron density of 
palladium when complexed to an electron rich alkyl phosphine, such as the 
trialkylphosphane (PCy3) compared to an aryl phosphine, which would accelerate this 
step by facilitating the oxidative addition of the Ar-Cl to the Pd(0).  
 
The reactions were investigated using ligands 1 and 2, both containing the bulky PCy 
group, where ligand 1 contains a water solubilising sulfonate group. Initially the 7-chloro 
compound 162 was treated with ligand 1 in water, under microwave conditions (Scheme 
54), to only afford the starting material and a trace amount of the 7-
(phenyl)isoxazolopyridone 174. In a second reaction, using the same reactants with 
ligand 2 and heating at reflux in toluene gave the same result.  
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Scheme 54 
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OMeMeO
SO3Na
PCy2
OMeMeO
 
 
                                         ligand 1              ligand 2 
With these poor findings, further reactions were explored using the protected 7-
chloroisoxazolopyridone 177, which was achieved by treating the 7-
chloroisoxazolopyridone 162 with 4-methoxybenzyl bromide (Scheme 55). Further 
reactions made use of both ligands 1 and 2 under microwave and reflux conditions (Table 
3), to afford mainly starting material and only trace amounts of the biaryl product 174.  
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Table 3 
 
R Group Solvent Reaction conditions Ligand Base 
R=H Water MW at 150 ºC 10 mins 1 K2CO3 
R=H Toluene Reflux 24 h  2 K3PO4 
R=Bn Water MW at 150 ºC 10 mins 1 K2CO3 
R=Bn Toluene Reflux 24 h  2 K3PO4 
R=Bn Toluene MW at 150 ºC 10 mins 2 K3PO4 
 
Further investigation into coupling reactions of the aryl chloride was followed using 
Grignard reagents, commonly seen in the Kumada reaction.67 This type of reaction is still 
young in the synthetic field compared to the reactions described previously. The use of 
Grignard reagents is often limited due to their incompatibility with functional groups. 
The following reactions were conducted based on the literature method; the benzyl 
protected 7-chloroisoxazolopyridone 178 (prepared from benzyl bromide using the 
method in Scheme 55) was treated with magnesium turnings in THF and heated at reflux 
for 5 h (Scheme 56). Addition of the palladium catalyst and the phenylboronic acid 
followed, and the mixture was heated at reflux for 24 h, to afford only the starting 
material. There was no observation of the homo-coupled product, dehalogenated material 
or the desired product 180. It is possible the chloromagnesium intermediate had 
decomposed.  
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Phenyl boronic acid
 
Na2CO3, THF
180  
Scheme 56 
 
Knochel and co-workers have reported the use of benzylic zinc reagents to aid coupling 
reactions of aryl chlorides (Scheme 57). 68  The zinc reagents are compatible with 
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numerous functional groups, and combined with their highly reactive nature they are 
becoming attractive synthetic intermediates. The authors have reported the use of LiCl to 
accelerate the insertion of metals such as zinc and magnesium into the halide to give the 
reactive zinc intermediate, followed by subsequent reaction with an electrophile.   
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Scheme 57 
 
We followed the synthesis by treating the 7-chloroisoxazolopyridone 162 with LiCl, Mg 
turnings and ZnCl2 in THF for 2 h at 23 ºC. The unstable chloromagnesium intermediate 
readily decomposes in the absence of ZnCl2, therefore it was transmetalated in situ to the 
reactive chlorozinc intermediate 181 (Scheme 58). This intermediate was neither isolated 
nor purified. The LiCl solution was prepared by drying in a Schlenk-flask under vacuum 
at 140 ºC for 5 h, cooled and THF was added. The ZnCl2 solution was prepared in the 
same manner. For the coupling step, a palladium catalyst and the phenylboronic acid 
were added to the presumed chlorozinc intermediate 181. The reaction mixture was 
stirred at 23 ºC and monitored by TLC analysis. There was no change in the reaction after 
several hours, so the reaction was heated at 50 ºC for several hours, to afford the starting 
material and a trace amount of the 7-(phenyl)isoxazolopyridone 174. The reaction was 
repeated with an alternative procedure to form the chlorozinc intermediate. This involved 
the addition of the reagents, LiCl, ZnCl2 and the 7-chloroisoxazolopyrdione 162 in THF, 
and the mixture was stirred for 24 h at 23 ºC. After this point, the addition of a palladium 
catalyst and the phenylboronic acid followed and the mixture was heated at reflux for 24 
h, to provide only recovery of the starting material. It is possible the current conditions 
for the cross coupling reaction with the aryl chloride is not compatible in this case, and 
the formation of the pyridone chlorozinc intermediate 181 remains uncertain.  With very 
little success, we decided not to explore this further, since we had access to the 7-
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(phenyl)isoxazolopyridone 174 via the 7-iodo compound and a Sukuki coupling (Scheme 
51).      
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Scheme 58 
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2.4 Elaboration at the C-3’ of the isoxazolopyridone 
 
2.4.1 Aldol Reactions 
 
The natural product tenellin 3 and others belonging to the same family, all possess an 
unsaturated acyl side chain at C-3 (corresponding to an unsaturated substituent at 
isoxazolopyridone C-3). The current strategy applied towards the construction of such 
side chains and analogues, is the use of aldol-type chemistry. A typical reaction would 
entail the use of a base, such as LDA or n-BuLi, to deprotonate at the C-3’ methyl 
position of the isoxazolopyridone, forming an anion. It is also possible to form dianion or 
trianion species by deprotonating at the N-H proton and/or the O-H in the case of the 7-
(4-hydroxyphenyl)isoxazolopyridone. Once the anion is formed by addition of the base, it 
can be trapped with an electrophile, such as an aldehyde. The aldehydes are suitable 
electrophiles as they would form an alcohol adduct, which can undergo dehydration to 
the unsaturated side chains as observed in the natural products. Also, should a reaction 
take place at the nitrogen, it would be reversible upon work up back to the 2-pyridone.     
 
In a test reaction, n-BuLi (2.2 eq) was added dropwise to the bicyclic lactam 157 in THF 
at -78 ºC. The resulting solution was stirred for 1 h at -78 ºC, followed by the addition of 
excess benzaldehyde (20 eq), and the mixture was stirred for a further 5 minutes. After 
work up and column chromatography, the benzaldehyde adduct 182 was isolated in 70% 
yield (Scheme 59). 
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Scheme 59 
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Following this we repeated the reaction using the unsaturated isoxazolopyridone 1 under 
the same reaction conditions described for the bicyclic lactam 157. The resulting 
benzaldehyde adduct was isolated in poor yield, and the starting material was recovered. 
Repeating the reaction a second time gave a similar result, and after several repeat 
reactions variable results were obtained. The methodology developed here is clearly not a 
reliable method for developing side chains since we are not observing reproducible 
results. In order to develop a reliable methodology, the reaction conditions were 
investigated further. It is possible the reactions are proceeding via a dianion intermediate 
as there are two possible sites of anion formation, and the stability of these anion species 
remains uncertain. The current experimental conditions were carried out at -78 ºC with 
stirring for an hour; it is uncertain if the anions are formed at this temperature and their 
stability is unknown. There have also been several reports of aldol type reactions carried 
out at -78 ºC with warming to -20 °C for 30 minutes, to allow formation of the anion and 
then cooled back to -78 °C, before trapping the anion with an electrophile. There are also 
issues based around the solubility of these anion species, whether they remain in solution 
or precipitate. Before we started experimenting with different temperatures to carry out 
the reactions, we conducted several experiments by varying the time to allow the 
formation of the anion species. This was pursued by carrying out a series of six reactions 
by varying the time at which n-BuLi was allowed to stir at -78 ºC, from 0.5 h to 3 h 
before the addition of the benzaldehyde. The procedure was as follows; to a solution of n-
BuLi (10 eq) in THF at -78 ºC was added isoxazolopyridone 1 dropwise. The resulting 
solution was stirred at -78 ºC for the required time, followed by the addition of excess 
benzaldehyde (20 eq), and the resulting reaction mixture stirred for a further 2 h. The 
crude mixtures were worked up, and then were subjected to GC-MS to allow the 
investigation of the optimum reaction conditions. From the results obtained (Table 4, 
Graph 1), the conversions to the benzaldehyde adduct 183 are at best using 2 h and 3 h 
reaction time, however the results show a decrease in conversion from 2 h to 2.5 h. This 
could be an anomaly and also the reactions need to be repeated in order to obtain 
reproducible data. In the meantime the following reactions (Scheme 60) were carried out 
with 2 h for anion formation, as the stability of the anion for a longer period of time 
remains uncertain. These reactions were repeated using excess base (10 eq) and 
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benzaldehyde (20 eq), which always ensured reproducible results. It was later determined 
that using less base (5 eq) and benzaldehyde (10 eq) also gave similar results.     
 
Table 4 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Graph 1. Conversion to the benzaldehyde adduct by varying the reaction time. 
 
From the results obtained, the following reaction was confirmed using the procedure 
developed. The isoxazolopyridone 1 was treated with  n-BuLi (10 eq) for 2 h at -78 ºC, 
before the addition of benzaldehyde (20 eq), and then a work up and column 
chromatography afforded the benzaldehyde adduct 183 in 55 % yield (Scheme 60) 
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Scheme 60 
 
Thus we have developed a reliable method for the aldol chemistry, and by this method we 
have so far developed aromatic side chains. The next step of the synthesis was to develop 
aliphatic side chains, such as the ones observed in the natural products. In a first attempt, 
we used a non-enolisable aldehyde, 2,2-dimethylpent-4-enal, to construct the side chain. 
This was achieved readily in THF and excess n-BuLi (10 eq) at -78 °C, followed by 
addition of 2,2-dimethylpent-4-enal (20 eq), to leave the desired alcohol adduct 184 in 
34 % yield along with the recovery of starting material (Scheme 61).  
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Scheme 61 
 
 
Treating the 7-chloroisoxazolopyridone with ethanal and n-BuLi in the same manner as 
the above reaction furnished the alcohol adduct 185 in 80 % yield (Scheme 62).  
 
N O
ON
H
Cl
N O
ON
H
Cl
OH
n-BuLi, THF, -78  C°
Ethanal
80%
162 185  
Scheme 62 
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The same procedure was applied using 2-methylbutanal (Scheme 63). This reaction 
proved to be unsuccessful and majority of the starting material was recovered. However, 
a trace amount of the alcohol adduct 186 was isolated from the crude mixture. A possible 
explanation for the lack of success of this reaction would be the enolisable aldehyde 
interfering with the reaction, and therefore only a trace amount of this compound was 
observed.   
1 186
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Scheme 63 
 
Having successfully synthesised isoxazolopyridones with aromatic and aliphatic side 
chains, we pursued our research towards the synthesis of tenellin aliphatic side chain. The 
aldehyde required to construct the tenellin side chain is not commercially available, 
therefore we synthesised this in two steps (Scheme 64).69 
 
The first step involved the formation of the imine of propanal, by dropwise addition of 
propanal 187 to tert-butylamine 188 at 0 °C. After the addition was complete, potassium 
hydroxide pellets were added. The resulting solution was allowed to separate at 0 °C over 
a period of 12 h. Once separation of the layers were visible, the upper yellow layer was 
decanted and distilled from potassium hydroxide at atmospheric pressure to yield the tert-
butylpropylideneamine 189 as a colourless oil. It is then possible to store the imine 189 
over molecular sieves at 0 °C, however distillation is required prior to further use.  
 
In the second step of the synthesis, the previously prepared tert-butylpropylideneamine 
189 was freshly distilled. To a solution in THF, at -78 °C, was added n-BuLi, the 
resulting solution was stirred for 30 minutes and then 2-methylbutanal 190 was 
introduced. An aqueous acidic work up followed, and purification of the crude material 
by column chromatography afforded the desired aldehyde 191 as a colourless oil 
(Scheme 64). 
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Scheme 64 
 
With the tenellin aldehyde 191 (2,4-dimethylhex-2-enal) available, we continued the 
anion chemistry using the procedure described previously, to furnish the alcohol adduct 
192 in 58 % yield (Scheme 65). 
 
1 192
N O
ON
H
OH
N O
ON
H
n-BuLi, THF, -78  C°
2,4-Dimethylhex-2-enal
58 %
 
Scheme 65 
 
The natural product tenellin 3 contains the 4-hydroxyphenyl group on C-5 corresponding 
to the C-7 of the isoxazolopyridone, and also the unsaturated polyene chain system on the 
C-3’ site of the isoxazolopyridone. We have been able to prepare the aromatic ring on the 
C-7 position of the isoxazolopyridone and also developed the tenellin side chain in 
separate reactions. To further functionalise these compounds, it was necessary to consider 
the order of the reactions, whether to functionalise the C-7 before or after C-3’ of the 
isoxazolopyridone. The 7-iodoiosxazolopyridone 170 used in the cross coupling reactions 
would interfere with the metallation in the aldol reactions, and the unsaturated C-3’ side 
chain would be reactive during the C-7 iodination step. It was therefore decided to pursue 
the construction of the C-3’ side chain after the cross coupling reaction to form the 7-(4-
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hydroxyphenyl)isoxazolopyridone 172.         
 
In the early stage of the synthesis, we attempted a number of reactions with the 7-(4-
hydroxyphenyl)isoxazolopyridone 172 to develop the C-3’ side chains (Scheme 66). We 
anticipated the reaction to proceed via a possible trianion intermediate, since the n-BuLi 
could possibly deprotonate at three sites in 172. The pKa values of the core 2-pyridone 
unit and phenol are 24 and 18 respectively in DMSO,70 therefore the phenol is likely to 
deprotonate first. In these reactions excess n-BuLi and the freshly distilled aldehydes 
were used. The aromatic benzaldehyde was used as this has proven to be successful as 
noted previously and but-2-enal, since it has a similar functionality to the side chain of 
tenellin 3. Neither of the products 193/194 were isolated in pure form, and after several 
attempts to purify them using column chromatography and preparative TLC, only trace 
amounts of the products and starting material were recovered. In the case of but-2-enal 
the 1H NMR spectrum revealed signals corresponding to the alkene in the side chain. 
However, TLC analysis revealed five spots very close together, which proved to be very 
difficult to separate. A sample was submitted for mass spectrometry and a signal at 
313.11883 was observed, corresponding to the mass of the but-2-enal adduct 194. With 
some evidence the reaction had taken place, even though no pure sample was isolated, we 
turned our attention to an alternative weaker base, LDA, which also proved to be 
unsuccessful. With no obvious explanation to why the reaction was unsuccessful, our 
immediate suspicions were either the possible trianion intermediate was no longer in 
solution upon its formation, and/or this intermediate failed to form due to stability issues.   
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With the possibility the 4-hydroxyphenyl group might be interfering with the anion 
chemistry, we investigated similar reactions in the absence of the hydroxyl group. We 
anticipated the reaction to proceed via a dianion intermediate of the 7-
(phenyl)isoxazolopyridone 174, the two obvious reactive sites being the nitrogen and the 
methyl positions (Scheme 67); therefore the initial treatment with excess n-BuLi (10 eq) 
would aid the formation of such an intermediate, and the addition of excess benzaldehyde 
would ensure maximum interaction between the dianion intermediate and the aldehyde. 
In an initial reaction, once the n-BuLi (10 eq) was added to the reaction mixture, the 
reaction was allowed to stir for only 1 h before the aldehyde was added. We were 
reluctant to allow for a longer reaction time for the anion formation due to stability 
issues, however the product was isolated in poor yield. Following this, the resulting basic 
mixture was allowed to stir at -78 °C for 2 h and then the addition of benzaldehyde (20 
eq) followed; the resulting reaction mixture was stirred at -78 °C for a further 2 h before 
allowing the reaction to reach room temperature. After which point, work up and 
purification was conducted to leave the benzaldehyde adduct 195 as a white solid in 70 % 
yield (Scheme 67).  Analysis of this compound revealed 1H NMR signals at 3.56 and 5.19 
ppm corresponding to signals produced by the CHCH2 and CH2CH protons, and the 
methyl signal was absent.  
 108
 
195174
N O
ON
H
 n-BuLi, THF, -78  C
Benzaldehyde, 70 %
°
N O
ON
H
OH
 
Scheme 67 
 
Applying the same experimental procedure with 2-methylbut-2-enal, the alcohol adduct 
196 was isolated in 68 % yield, which provides a similar backbone to that of tenellin 3 
(Scheme 68).  
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The corresponding dehydrated side chain has not been isolated in the biosynthesis of 2-
pyridones, however the acyltetramic acid containing a side chain that would be derived 
from 2-methylbut-2-enal has previously been observed in prototenellin B 33, and was 
discussed in the introduction part of this thesis.  
N
H
HO HO
O
O
 
               33 
We continued the synthesis to develop the tenellin side chain using the 7-
(phenyl)isoxazolopyridone 174 with the previously prepared 2,4-dimethylhex-2-enal. 
Applying the same procedure used previously, the 7-(phenyl)isoxazolopyridone 174  was 
treated with n-BuLi (10 eq) and 2,4-dimethylhex-2-enal (20 eq) in THF, to yield the 
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desired compound 197 in 54 % yield and recovery of some starting material (Scheme 69). 
It is worth noting the Rf values of the starting material and the aldehyde adduct are 
similar causing difficulty during purification. The mixtures were separated using column 
chromatography and eluted with light petroleum and a steady increase of polarity to light 
petroleum and ethyl acetate (1:1 v/v). Although, there were fractions from the column 
containing both starting material and the product, this could be followed through to the 
dehydration step (see next section) where good separation was observed during 
purification to isolate any unreacted starting material.  
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Scheme 69 
 
Having synthesised the tenellin side chain using the 7-(phenyl)isoxazolopyridone 174, we 
exploited the same reaction conditions with the 7-(4-hydroxyphenyl)isoxazolopyridone 
172. In this case with the presence of the extra 4-hydroxy group, it is possible this 
reaction would proceed via a trianion intermediate. Following the reaction through 
resulted in a complex mixture and after further purification, the desired tenellin-like 
adduct 198 was obtained in a low yield of 10 % along with recovery of the starting 
material (Scheme 70) 
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2.4.2 Dehydration Reactions 
 
The alcohol adducts previously prepared would require a dehydration to the 
corresponding condensation product, to leave the unsaturated side chains as seen in the 
natural products.  
 
Dehydration of the benzaldehyde adduct 182 was achieved by reaction in toluene, under 
acidic conditions using para-toluenesulfonic acid, and heating at reflux overnight under 
Dean-Stark conditions (Scheme 71). The reaction was monitored by TLC analysis, and 
after 24 h of reflux all the starting material had been consumed, and the unsaturated 
benzaldehyde adduct 199 was obtained in 65 % yield.  It seems that some of the starting 
material may have decomposed during the reaction, which may account for recovery of 
only 65 %.  
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Scheme 71 
 
The same procedure was followed through using the benzaldehyde adduct of the 
unsaturated pyridone 183 to leave the condensation product 200 in 70 % yield (Scheme 
72). 
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Dehydration of the alcohol adduct 185 was also successful to leave the unsaturated 
adduct 201 in 85 % yield (Scheme 73).    
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Dehydration of the alcohol adduct 192 followed to leave the unsaturated side chain 202 
as seen in tenellin, which was observed in 35 % yield. (Scheme 74); it is possible that 
some starting material had decomposed. An alternative to the current method of 
dehydration might be to substitute the reaction solvent, toluene, for polar protic solvent 
such as methanol, which would aid the reaction and may avoid possible loss of material. 
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Dehydration of the 7-substituted compounds, such as the 7-(phenyl)isoxazolopyridone 
benzaldehyde adduct 195 was achieved in 60 % yield, whilst the dehydration of the (2-
hydroxy-3-methylpent-3-enyl)-7-(4-hydroxyphenyl)-5H-isoxazolo[4,3-c]pyridin-4-one 
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196 was observed in 81 % yield (Scheme 75). In the case of the condensation product 
204 of 2-methylbut-2-enal, the unsaturated side chain was observed in an acyltetramic 
acid intermediate during studies of the biosynthesis of 2-pyridones; however this has yet 
to be discovered in 2-pyridones.   
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To complete the synthesis of the tenellin side chain in the isoxazolopyridone with a 7-
substituted phenyl substituent, the corresponding alcohol adduct 197 was subjected to a 
dehydration reaction to furnish the unsaturated tenellin-like side chain 205 in 86 % yield. 
This isoxazolopyridone is a near analogue of pretenellin B 17 (Scheme 76).   
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Dehydration of the corresponding 7-(4-hydroxyphenyl) substituent 198 proved to be 
difficult during purification and for this reason we were unable to obtain full structural 
analysis. After several attempts to purify the compound 206, it was observed in 
approximately 73 % yield with some unidentified impurities (Scheme 77), to give another 
close analogue of pretenellin B 17.     
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2.4.3 Towards the synthesis of tricyclic side chains 
 
To date we have synthesised the tenellin side chain and other aliphatic C-3’ side chains of 
the isoxazolopyridone core. The aldol reaction with benzaldehyde afforded an aromatic 
ring, which is the only example of an aromatic substituent at C3’. We were interested in 
developing other alicyclic side chains; such systems have been observed in natural 
products like ilicicolin 3 to show a trans-decalin ring system. We pursued our interests to 
develop a simple model of this ring system.    
 
N O
HO
H
OH O
CH3
CH3
H
H
 
                                                                          3 
Our proposed method for developing such a ring system incorporates the aldol synthesis 
method in the development of side chains using an aldehyde reported in the literature 
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(Scheme 78). 71 , 72  We suggest the model tricyclic side chain, which indicates a 
retrosynthetic analysis via an intramolecular Diels-Alder reaction. The cycloaddition 
precursor would be available via the aldol chemistry.    
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The required aldehyde 211 was prepared in 4 steps, via a novel palladium-catalysed 
decarboxylative ring opening of cyclic carbonates (Scheme 79). The methodology 
involved the aldol addition of α-tetralone 207 with propenal in the presence of the base 
lithium diisopropylamide. The second step involved the reduction of the β-hydroxyketone 
208, which was achieved using lithium aluminium hydride in ether to give the 1,3-diol 
209 in 75 % yield. The next step was the synthesis of the cyclic carbonate 210 by treating 
the 1,3-diol 209 with methyl chloroformate in 74 % yield. In a final step, compound 210 
was treated with palladium dibenzylideneacetone [Pd2(dba)3] in dry acetonitrile to afford 
the aldehyde 211 in 65 % yield.72,72   
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After the synthesis of the aldehyde 211, we pursued our interest in the development of 
polycyclic side chains. The synthesis commenced with an aldol condensation reaction 
with the bicyclic lactam 157 using the methodology previously developed, to afford the 
alcohol adduct 212 in 64 % yield as the major product (Scheme 80). A minor product, the 
dehydrated analogue 213 was also observed. For complete conversion, the dehydration of 
the alcohol adduct was readily achieved in toluene, under acidic conditions using para-
toluenesulfonic acid, and heating at reflux overnight under Dean-Stark conditions. The 
unsaturated 213 analogue was isolated in 78 % yield. In order to develop the tricyclic ring 
system, compound 213 in toluene, in an NMR tube was heated at 100 ºC. The reaction 
was monitored initially for 5 h and 1H NMR analysis appeared to only show the starting 
material. After 24 h, the disappearance of the terminal alkene in the 1H NMR spectrum 
and a shift in the other alkene signals were observed. TLC analysis also showed that the 
entire unsaturated compound 213 had been consumed and new spots in the TLC plate 
appeared. Purification of the crude material by chromatography followed to afford a 
white solid.  Extensive 1H NMR and 13C NMR analysis of the new material proved to be 
a challenge, as a complex NMR spectrum was obtained to show the presence of a 
possible diastereomeric mixture. Further analysis revealed the accurate mass to be 
321.1602 (H+) of the desired tricyclic ring system 214. We were unable to obtain any 
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crystals of the sample, as X-ray crystal analysis would solve the structure. With all the 
material consumed in the structural analysis our conclusion, using evidence from the 
NMR spectra, the accurate mass and absence of the starting material (dehydrated adduct), 
is to suggest the tricyclic cycloadduct as a possible result in this synthesis.         
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2.5 Pyridone N-protection 
 
 
2.5.1 Allyl protection of the pyridone   
 
Difficulty arising with the anion chemistry previously with the 7-(4-
hydroxyphenyl)isoxazolopyridone could be due to a number of reasons; it may be 
difficult to form a trianion intermediate, although we do not have any evidence 
suggesting the formation of such intermediate and if this is formed at all, it may be 
unstable. A possible strategy to tackle this problem would be to protect the functional 
groups. Protecting groups, such as the allyl group, could be employed to protect the 
amide and the phenol group simultaneously. With these functional groups protected, the 
anion chemistry could then proceed via a possible mono-anion intermediate.  
 
On a small scale the allyl group protection was tested on the bicyclic lactam 157 (Scheme 
81). The bicyclic lactam was treated with excess n-BuLi in THF at -78 °C and stirred for 
2 h, followed by the addition of allyl bromide (1 eq). The reaction mixture was stirred at -
78 °C for a further 2 h before being allowed to reach room temperature. Work up and 
purification was then conducted, which showed the presence of the starting material and a 
C-3’-alkylated product. It seems the allyl group preferred to react at the C-3’ methyl 
position of the isoxazolopyridone. The 1H NMR spectrum revealed the presence of the 
broad NH signal at 5.8 ppm, the alkene signals were observed, and absence of the methyl 
signal confirmed the formation of the compound 215.  
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Further investigation was undertaken using the isoxazolopyridone 1, which was treated 
with an excess of n-BuLi and excess allyl bromide in the same manner as the previous 
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reaction. It seems, as expected, that the allyl group reacted at both the methyl position 
and at the amide to leave a mixture of three compounds (Scheme 82). Investigation of the 
crude mixture in GC-MS resulted in two major mass signals at 190 and 230 
corresponding to compounds 216/217 and 218. The three compounds were all isolated in 
ratio 3 (216) : 3 (217)  : 1 (218)  
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Scheme 82 
 
The strategy to protect the amide using allyl protection may not be best suited, as using 
only one equivalent of allyl bromide results in the C-3’-alkylated compound 215, where 
the allyl group reacts on the methyl position of the isoxazole. It is in our interest to avoid 
this and leave this site vacant for constructing side chains. The amide protection was 
achieved using excess allyl bromide, however this also yields unwanted compounds. For 
this reason we did not pursue allyl protection or other alkyl, and further investigation is 
required to protect the pyridone prior to the anion chemistry with the 4-hydroxyphenyl 
pyridone, in order to develop further side chains.    
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2.6 N-Oxidation 
 
Having investigated the anion chemistry at the C-3’ position of the isoxazolopyridone 1, 
and demonstrated successful Suzuki cross-coupling reactions to introduce C-C bonds at 
the C-7 of the isoxazolopyridone, we pursued our research to develop the hydroxamic 
acid functionality via N-oxidation of the pyridone 1. The natural product tenellin contains 
the hydroxamic acid as do other natural products such as bassianin 4 and leporine 124. 
The strategy proposed for the N-oxidation was O-silylation of the amide, followed by 
oxidation using a molybdenum complex.   
 
2.6.1 O-Silylation and Oxidation  
 
Rigby and co-workers have achieved the N-oxidation by O-silylation of the amide in 
related pyridones, followed by a treatment with 
oxodiperoxymolybdenum(pyridine)(HMPA) complex to form the hydroxamic acid 
functionality as in tenellin 3. 73, 74  With hexamethylphosphoric triamide (HMPA) being 
carcinogenic, we looked at an alternative options. Sammes and co-workers reported the 
use of an alternative molybdenum complex 220 for the N-oxidation step.75  
 
The synthesis of the complex 220 was attempted using the procedure described by 
Sammes and co-workers (Scheme 83),75 which involved treatment of molybdic acid with 
30% hydrogen peroxide at 35 °C, resulting in a yellow solution. This was cooled to 15 °C 
and two equivalents of dimethylformamide (DMF) were added to yield the desired 
molybdenum complex 220 as a yellow solid. The procedure was repeated and a yellow 
solid was obtained, however mass spectrometric data were unable to confirm the 
presence of the molybdenum complex due to solubility issues. In the meantime, assuming 
the complex had formed with support from IR data, we progressed through to the next 
step of the synthesis.                
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Before treatment with the molybdenum complex 220, we pursued O-silylation of the 
amide (Scheme 84). The isoxazolopyridone 1 was treated with an excess of 
hexamethydisilazane (HMDS), and a few drops of trimethylsilyl chloride, and heated at 
reflux for 24 h. The HMDS was removed under reduced pressure and the resulting 
precipitate was analysed by 1H NMR spectroscopy. Assuming that the O-silylation had 
taken place due to the presence of the TMS signal in the 1H NMR spectrum at 0.09 ppm, 
and since intermediate 221 is extremely moisture sensitive, the precipitate was treated 
with the molybdenum complex 220 in DCM at 20 °C and stirring for 12 h followed 
immediately. After this time, a work up with 1M - Na3(ethylenediaminetetraacetic acid) 
(EDTA) was applied to release the molybdenum ion from the expected hydroxamic acid. 
Extraction with DCM and purification of the crude material by column chromatography 
resulted in the recovery of the starting material 1.  
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Scheme 84 
 
Further conditions were explored for the N-oxidation as there are uncertainties regarding 
the formation of the silyl enol ether intermediate 221 and the oxidation step with 
molybdenum complex. Since trimethylsilylation of organic compounds is well known in 
preparative organic chemistry.76 The isoxazolopyridone 1 was treated with an excess of 
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hexamethydisilazane (HMDS), and a few drops of trimethylsilyl chloride, and heated at 
reflux for 24 h in an attempt to form the silyl enol ether 223 (Scheme 85). The HMDS 
was removed under reduced pressure and the resulting precipitate was analysed by 1H 
NMR spectroscopy, which indicated some evidence that the silylation had taken place 
due to the presence of a signal at 0.09 ppm. Therefore assuming the O-silylation had 
taken place we pursued the oxidation step. Treatment of the double bond with a peracid 
such as mCPBA as in an epoxidation reaction should form the strained three membered 
oxaziridine ring 224. Relief of the ring strain would encourage rearrangement with the 
loss of the silyl group to present the hydroxamic acid functionality 222.  
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For the oxidation step, DCM was used as a suitable solvent since previous reports of 
similar successful expoxidation reactions support this.77 mCPBA is a strong oxidising 
agent, it is highly reactive and more selective than other peracids such as hydrogen 
peroxide. We therefore utilised this as a suitable oxidising agent. The crude material 
containing the possible intermeidate 223 in DCM was treated with mCPBA and was 
stirred at room temperature. The progress of the reaction was monitored for several days 
and no change was observed. The reaction was then heated at 35 ºC followed by heating 
at reflux, which also resulted in no change in the reaction progress. All these attempts 
failed and we only observed the starting material 1.  
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We revised the approach by focusing on trialkylsilyl intermediates,78 in hope that bulky 
trialkylsilyl intermediates would be stable and therefore isolable. However, with bulky 
groups on the silicon, the formation of silyl enol ether intermediates may prove to be 
difficult due to steric hindrance. To aid this type of reaction a catalytic amount of, for 
instance a weak base such as imidazole could be used to increase the rate of reaction. 
Stronger conditions are required for the removal of bulky silicon-based protecting groups, 
such as the use of tetrabutylammonium fluoride (TBAF).     
 
Further attempts were made to trap the bulky trialkylsilyl intermediate by treating the 
isoxazolopyridone 1 with excess nBuLi at -78 °C to form a possible enolate intermediate 
followed by addition of triisopropylsilyl chloride (TIPSCl) or and tert-
butyl(diphenyl)silyl chloride in separate reactions. Although there was little evidence 
from the 1H NMR spectrum to suggest the formation of these intermediates, we pursued 
further investigation by treating the crude material with mCPBA to result in the isolation 
of the starting material. It is possible that the bulky silyl enol ether intermediates are not 
forming due to steric hindrance.   
 
Since we were unable to isolate the silyl enol ether intermediates, and unsure if the 
intermediates had formed, further investigation was undertaken. We continued by 
exploring the use of more potent silylating reagents. 79 , 80  N,O-
bis(Trimethylsilyl)acetamide (BSA) is a common silylating reagent, it is reactive and is 
used to silylate a wide range of functional groups, such as alcohols and amides. The 
reactivity of BSA can be enhanced by addition of a catalyst and the use of polar solvents 
as they are thought to accelerate the reaction. 
 
BSA was added to a mixture of isoxazolopyridone 1 in anhydrous toluene (Scheme 86),79, 
80 and the reaction was stirred for 1 h before the progress was analysed by TLC. With 
only the starting material present the resulting mixture was stirred overnight, and 
following further TLC analysis, an unidentified spot and starting material were present. 
Since the silyl enol ether intermediate 225 is susceptible to hydrolysis, the oxidation step 
immediately followed in freshly distilled DCM using excess m-CPBA. Extraction with 
DCM and purification of the crude material by column chromatography resulted in the 
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recovery of the starting material 1. These conditions were repeated using more potent 
silylating agents, for example TMSCl was introduced to increase the reactivity of BSA 
(BSA ; TMSCl 5:1 ratio) and in another attempt BSA, TMSCl, and N-
trimethylsilylimidazole were all used in one pot.79, 80 N-trimethylsilylimidazole is known 
to react quickly with unhindered hydroxyls and carbonyls, therefore this was utilised. The 
three reagents together are highly potent silylating reagents, but applying the reagents in a 
similar manner as previous reactions proved to be unsuccessful.  
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2.6.2 O-Methylation 
 
The silyl enol ethers are highly susceptible to hydrolysis, and therefore isolation of such 
intermediates remains difficult. The ease of derivatisation of various functional groups 
using silylating agents follows this order; alcohol > phenol > carboxylic acid > amine > 
amide. We therefore devised a new strategy, avoiding the use of silylating agents, to form 
imino ethers, by O-methylation. Ideally the imino ethers formed should be stable 
intermediates and therefore isolable. It has been previously shown that both N-
methylation and O-methylation have been achieved using dimethyl sulfate in benzene.81-
82 We therefore incorporated these methods using the isoxazolopyridone 1 in order to 
determine the site at which methylation would take place. The isoxazolopyridone 1 was 
treated with dimethyl sulfate in toluene, and heated at reflux overnight (Scheme 87). At 
this point TLC analysis only presented the starting material, and as a result the reaction 
was heated at reflux for a further 24 h, until an unidentified spot was observed on the 
TLC plate along with the starting material. Further reflux for 24 h resulted in no change 
since the previous TLC analysis. Following work up, the crude mixture was analysed 
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using column chromatography and the fractions were isolated. The starting material was 
obtained along with the unidentified spot, which was analysed initially by 1H NMR 
spectroscopy. The signals observed seemed to correspond to the imino ether 226. It is 
possible O-methylation had taken place, as a signal appeared at 3.74 ppm which would be 
a typical signal expected for OMe, whereas N-methyl signals in the 1H NMR spectrum 
would be upfield of this. 
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Mass spectrometry revealed a signal at m/z 186, which does not correspond to the mass of 
the desired imino ether 226. A mass at 186 coincides with that of toluenesulfonic acid 
methyl ester 227 and this structure is consistent with the 1H NMR signals. A possible 
explanation for the formation of the toluenesulfonic acid methyl ester 227 is the 
sulfonation of toluene. The sulfur atom is acting as an electrophile, and the reaction 
proceeds via an electrophilic substitution mechanism between toluene and dimethyl 
sulfate, with methanol as the by-product. The electrophilic substitution reaction is fairly 
slow, no change in reaction was observed in the first 24 h, and after refluxing for 48 h the 
toluenesulfonic acid methyl ester was isolated in poor yield, this suggests that the sulfur 
in this case is a poor electrophile. 
S
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Similar reactions were reported by Hutchinson and co-workers, 83  who carried out 
reactions in neat dimethyl sulfate, and applied heat up to 55 °C to present good yields of 
such imino ethers. Implementing these conditions using the isoxazolopyridone 1 only 
afforded the recovery of the starting material. The conditions were then adjusted to heat 
these at reflux in neat dimethyl sulfate, however, these reaction proved to be unsuccessful 
and starting material was again recovered (Scheme 88, Table 5, entry 1 and 2 ) 
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Table 5 
 
 
 
In another reaction the isoxazolopyridone 1 was treated with nBuLi in THF at -78 °C and 
the mixture was stirred for 1 hour. Dimethyl sulfate was then added to the reaction 
mixture, which was stirred for 1 hour at -78 °C. Following work up, purification and 
analysis, the imino ether was not present, but the N-methyl pyridone 228 was obtained as 
indicated by the 1H NMR signal at 3.44 ppm to correspond to that of an N-Me signal 
(Scheme 88, Table 5, entry 3). 
Entry Solvent Reagent(s) Temperature 
(ºC) 
Time 
(h) 
Result 
1 - (CH3O)2SO2 55 24  SM 
2 - (CH3O)2SO2 Reflux 24 SM 
3 THF nBuLi, (CH3O)2SO2 -78 2 228 (65 %) 
4 MeCN Ag2CO3, MeI (MW) 90 10 
mins  
SM 
5 CHCl3 Ag2CO3, MeI 55 24  SM/228 
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Further investigation into the imino ether of the isoxazolopyridone led us in the direction 
of microwave (MW) reactions. Early studies of the use of MW in organic synthesis were 
reported by Gedye and co-workers during 1986. 84  The use of MW technology has 
recently been very popular and a useful technology in organic synthesis, and is described 
as a general tool for improving the overall efficiency of reactions and rate enhancement. 
High temperature and pressure are often readily obtained, and as a result increase in 
yields and reduction in reaction time are observed. For instance, it has been demonstrated 
that the esterification of benzoic acid was 100 times faster in a MW oven compared to 
under reflux.84 
 
The isoxazolopyridone 1 was dissolved in acetonitrile and treated with silver carbonate 
and iodomethane. The resulting mixture was irradiated in a microwave system (Biotage 
Initiator Eight EXP) for 10 minutes at 90 °C, followed by work up to only give the 
starting material (Scheme 88, Table 5, entry 4). 
 
Failure of the microwave reactions was disappointing, however a final attempt using 
silver carbonate and iodomethane was considered for O-methylation. In a previous report 
a bromopyridone 230 was heated with silver carbonate and iodomethane in the dark at 
55 °C for a period of 24 h to yield the O-methylated pyridine 231 (Scheme 89).85 
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Thus, to a solution of isoxazolopyridone 1 in chloroform were added silver carbonate and 
iodomethane, and the mixture stirred in the dark for 24 h at 55 °C (Scheme 88, Table 5, 
entry 5). Purification of the crude material by column chromatography afforded two 
fractions, which were subjected to analysis to identify one fraction as the starting material 
1 and the other as the unexpected N-methylpyridone 228. The 1H NMR and the 13C NMR 
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spectra for compound 228 presented signals at 3.44 and 34 ppm respectively to 
correspond to that of a N-Me signal. With the bulk of the starting material recovered, 
only a small percentage of the N-methylpyridone 228 was isolated. We initially 
anticipated reactions with silver carbonate would take place at the oxygen which was 
demonstrated by previous reports,85 however, in this case it seems silver carbonate may 
be acting as a weak base to allow methylation to take place at the nitrogen.  
 
The strategy was reviewed and we explored alternative ways to synthesise the enol ethers. 
There are several examples of synthesis of imino-chlorides from 2-pyridones, which can 
subsequently be treated with sodium methoxide to give the enol ether via an addition-
elimination (overall substitution) reaction.86,87,88 A number of chlorinating reagents were 
explored in attempts to synthesis the imino-chlorides and the details are discussed below 
(Scheme 90 and Table 6 ).  
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Scheme 90 
 
The 7-chloroisoxazolopyridone 162 in dichloroethane (DCE), phosphorus oxychloride 
(POCl3) and catalytic amount of dimethylformamide (DMF) was stirred at room 
temperature. The reaction was monitored by LC-MS, and no change was observed in the 
reaction. The reaction mixture was then heated at reflux for 24 h to leave a trace amount 
of  the imino-chloride 232, and also the starting material was recovered (Table 6, entry 1). 
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Table 6 
 
 
 
The reaction was repeated in acetonitrile using POCl3, and the reaction was heated at 
reflux overnight (Table 6, entry 2). The reaction was monitored by TLC analysis until all 
the starting material had been consumed. On cooling, the acetonitrile solution was 
decanted from the insoluble sludge, and evaporated in vacuo. The residue was extracted 
with hot ethyl acetate and then concentrated under reduced pressure to leave a red solid, 
which was stirred with diethyl ether overnight at 23 °C. The ethereal solution was 
decanted from the red solid and concentrated under reduced pressure to an oil. After 
purification, the 7-chloroisoxazolopyridone 162 was isolated along with a second 
compound, which proved difficult to characterise and provided a complex 1H NMR 
spectrum, which indicated the presence of a possible broad NH signal. A second attempt 
at this reaction using excess POCl3 (10 eq) in acetonitrile again provided only the 
recovery of the starting material (Table 6, entry 3). The reaction was repeated using only 
the POCl3 reagent in the absence of any solvent and heated at 80 °C overnight. An 
aqueous workup and extraction with ethyl acetate afforded only starting material (Table 6, 
entry 4). The reaction was repeated using excess POCl3 reagent and the reaction mixture 
was heated at reflux overnight, followed by a non-aqueous workup to recover only the 
Entry Solvent Reagent(s) Temperature (ºC) Time (h) Result 
1 DCE POCl3 (excess) 
DMF 
23/Reflux 24  SM 
2 MeCN POCl3 (1.5 eq) Reflux 24 SM 
3 MeCN POCl3 (10 eq) Reflux 24 SM 
4 - POCl3 (excess) 80 24  SM 
5 - POCl3 (excess) Reflux 24  SM 
6 - SOCl2 (7 eq), 
DMF (7 eq) 
Reflux 24 SM 
7 MeCN PCl5 (10 eq) 23  24 Complex 
mixture 
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starting material (Table 6, entry 5). Similar results were observed using thionyl chloride 
and DMF (Table 6, entry 6). In another attempt the 7-chloroisoxazolopyridone was 
treated with phosphorus pentachloride in acetonitrile and after stirring for 24 h only the 
starting material was recovered (Table 6, entry 7). The failed attempts to form the imino-
chloride 232 were rather disappointing, in our case only the starting 7-
chloroisoxazolopyridone 162 was isolated. It appears that the isoxazolopyridone does not 
behave like traditional 2-pyridones.     
 
It is possible the previous attempts to synthesis the imino-chlorides 232 were susceptible 
to hydrolysis therefore in numerous experiments we pursued the synthesis of the enol 
ether without isolating the imino-chloride 232. There have been several reports of the 
nucleophilic displacement of a chloro substituent by treatment with sodium methoxide to 
give a methoxy compound.89 The crude material from Table 6, entry 1 was treated with 
sodium methoxide and methanol (Scheme 91) and stirred at 23 °C, but no change was 
observed in the reaction, and thereafter the reaction was heated at reflux for 24 h. 
Following workup and purification, very little success was observed, there was no 
indication of the enol ether 233 and the 1H NMR spectrum indicated the presence of the 
7-chloroisoxazolopyridone 162.    
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Scheme 91 
 
With these disappointing results, we looked at introducing alternative functional groups 
at C-4 of the isoxazolopyridone. Triflates and mesylates are very good leaving groups in 
nucleophilic substitution reactions. By introducing such functionality at C-4 of the 
iosxazolopyridone, a nucleophilic displacement by, for instance, sodium methoxide 
would introduce the enol ether.  
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In the first instance we pursued the synthesis of the highly reactive triflate (Scheme 92). 
To the 7-chloroisoxazolopyridone 162 in DCM, was added triethylamine and 
trifluoromethanesulfonic anhydride at 0 °C and the reaction was stirred at 5 ºC and 
monitored by TLC analysis. After no indication of any product, the reaction was stirred at 
23 ºC for 3 h before subjected to a workup. The TLC analysis indicated the possible 
presence of the unstable trifluoromethanesulfonate intermediate 234, which was not 
characterised and used without further purification in a reaction with sodium methoxide 
in an attempt to form the enol ether compound 233. The sodium methoxide was prepared 
in situ from sodium hydride and methanol at 0 °C and stirred for 30 minutes before the 
addition of the possible trifluoromethanesulfonate intermediate 234. The reaction mixture 
was stirred for 4 h at 23 ºC and the reaction was monitored by LC-MS but no change was 
observed. The reaction was then heated at reflux for 24 h, followed by workup and 
purification to return the 7-chloroisoxazolopyridone 162 and no enol ether 233 was 
observed. 
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Since we had little success with the triflate intermediate 234 and the formation of the enol 
ether 233, the mesylate compound 235 was our next interest (Scheme 93). To a stirred 
solution of the 7-chloroisoxazolopyridone 162 was added triethylamine and 
methanesulfonyl chloride at 0 °C, and the mixture was stirred for 3 h at 23 °C, by which 
point the reaction had gone to completion by TLC analysis and LC-MS. After workup 
and purification by column chromatography the methanesulfonyl intermediate 235 was 
isolated in 72 % yield. The next step of this sequence was to prepare the enol ether 233, 
the mesylate was treated with methanol and triethylamine under microwave conditions 
for 20 minutes at 50 °C, to only afford the 7-chloroisoxazolopyridone 162. The mesylate 
intermediate 235 was not recovered. In this case, it appears the nucleophile is attacking 
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the sulfur atom of the mesylate to liberate the 7-chloroisoxazolopyridone 162 instead of 
attacking the C-4 centre to provide the enol ether 233. 
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Scheme 93 
 
Finally for the first time we had successfully functionalised the C-4 position of the 
isoxazolopyridone, however the challenge remained to form the enol ether. An alternative 
synthesis for the enol ether was investigated by treating the mesylate 235 with cesium 
fluoride to afford an imino-fluoride intermediate 236 (Scheme 94). Cesium fluoride being 
a good fluoride source should displace the mesylate to a possible unstable imino-fluoride 
intermediate 236, and treatment with methanol would afford the enol ether 233. The 
mesylate 235 in methanol was treated with triethylamine and cesium fluoride, and the 
reaction mixture was heated at reflux overnight. The reaction progress was monitored by 
LC-MS, which indicated no sign of the fluoropyridine 236 or the enol ether 233. 
Following preliminary purification, a complex mixture was obtained making 
characterisation difficult. Again some of the starting 7-chloroisoxazolopyridone 162 was 
isolated indicating nucleophilic attack on the sulphur atom of the mesylate 235.      
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Earlier in our studies, the oxidising agent m-CPBA was used in several attempts to 
oxidise the silyl compounds to introduce the hydroxamic acid functionality. The same 
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procedure was applied with the mesylate 235 but again the reaction was not successful 
(Scheme 95). A similar reaction was investigated using an alternative oxidising agent 
dimethyldioxirane (DMDO) in acetone. Again the mesylate 235 was recovered with no 
indication of the hydroxamic acid derivative 237.        
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We were not sure if the previous attempts to form the enol ether from the mesylate 235 
were either a difficult substitution or we were just using the wrong conditions, so we 
attempted another reaction using a saturated solution of ammonia with the mesylate 235 
(Scheme 96). In a nucleophilic substitution reaction, the ammonia should attack at the C-
4 position of compound 235 and displace the mesylate. However, the nucleophilic 
displacement to give the amine 238 was not observed; only the 7-
chloroisoxazolopyridone 162 was isolated. From the results it was concluded that since 
the nucleophilic ammonia appears unable to attack at the C-4 position to give the amine, 
it would be difficult to find other suitable reagents to afford the enol ether. Also it is 
possible that the corresponding N-mesylate is formed rather than compound 235. With 
time constraints we did not pursue further experiments but it may be worth revisiting the 
triflate chemistry in future, as it should be more reactive than the mesylate intermediate.      
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2.6.3 N-Methylation 
 
Many naturally occurring compounds with the 3-acyl-4-hydroxypyridone core contain 
the hydroxamic acid functionality, and some also contain the N-methyl group as in 
funiculosin 6. There are many literature reports for N-methylation, and a methylating 
reagent widely used in such reactions is iodomethane.81 
 
Applying the literature procedure to the isoxazolopyridone 1, using nBuLi (1.5 eq) and 
iodomethane (1.5 eq) resulted in the N-methylpyridone 228 in 65 % yield and O-
methylation to 226 was not observed. The 1H NMR spectrum revealed a signal at 3.44 
ppm, which corresponds to an N-Me signal and the broad NH signal was absent. 
Iodomethane is a good substrate for an SN2 substitution reaction, the anion formed upon 
addition of the base, nBuLi, is able to attack the sterically unhindered iodomethane to 
leave compound 228 (Scheme 97). The N-methylation had also been observed previously 
using similar conditions with dimethyl sulfate as methylating agent (Table 5).  
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Scheme 97 
 
Applying similar conditions in a second reaction, in which only excess nBuLi and excess 
iodomethane were used, afforded a mixture of compounds 228, 239, and 240 in ratio 3: 1: 
3 respectively (Scheme 98), which again indicates the acidity at the C-3’(Me) along with 
the N-5(H). 
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Applying similar conditions to the bicyclic lactam 157 using nBuLi (1.5 eq) and 
iodomethane (1.5 eq) afforded the N-methylpyridone 241 and O-methylation was also not 
observed in this reaction. The 1H NMR and 13C NMR spectra revealed a signal at 3.0 and 
33 ppm repectively, which corresponds to the N-Me signal, and the broad NH signal was 
absent (Scheme 99).  
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Scheme 99 
 
In the examples shown above, the reactions with iodomethane prefer to form 
predominantly the N-methylpyridone. Also as demonstrated earlier in the report, the 
reaction of the unsaturated pyridone with n-BuLi and excess allyl bromide also prefer to 
react at the N-5(H) as well as the C3’ (Me). From these reactions it is obvious the 
reaction is proceeding via a dianion intermediate.   
 
To confirm the reactivity at these possible sites, we continued the enolate type chemistry 
with the isoxazolopyridone 1 using both iodomethane and allyl bromide in one pot. To 
the isoxazolopyridone 1 in THF was added excess n-BuLi at -78 °C, followed by addition 
of iodomethane (1.1 eq), and the resulting mixture was stirred at this temperature for 30 
minutes. Allyl bromide (1.1 eq) was then added and the reaction stirred for a further 1 h. 
Following work up, both N-substituted compounds 228 and 217 were isolated in ratio 
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1:1.3 respectively (Scheme 100). This reaction confirms the reactivity of the nitrogen 
anion over the methyl anion, since only N-substituted compounds were observed and no 
other compounds were isolated from the reaction.  
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217
27 %
228
21 %
                                                 
Scheme 100 
 
However, after analysing a small portion of the crude material in the GC-MS, a range of 
m/z values were observed corresponding to analogues of 228 and 217. The chromatogram 
revealed m/z values at 164, 178, 190 and 204 (Scheme 101). These represent monomethyl, 
dimethyl, monoallyl and methyl/allyl dialkylated derivatives, respectively. The ratio of 
the individual substituted pyridones remains uncertain as some of the products are 
isomeric. The N-methyl or the N-allyl pyridones seem to be present in most cases. Clearly 
examples of isoxazolopyridones are also observed, where reaction has taken place at the 
C-3’(Me) of the isoxazolopyridone. However, these compounds are only seen as trace 
amounts.  
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2.7 Isoxazole unmasking to reveal the tricarbonyl moiety 
 
 
Having functionalised the isoxazolopyridone to develop the aromatic rings via coupling 
reactions and construction of the polyene side chains, we need to cleave the N-O bond of 
the isoxazolopyridone to prove its validity in the synthetic strategy.  
 
There are several reports of N-O bond cleavage of isoxazoles using molybdenum 
hexacarbonyl Mo(CO)6 in moist acetonitrile. 90 , 91  Other reports include the use of 
samarium iodide, which is also known as Kagan’s reagent, and titanium(III) chloride.92, 93   
 
The use of hydrogen and a palladium catalyst to cleave the weak N-O bond has been of 
great interest in synthetic studies.94 These reactions are simple to carry out and the work 
up requires only filtering of the catalyst, and often further purification is not necessary. 
We pursued our interest in the isoxazole cleavage via a number of methods (Scheme 102, 
Table 7). In the first instance the 7-chloroisoxazolopyridone 162 was subjected to 
hydrogenolysis. The 7-chloroisoxazolopyridone 162 was treated with palladium on 
carbon (5 % w/w) in methanol and treated with hydrogen with a Buchi pressflow gas 
controller at 2 bar pressure for 3 h to yield the enaminone 245 in 84 %. The reaction was 
also repeated in the H-cube in order to optimise the reaction conditions. Thus, treatment 
of the 7-chloroisoxazolopyridone 162 in a mixture of methanol/acetone for 10 minutes at 
80 bar pressure and 100 ºC over palladium on carbon gave the enaminone 245 in 30 % 
yield. The reaction was repeated a third time using palladium on carbon (10 % ww) in 
methanol, and the reaction was stirred for 5 h at 23 ºC at atmospheric pressure to leave 
the enaminone 245 in 80 % yield. The use of hydrogen and palladium/carbon has thus 
been proven to be successful in the cleavage of the weak N-O bond of the 7-
chloroisoxazolopyridone (Scheme 102).  
 
The reduction of the N-O bond for the more complex isoxazolopyridones prepared, such 
as the tenellin analogues, using the hydrogen and palladium/carbon method may cause 
complications. These compounds contain an unsaturated side chain, therefore this method 
would not be suitable since it would cause over-reduction of the side chain. The proposed 
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method for cleaving the N-O bond would require the use of the reagent, Mo(CO)6, which 
should selectively reduce the N-O bond and leave the unsaturated side chain intact.95,46 
The 7-chloroisoxazolopyridone 162 was treated with Mo(CO)6 in moist acetonitrile, and 
heated at reflux for 3 h to leave the enaminone 245 in 54 % yield.  
 
162 245
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Reduction
 
Scheme 102 
 
Table 7 
Condition/Reagent Yield (%) 
Pd/C, H2 (Buchi pressflow) 84 
Pd/C, H (H Cube) 30 
Pd/C, H2 80 
Mo(CO)6/H2O 54 
 
The proposed mechanism for the reductive cleavage of the N-O bond to the enaminone 
249 requires the molybdenum to complex with the nitrogen atom of the 
isoxazolopyridone 1. As the N-O bond breaks, a possible intermediate 246 will form a 
complex with the molybdenum, and finally hydrolysis will follow to the leave the 
enaminone 249 (Scheme 103).95  However, we propose an additional dianion intermediate 
248 as a result of reduction, which would then follow hydrolysis to the enaminone 249.     
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Scheme 103 
 
With the successful reduction of the N-O bond, we pursued the development of the 4-
hydroxypyridone to reveal the tricarbonyl moiety. It has previously been shown in our 
research group, the reduction of pyrroloisoxazoles to the corresponding enaminone was 
achieved under hydrogenation conditions (H2, Pd/C, MeOH), followed by subsequent 
hydrolysis (1M aq NaOH, THF, reflux) to reveal the tricarbonyl moiety in acyl tetramic 
acids.46 We incorporated this base-catalysed hydrolysis of the amine to the alcohol; the 4-
amino-5-chloropyridone 245 was treated with excess sodium hydroxide in THF and 
heated at reflux for 8 h. The reaction was monitored every hour, and only the starting 
material was recovered. Clearly C-4 was not sufficiently electrophilic. In a second 
reaction we investigated a diazotisation procedure to reveal the tricarbonyl moiety 
(Scheme 104). The 4-amino-5-chloropyridone 245 in water was stirred at 23 ºC to ensure 
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it was in suspension, the reaction mixture was then cooled to 0 ºC and a solution of 
sodium nitrite in hydrochloric acid (2M) was added, ensuring the temperature did not 
exceed 5 ºC. The resulting mixture was stirred for 1 h at this temperature, and then 
another 1 h at 50 ºC. Following work up and purification, the 4-hydroxypyridone 250 was 
revealed in 65 % yield.   
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Scheme 104 
 
The isoxazolopyridone 1 was treated with Mo(CO)6 to leave the enaminone 252, which 
was used without further purification in a diazotisation step to yield the 4-
hydroxypyridone 252 in 20 % yield.  
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Scheme 105 
 
Further reactions were investigated using the 7-phenylisoxazolopyridone 174, under the 
hydrogenation conditions. The phenyl compound 174 was treated with palladium on 
carbon (5 %, w/w) in methanol, with the Buchi pressflow gas controller at 2 bar pressure 
for 3 h to yield the enaminone 253 in 53 %. To reveal the tricarbonyl moiety, a 
diazotisation reaction followed to yield the 4-hydroxy adduct 254 in 30 % (Scheme 106).  
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Scheme 106 
 
To cleave the N-O bond of the C-3 benzaldehyde condensation product 203, the 
molybdenum hexacarbonyl method was pursued to avoid side chain reduction. The 
benzaldehyde adduct 203 was treated with Mo(CO)6 in moist acetonitrile and heated at 
reflux for 3 h. The result of this reaction was very surprising; we did not see the desired 
enaminone 256, but the reduced side chain analogue 255 was observed (Scheme 107). 
The 1H NMR spectrum clearly indicated the presence of the two CH2 triplets at 2.89 and 
3.47 ppm confirming the saturated bond and the alkene signals were absent. An accurate 
mass of the compound 255 was obtained; a molecular ion of m/z 319.1445 supports the 
side chain reduction. This reaction was repeated several times to confirm the results. A 
thorough literature search of Mo(CO)6 reactivity to support such side chain reduction 
resulted in no hits.91, 96 , 97  We are unsure of the mechanism by which this reaction 
proceeds, and the hydrogen source remains unknown. A speculation for the exceptional 
result, which contrasts with literature reports and with our research group’s experience 
with pyrroloisoxazoles leading to the acyltetramic acids,46 would relate to the extended 
conjugation in the 3-(2-phenylethenyl) bicycle possibly via electron transfer reactions. 
We pursued our investigation by conducting the N-O bond cleavage of the benzaldehyde 
adduct 203 using palladium on carbon (10 % w/w) in methanol. We would expect the 
side chain reduction in this case and it would allow the direct comparison of the two 
results, therefore confirming the structure. The reaction was stirred for 5 h at 23 ºC at 
atmospheric pressure to leave the enaminone 255 with the expected side chain reduction 
in 38 % yield. The 1H NMR spectra of the two samples were identical, the presence of 
the two CH2 triplets at 2.89 and 3.47 ppm confirming the saturated bond. Finally we 
obtained an X-ray crystal structure of the reduced product from the Mo(CO)6 method, 
which proves the N–O reduction accompanied by the side chain reduction (Figure 2).    
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Figure 2. X-Ray crystal structure of reduction product 255 (disorder in phenyl ring; 
crystallographic numbering) 
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As we felt the alkene reduction using Mo(CO)6 in the above example was exceptional, 
and due to the extended conjugation in the phenyl ethenyl system, we decided to proceed 
with the Mo(CO)6 protocol. The 3-(3-methylpenta-1,3-dienyl)-7-phenyl-5H-
isoxazolo[4,3-c]pyridin-4-one 204 was treated with Mo(CO)6 in moist acetonitrile and 
heated at reflux for 3 h, to leave the enaminone 257 in 67 % yield (Scheme 108), with no 
side chain reduction. Diazotisation of this compound using the previously described 
procedure was attempted to leave trace amounts of the starting material 257, and the 
tricarbonyl adduct 258 was not observed. It appears the compound may have decomposed 
during the diazotisation step or due to the smale scale nature of the reaction the 
compound 258 was not observed.  
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Scheme 108 
 
The 3-(3,5-dimethylhepta-1,3-dienyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 205 
was similarly treated with Mo(CO)6 in moist acetonitrile and heated at reflux for 3 h to 
leave the enaminone 259 in 57 % yield (Scheme 109). Diazotisation of this compound 
was attempted to leave trace amounts of the starting material 259, and the tricarbonyl 
adduct 260 was not observed. It again appears again that the compound may have 
decomposed during the diazotisation step or due to the smale scale nature of the reaction 
the compound 260 was not observed. In the earlier examples of the 7-
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chloroisoxazolopyridone 162, diazotisation of the enaminone 245 (Scheme 104) was 
successful although the yields were low. Further investigation is required to reveal the 
tricarbonyl moiety in the more complex structures containing the aliphatic side chain, to 
avoid possible decomposition of the material.  
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2.8 Conclusion 
 
This work has demonstrated the development of the building block containing the 3-acyl-
4-hydroxypyridone core, by masking it in the form of an isoxazolopyridone building 
block, and has proven this to be a valid synthetic strategy. The isoxazolopyridone has 
been synthesised in 7 steps, from the commercially available β-alanine. The keys steps in 
the synthesis of the building block involved a 1,3-dipolar cycloaddition and photolytic 
dehydrochlorination reactions. The nitrile oxide from the oxime underwent a 1,3-dipolar 
cycloaddition reaction to construct an isoxazole. The development of the C6-C7 
isoxazolopyridone unsaturated bond was achieved using a medium-pressure Hg Hanovia 
lamp in a photolytic dehydrochlorination reaction.         
 
The construction of substituents at the C-3’ of the isoxazolopyridone was successful with 
both aliphatic and aromatic aldehydes. The tenellin side chain was successfully 
constructed in the isoxazolopyridone. The Suzuki palladium-catalysed cross-coupling 
reactions were employed to synthesise biaryls. We have incorporated both the phenyl and 
the 4-hydroxyphenyl substituent in the C-7 position of the isoxazolopyridone. To reveal 
the 3-acyl-4-hydroxypyridone, we successfully cleaved the N-O bond of the 
isoxazolopyridone to prove its validity in the synthetic strategy. The cleavage of the N-O 
bond afforded the enaminone, which was followed by a diazotisation reaction, to reveal 
the tricarbonyl moiety. Although, the diazotisation reaction employed previously on the 
less complex isoxazolopyridones proved to reveal the tricarbonyl moiety, this was not the 
case with the more complex analogues. This step requires further investigation.    
 
Many attempts to develop the hydroxamic functionality failed. Standard pyridone 
chemistry to develop the imino-chlorides from 2-pyridones was unsuccessful. We 
therefore concluded the isoxazolopyridone does not behave like a typical 2-pyridone. 
 
This thesis has contributed towards the development of tenellin and the 3-acyl-4-
hydroxy-pyridone analogues.98 A final step would reveal the tricarbonyl moiety from the 
enaminone to afford the natural and unnatural analogues of tenellin.  
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Experimental 
 
General Details 
 
1H NMR spectra were measured using a Bruker DPX 400 MHz spectrometer or a Varian 
400 MHz spectrometer. Chemical shift, δ, values are given in ppm (parts per million) and 
coupling constants in hertz.   
Multiplets are denoted by the following symbols: s, singlet; d, doublet; t, triplet; q, 
quartet and m, multiplet.   
13C NMR were recorded on a Bruker DPX 400 MHz instrument operating at 100.62 
MHz. All spectra were recorded using tetramethylsilane (TMS) as the internal reference 
in CDCl3 or d6-DMSO as solvent. 
IR spectra were determined using a Perkin Elmer FT-IR Paragon 1000 spectrometer or a 
Perkin Elmer Spectrum One spectrometer.   
All the infrared spectra were recorded in the range 4000-600 cm-1. 
Distillation of reagents was carried out 1 atmospheric pressure unless otherwise stated.  
Mass spectra were recorded on a Joel SX-102 spectrometer (FAB and EI) and the 
Thermo Exactive (Orbi) accurate mass spectrometer (ESI), fitted with a Triversa Advion 
Nanomate sample delivery system using nano-ESI of methanol or methanol(1% w/w 
acetic acid). In the description of mass spectra [M+H+] and M+ refer to the molecular ion 
peak obtained by ionisation. The intensity of principle peaks (m/z) are given as a 
percentage relative to the base peak. GC-MS used was Fisons GC 800 with autosampler, 
Fisons mass lab MD 800 EI+ and DB5-MS 30 m column.   
Melting points were determined using an Electrothermal-IA 9100 and are uncorrected. 
They are given in degree Celsius (°C). 
Thin Layer Chromatography using silica gel as the absorbent was carried out with 
aluminium backed plates with silica gel.  
Column Chromatography using silica gel was carried out with Zeoprep 60 HYD 40-63 
Micron silica.  
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HPLC analysis was conducted in a Waters Fraction Lynx system comprising a 2767 
injector/collector with a 2525 gradient pump, CFO, 2996 photodiode array, 2420 ELSD 
and Micromass ZQ2000 equipped with a Waters XBridge dC18 column (column length 
20 mm, internal diameter of column 3 mm, particle size 3.5 micron). The analysis was 
conducted using a three minute run time using H2O with 10mM Ammonium Acetate and 
CH3CN.  
Solvents were distilled before use. Petroleum ether (b.p. 40-60 °C) and ethyl acetate were 
distilled from calcium chloride. Dichloromethane (DCM) was distilled from calcium 
hydride. Tetrahydrofuran (THF) was freshly distilled from sodium and benzophenone 
under an atmosphere of nitrogen. Methanol was freshly distilled from magnesium 
methoxide. 
Hydrogenation reactions were carried out in a Buchi Pressflow gas controller pbc 1202 
or the H-cube (where stated). 
Microwave reactions were carried out in a Biotage Initiator Eight EXP microwave 
system.  
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Methyl 2,3-diaminopropanoate dihydrochloride 143 
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ClH3N
O
ClH3N OMe
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                                          142                                                       143      
 
To a stirred suspension of 2,3-diaminopropionic acid monohydrochloride 142 (6.20 g, 
41.1 mmol) in dry methanol (200 mL) was added freshly distilled acetyl chloride (70.6 g, 
900 mmol) dropwise over 2 h at 0 °C. The mixture was warmed to room temperature and 
heated at reflux for 4 days. The resulting white precipitate was filtered and treated with 
methanol and acetyl chloride in the same manner for a further 2 days. The resulting white 
precipitate was filtered, washed with methanol (20 mL) and dried to give the title 
compound 143 (6.8 g, 81%) as a white solid; δH (400 MHz; D2O) 3.47 (1H, dd, J 13.8 & 
8.4 CHCH2, HA), 3.47 (1H, dd, J 13.8 & 5.6, CHCH2, HB), 3.79 (3H, s, CH3) & 4.42 (1H, 
dd, J 8.4 & 5.6, CH2CH); δC (100 MHz; D2O) 37.9 (CH2), 49.6 (CH), 54.3 (CH3) & 
167.3 (C).  
 
 
Methyl 2,3-bis(tert-butyloxycarbonylamino)propanoate 144 
 
ClH3N OMe
ClH3N
O
BOCHN
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BOCHN
O
 
                                      143                                                               144 
  
To a stirred suspension of methyl 2,3-diaminopropanoate dihydrochloride 143 (4.01 g, 
20.9 mmol) in dichloromethane (100 mL) was added di-tert-butyl dicarbonate (9.60 g, 
43.9 mmol) in one portion followed by triethylamine (8.46 g, 83.8 mmol) dropwise over 
1 h at 0 °C, and the mixture stirred for 18 h. The resulting mixture was washed with 
aqueous citric acid (1M, 100 mL), saturated aqueous sodium hydrogen carbonate (2 × 50 
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mL), brine (50 mL), dried (MgSO4), filtered and the solvent was evaporated under 
reduced pressure to give the title compound 144 (6.32 g, 94%) as a colourless oil; νmax 
(DCM)/cm-1 3366, 2976, 1786, 1716, 1515, 1392, 1366, 1250, 1165 & 1077; δH (400 
MHz; CDCl3) 1.27 (18H, s, 2 × C[CH3]3), 3.28-3.35 (2H, m, NCH2CH), 3.54 (3H, s, 
OCH3), 4.13 (1H, br, NHCHCH2), 5.36 (1H, br, CHCH2NH) & 5.64 (1H, br, 
CH2CHNH); δC (100 MHz; CDCl3) 27.6 (CH3), 28.0 (CH3), 41.9 (CH2), 52.1 (CH3), 54.2 
(CH), 84.9 (C), 146.5 (C), 155.3 (C), 156.2 (C) & 171.2 (C); m/z (ESI) 319.1862 ([M + 
H+], C14H27N2O6  requires 319.1864). 
 
 
2,3-Bis(tert-butyloxycarbonylamino)propanal oxime 146 
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              144                                                       145                                                      146 
 
Preparation of the aldehyde 145 
 
To a solution of methyl 2,3-bis(tert-butyloxycarbonylamino)propanoate 144 (6.32 g, 19.8 
mmol) in toluene (100 mL) was added DIBAL-H (1M in toluene, 79 mL, 79 mmol) 
dropwise over 1 h at -78 °C. After stirring the mixture at 23 °C for a 1 h, methanol (20 
mL) was added slowly followed by potassium sodium tartrate solution (100 g in 200 mL 
water) and the mixture stirred vigorously at 23 °C for 1.5 h. The organic phase was 
separated, and the aqueous phase extracted with ethyl acetate (3 × 50 mL), the organic 
phases were combined, washed with brine (2 × 50 mL), dried (MgSO4), filtered and 
evaporated under reduced pressure to yield the crude aldehyde 145 as a viscous oil (5.5 
g). The aldehyde prepared was used immediately and without further purification.          
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Preparation of the Oxime 146 
                                                              
To hydroxylamine hydrochloride (2.75 g, 39.6 mmol) and sodium acetate (9.73 g, 118 
mmol) in water (50 mL), was added the crude aldehyde 145 (5.5 g) in ethanol (10 mL). 
The reaction mixture was warmed to 70 °C for 15 minutes, cooled and the organic phase 
extracted with ethyl acetate (3 × 100 mL), the organic fractions were combined, washed 
with brine (50 mL), dried (MgSO4), filtered and the solvent was evaporated under 
reduced pressure to give the title compound 146 (5.21 g, 87%) as a colourless oil; νmax 
(DCM)/cm-1 3342, 2977, 2932, 2358, 1693, 1519, 1455, 1393, 1367 & 1251; δH (400 
MHz; [CD3]2SO) (isomer one) (partially assigned by COSY and HMQC) 1.36 (18H, s, 2 
× C[CH3]3) [or 1.36 and 1.37 (2 × 9H, C[CH3]3)], 3.14 (2H, m, CHCH2), 4.15 (1H, m, 
CH2CH), & 7.11 (1H, d J 6.4, CHCHN), (isomer two) 1.37 (18H, s, 2 × C[CH3]3), 3.38 
(2H, m, CHCH2), 4.62-4.75 (1H, m, CH2CH), & 6.50 (1H, d J 6.2, CHCHN); δC (100 
MHz; CDCl3) 28.1 (CH3), 40.4 (CH2), 50.0 (CH), 148.2 (CH), 155.6 (C) & 175.7 (C); 
m/z (EI) 303.1786 (M+, C13H25N3O5  requires 303.1794), 57 (100 %), 60 (100), 73(16), 85 
(23), 101(22), 103 (32), 104 (42), 117 (60), 118 (70), 130 (14), 156 (2), 161 (27),  191 
(19) & 301 (1) which is in accordance with data published in the literature.45 
 
Ethyl 3-(pyrrolidin-1-yl)but-2-enoate 148 
 
O
CO2Et
N
CO2Et  
 
Ethyl acetoacetate (21.75 g, 167.1 mmol) and pyrrolidine (13.55 g, 190.5 mmol) were 
heated together in toluene (100 mL) at reflux under Dean-Stark conditions. After 24 h the 
mixture was cooled and the solvent was evaporated under reduced pressure to yield the 
title compound 148 (31.12 g) as a brown oil; δH (400 MHz; CDCl3) 1.24 (3H, t, J 7.1, 
CH2CH3), 1.91-1.92 (4H, m, NCH2CH2CH2), 2.45 (3H, s, CH3), 3.21-3.27 (4H, m, 
CH2NCH2), 4.06 (2H, q, J 7.1, CH3CH2) & 4.44 (1H, s, COCH).  
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Ethyl 3-[1,2-bis(tert-butoxycarbonylamino)ethyl]-5-methylisoxazole-4-carboxylate 
149 
 
BOCHN
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BOCHN
N
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BOCHN
BOCHN
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                                      146                                                             149 
 
To a stirred solution of 2,3-bis(tert-butyloxycarbonylamino)propanaldehyde oxime 146 
(5.66 g, 18.7 mmol) in freshly distilled DCM (150 mL) was added N-chlorosuccinimide 
(NCS) (2.70 g, 20.5 mmol) and the mixture was heated at reflux for 2 h. A second 
addition of NCS (2.70 g, 20.5 mmol) followed and the resulting mixture was heated at 
reflux overnight. The mixture (blue/green solution) was cooled to 23 ºC and a solution of 
ethyl 3-(pyrrolidin-1-yl)but-2-enoate 148 (11.91 g, 66.48 mmol) in DCM (10 mL) was 
added in one portion, followed by dropwise addition of triethylamine (3.20 g, 31.7 mmol) 
over 2 h. The mixture was heated at reflux overnight, cooled, washed with aqueous citric 
acid (100 mL), saturated aqueous sodium hydrogen carbonate (100 mL), and brine (50 
mL), dried (MgSO4), filtered and the solvent removed under reduced pressure. The crude 
oil was purified by column chromatography eluted with light petroleum : ethyl acetate 
(4:1, v/v) to give the title compound 149 (3.39 g, 44%) as a yellow oil; νmax (DCM)/cm-1 
3372, 2976, 2359, 1715, 1606, 1507, 1455, 1391, 1366, 1304 and 1250; δH (400 MHz; 
CDCl3) 1.30 (9H, s, C[CH3]3), 1.32 (3H, t, J 7.2, CH2CH3), 1.36 (9H, s, C[CH3]3), 2.59 
(3H, s, 5-CH3), 3.48 (2H, m, CHCH2), 4.29 (2H, q, J 7.2, CH3CH2), 4.87 (1H, br, NH), 
5.23 (1H, br, NHCH2CH) & 5.85 (1H, br, NH); δC (100 MHz; CDCl3) 13.5 (CH3), 14.2 
(CH3), 28.2 (CH3), 28.3 (CH3), 43.4 (CH2), 48.6 (CH), 60.8 (CH2), 77.3 (C), 80.0 (C), 
107.9 (C), 155.4 (C), 156.6 (C), 161.4 (C), 162.0 (C) & 175.9 (C); m/z (EI) 413.2173 
(M+, C19H31N3O7 requires 413.2162), 51 (100), 137 (39), 155 (50), 183 (79) & 228 (97).  
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Ethyl 3-(1,2-diaminoethyl)-5-methylisoxazole-4-carboxylate dihydrochloride 150 
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                                  149                                                                      150 
 
Trifluoroacetic acid (10.5 mL, 136 mmol) was added to ethyl 3-[1,2-bis(tert-
butoxycarbonylamino)ethyl]-5-methylisoxazole-4-carboxylate 149 (2.80 g, 6.78 mmol) 
and the mixture stirred for 4.5 h at 23 °C. The solution was then concentrated under 
reduced pressure. Aqueous hydrochloric acid (2M, 50 mL) was added and the mixture 
stirred for 30 minutes, after which time the solution was concentrated under reduced 
pressure, water added (40 mL) and washed with ethyl acetate (3 × 50 mL). The aqueous 
layer was concentrated under reduced pressure to give the title compound 150 (1.6 g, 
85%) as a pale brown solid, which was used without further purification.  
 
 
3-Methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1  
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Sodium carbonate was added to ethyl 3-(1,2-diaminoethyl)-5-methylisoxazole-4-
carboxylate dihydrochloride 150 (1.20 g, 4.19 mmol) in water (50 mL) at 23 °C and 
stirred overnight. The aqueous layer was then extracted with ethyl acetate (3 × 100 mL). 
The organic fractions were combined, dried over (MgSO4), filtered and the solvent 
removed under reduced pressure to yield amine 151 (0.53 g, 75%) as a white solid, which 
was used without further purification; δH(400 MHz; CDCl3) 2.63 (3H, s, 3-CH3), 3.36 
(1H, ddd, J 12.4, 7.6 & 2.4 ,CHCHH), 3.71 (1H, ddd, J 12.4, 5.2 & 3.2, CHCHH), 4.27 
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(1H, dd, J 7.6 & 5.2, CHCH2) & 5.82 (1H, br, NH); δC (100 MHz; CDCl3) 12.3 (CH3), 
44.2 (CH2), 48.8 (CH), 106.4 (C), 154.2 (C) ,164.3 (C) & 172.8 (C).  
 
A solution of sodium nitrite (0.33 g, 4.8 mmol) in hydrochloric acid (2M, 30 mL) was 
added to the amine 151 (0.53 g) in water (10 mL) at 0 °C and stirred for 1 h, and at 50 °C 
for 1 h. The organic layers were then extracted with ethyl acetate (3 × 50 mL), combined, 
dried (MgSO4), filtered and the solvent was evaporated under reduced pressure to yield 
the title compound 1 (0.39 g, 80%) as a white solid; m.p. 205-207°C (lit.mp.,45 206 
°C); νmax (DCM)/cm-1 3425, 3224, 2987, 1696, 1643, 1382 & 1324; δH (400 MHz; 
CDCl3) 2.81 (3H, s, 3-CH3), 6.32 (1H, d, J 7.6, NHCHCH), 6.89 (1H, dd, J 7.6 & 5.6, 
NHCH) & 8.92 (1H, br, NH); δC (100 MHz; CDCl3) 13.1 (CH3), 95.1 (CH), 108.2 (C), 
132.8 (CH), 158.7 (C), 162.5 (C) & 171.2 (C); m/z (EI) 150.0427 (M+, C7H6N2O2 
requires 150.0429), 53 (9),1 80 (21), 108 (12) & 150 (100).  
 
 
Ethyl 3-tert-butoxycarbonylaminopropanoate 153 
 
OEt
O
ClH3N OEt
O
BOCHN  
                                 152                                                                       153 
  
To a stirred suspension of β-alanine ethyl ester hydrochloride 152 (2.90 g, 18.9 mmol) in 
DCM (100 mL) was added di-tert-butyl dicarbonate (8.68 g, 39.7 mmol) in one portion, 
followed by triethylamine (7.66 g, 75.5 mmol) dropwise over 1 h at 0 °C, and the mixture 
was stirred for 18 h. The mixture was washed with aqueous citric acid (1M, 100 mL), 
saturated aqueous sodium hydrogen carbonate (2 × 50 mL), and brine (50 mL), dried 
(MgSO4), filtered and the solvent removed under reduced pressure to give the title 
compound 153 (4.02 g, 99%) as a colourless oil; νmax (DCM)/cm-1 3385, 2979, 2936, 
1808, 1716, 1510, 1459, 1392, 1370 & 1251; δH (400 MHz; CDCl3) 1.32 (3H, t, J 7.1, 
CH2CH3), 1.37 (9H, s, C[CH3]3), 2.41 (2H, t, J 6.2, NHCH2CH2), 3.27 (2H, t, J 6.2, 
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NHCH2CH2), 4.01 (2H, q, J 7.1, CH3CH2) & 4.87 (1H, br, NH); δC (100 MHz; CDCl3) 
14.0 (CH3), 27.0 (CH3), 34.6 (CH2), 36.0 (CH2), 60.4 (CH2), 146.6 (C), 155.7 (C) & 
172.3 (C); m/z (FAB) 218.1389 ([M + H+], C10H20NO4  requires 218.1392), 57 (36), 116 
(28), 118 (66), 162 (100), 218 & (36).  
 
 
tert-Butyl (3-hydroxyiminopropyl)carbamate 154 
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To a solution of ethyl 3-tert-butoxycarbonylaminopropanoate 153 (4.60 g, 21.2 mmol) in 
toluene (100 mL) was added DIBAL-H (1M in toluene, 54 mL, 47 mmol) dropwise over 
1 h at -78 °C. After stirring the mixture at 23 °C for 1 h, methanol (20 mL) was added 
slowly, followed by addition of potassium sodium tartrate solution (100 g in 200 mL 
water) and the mixture stirred vigorously at 23 °C for 1.5 h. The organic phase was 
separated, and the aqueous phase extracted with ethyl acetate (3 × 100 mL). The organic 
phases were combined, washed with brine (100 mL), dried (MgSO4), filtered and the 
solvent was evaporated under reduced pressure to yield the corresponding aldehyde, 
which was used immediately and without further purification.          
 
To hydroxylamine hydrochloride (2.90 g, 41.7 mmol) and sodium acetate (6.95 g, 84.7 
mmol) in water (30 mL) was added the crude aldehyde in ethanol (5 mL). The reaction 
mixture was warmed to 70 °C for 15 minutes, cooled and the organic phase extracted 
with ethyl acetate (3 × 100 mL). The combined organic layers were washed with brine 
(100 mL), dried (MgSO4), filtered and the solvent was evaporated under reduced pressure 
to give the title compound 154 (3.30 g, 85%) as a colourless oil; νmax (DCM)/cm-1 3362, 
2978, 2935, 2360, 1689, 1529, 1479 1392, 1278, & 1170;  δH (400 MHz; CDCl3) (isomer 
one) 1.38 (9H, s, C[CH3]3), 2.33-2.30 (2H, m, NHCH2CH2), 3.18-3.26 (2H, m, 
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NHCH2CH2) & 7.37 (1H, br, CH2CHN),  (isomer two) 1.38 (9H, s, C[CH3]3), 2.45-2.50 
(2H, m, NHCH2CH2), 3.18-3.26 (2H, m, NHCH2CH2) & 7.72 (1H, br, CH2CHN); δC 
(100 MHz; CDCl3) 26.0 (CH2), 28.3 (CH3), 36.9 (CH2), 149.3 (CH), 157.2 (C) & 175.9 
(C); m/z (ESI) 189.1239 ([M + H+], C8H16N2O3 requires 189.1239).  
 
 
Ethyl 3-(2-tert-butoxycarbonylaminoethy)-5-methylisoxazole-4-carboxylate 155 
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To a stirred solution of tert-butyl(3-hydroxyiminopropyl)carbamate 154 (3.30 g, 17.6 
mmol) in freshly distilled DCM (100 mL) was added NCS (2.61g, 19.5 mmol) and the 
mixture was heated at reflux for 2 h, followed by a second addition of NCS (2.61g, 19.5 
mmol) and heated at reflux overnight. The reaction (blue/green solution) was allowed to 
cool 23 °C and ethyl 3-(pyrrolidin-1-yl)but-2-enoate 148 (6.28 g, 35.1 mmol) in DCM 
(10 mL) was added in one portion, followed by addition of triethylamine (1.95 g, 19.3 
mmol) over 2 h. The mixture was heated at reflux overnight, cooled, washed with 
aqueous citric acid (100 mL), saturated aqueous sodium hydrogen carbonate (100 mL), 
brine (100 mL) and dried (MgSO4). After filtration and removal of the solvent under 
reduced pressure, the crude oil was purified by column chromatography eluting with light 
petroleum : ethyl acetate (4:1, v/v) to give the title compound (3.45 g, 65%) as a 
colourless oil 155; νmax (DCM)/cm-1 3414, 2978, 2347, 1709, 1685, 1511, 1451,1391, 
1366 & 1250; δH (400 MHz; CDCl3) 1.34 (3H, t, J 7.2, CH2CH3), 1.42 (9H, s, C[CH3]3), 
2.66 (3H, s, 5-CH3), 3.06 (2H, t, J 6.4, NHCH2CH2), 3.54 (2H, m, NHCH2), 4.32 (2H, q, 
J 7.2, CH3CH2) & 5.00 (1H, br, NH); δC (100 MHz; CDCl3) 13.3 (CH3), 14.2 (CH3), 27.1 
(CH2), 27.9 ( CH3), 37.9 (CH2), 60.7 (CH2) , 79.1 (C), 155.8 (C), 161.2 (C), 162.2 (C) & 
171.1 (C) & 175.4 (C); m/z (ESI) 321.1419 ([M + Na+], C14H22N2O5Na requires 
321.1421).  
 157
2-(4-Ethoxycarbonyl-5-methylisoxazole-3-yl)ethylammonium chloride 156 
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Trifluoroacetic acid (12.9 mL, 168 mmol) was added to ethyl 3-(2-tert-
butoxycarbonylaminoethy)-5-methylisoxazole-4-carboxylate 155 (2.5 g, 8.4 mmol) and 
the solution was stirred for 4.5 h at 23 °C. The solution was then concentrated under 
reduced pressure. Hydrochloric acid (2M, 50 mL) was added and the mixture stirred for 
30 minutes. After this time the solution was concentrated under reduced pressure, water 
was added (10 mL) and the solution washed with ethyl acetate (3 × 50 mL). The aqueous 
layer was concentrated under reduced pressure to give the title compound 156 (1.63 g, 
99%) as a pale brown solid, which was used without further purification. 
 
 
3-Methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 157 
 
N O
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                                                156                                                  157 
 
Anhydrous sodium carbonate (1.07 g, 10.2 mmol) was added to a solution of 2-(4-
ethoxycarbonyl-5-methylisoxazole-3-yl)ethylammonium chloride 156 (1.61 g, 6.88 
mmol) in water (50 mL) at 23°C and stirred overnight. The aqueous layer was then 
extracted with ethyl acetate (3 × 100 mL). The organic fractions were combined, dried 
(MgSO4), filtered and the solvent removed under reduced pressure to give the title 
compound 157 as a white solid (0.82 g, 80%); m.p. 195-197 °C (lit.mp.,99 190 °C); νmax 
(DCM)/cm-1 3279, 3071, 1689, 1629, 1513, 1425, 1382, 1300, 1339, 1262 & 1142; δH 
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(400 MHz; CDCl3) 2.62 (3H, s, CH3), 2.94 (2H, t, J 6.4, NCH2CH2), 3.55 (2H, dt, J 2.8 & 
6.4, NCH2CH2) & 6.29 (1H, br, NH); δC (100 MHz; CDCl3) 12.3 (CH3), 21.4 (CH2), 40.7 
(CH2), 107.8 (C), 160.6 (C), 163.4 (C) & 172.1 (C); m/z (EI) 152.0584 (M+, C7H8N2O2  
requires 152.0586), 81 (28), 123 (30) & 152 (100).  
 
tert-Butyl hypochlorite50 
 
OH
NaOCl
OCl 
 
tert-Butanol (18 ml) and glacial acetic acid (12 ml) were added to commercial bleach 
(250 ml) at 5 °C in the absence of light. After stirring for 10 minutes, the organic phase 
was separated, washed with 10% aqueous sodium carbonate solution and water (50 ml) to 
leave the title compound as a yellow oil (9.6 g). 
 
 
5-Chloro-3-methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 158 
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H  
                                  157                                                        158 
 
To a solution of 3-methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 157 (1.22 g, 
8.03 mmol) in freshly distilled methanol (50 mL) was added tert-butyl hypochlorite (1.30 
g, 12.0 mmol) dropwise at 0 °C in the absence of light. The resulting mixture was stirred 
at 0 °C for 2 h and then at 23 °C for 2 h. The solvent was then removed under reduced 
pressure, water (30 mL) added and the organic phase extracted with ethyl acetate (3 × 
150 mL). The combined organic layers were washed with brine (100 mL), dried 
(MgSO4), filtered and the solvent was evaporated under reduced pressure to give the title 
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compound 158 as a yellow solid (1.21 g, 82%); m.p. 107-109 °C (lit.mp.,99 108 °C); νmax 
(DCM)/cm-1 2220, 1689, 1629, 1513, 1426, 1382, 1331, 1300, 1262, 1142 & 1088; δH 
(400 MHz; CDCl3) 2.62 (3H, s, CH3), 3.14 (2H, t, J 6.5, NCH2CH2) & 3.95 (2H, t, J 6.5, 
NCH2CH2); δC (100 MHz; CDCl3) 12.4 (CH3), 22.6 (CH2), 55.4 (CH2), 109.6 (C), 159.4 
(C), 160.4 (C) & 173.4 (C); m/z (FAB) 187.0279 ([M + H+], C7H8N2O235Cl requires 
187.0274). 
 
 
3-Methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1 
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5-Chloro-3-methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 158 (150 mg, 0.802 
mmol) in freshly distilled methanol (200 mL) was degassed for 10 minutes. Under a 
constant flow of nitrogen the solution was stirred for 1 h under irradiation medium 
pressure mercury Hanovia lamp. Concentrating the solvent under reduced pressure and 
purification of the crude residue using column chromatography, eluting with light 
petroleum : ethyl acetate (1:1, v/v) yielded the title compound 1 as a white solid (96 mg, 
80%), identical to a sample prepared from aminopyridone, see above.   
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7-Iodo-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 170 
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Iodine monochloride (1.0M in DCM, 5.0 mL, 5.0 mmol) was added to a solution of  3-
methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1 (0.50 g, 3.3 mmol) in DCM (10 mL) and the 
mixture was stirred for 72 h at 23 °C. The resulting purple precipitate was filtered and 
washed with DCM (10 mL) to yield the title compound 170 as a red/brown solid  (554 
mg, 60 %); m.p. 223-225 °C (lit.mp.,45 218 °C); νmax (DCM)/cm-1 2360, 1665, 1620, 
1519 & 1330; δH (400 MHz; [CD3]2SO) 2.82 (3H, s, 3-CH3), 7.50 (1H, d, J 5.0, NHCH) 
& 11.12 (1H, br, s, NH); δC (100 MHz; [CD3]2SO) 12.9 (CH3), 51.6 (C), 107.4 (C), 140.4 
(CH), 158.9 (C), 159.0 (C) & 175.2 (C); m/z (EI) 275.9394 (M+, C7H5N2O2127I requires 
275.9398), 91 (17), 108 (12), 234 (11), 276 (100)& 277 (15).  
 
 
7-Bromo-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 167 
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To a solution of degassed tert-butanol (10 mL) were added 3-methyl-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 157 (100 mg, 0.658 mmol) and recrystallised N-
bromosuccinimide (0.14 g, 0.789 mmol) under a nitrogen atmosphere. AIBN (9 mg, 0.05 
mmol) was added portionwise every hour for 5 h, and heated at reflux overnight. The 
solvent was removed under reduced pressure, and to the residue water (20 mL) was 
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added, and the mixture was extracted with DCM (4 × 40 mL). The combined organic 
extracts were dried (MgSO4), filtered and the solvent was removed under reduced 
pressure. Purification of the crude residue using column chromatography, eluting with 
light petroleum : ethyl acetate (1:1, v/v) yielded the title compound 167 as a off white 
solid (35 mg, 35%); m.p. 268-269 °C; νmax (DCM)/cm-1 3436, 1774, 1665, 1427, 1370, 
1296 & 1188 ; δH (400 MHz; [CD3]2SO) 2.78 (3H, s, 3-CH3), 7.48 (1H, s, NHCH) & 
11.32 (1H, br, s, NH); δC (100 MHz; [CD3]2SO) 12.7 (CH3), 104.5 (C), 107.4 (C), 136.7 
(CH), 156.9 (C), 159.6 (C) & 174.2 (C); m/z (EI) 227.9534 (M+, C7H5N2O279Br requires 
227.9534), 57(68), 73 (100), 147 (40) & 252 (70).   
 
 
7-Chloro-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 162 
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A solution of 5-chloro-3-methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 158 
(2.21, 11.9 mmol) in freshly distilled methanol (50 mL), under a constant flow of 
nitrogen, the reaction was stirred at 23 °C for 5 h while irradiated by a tungsten halogen 
UV lamp. The solvent was concentrated under reduced pressure and the residue was 
purified by column chromatography, eluting with light petroleum : ethyl acetate (1:1, v/v) 
to yield the title compound 162 as a white solid (0.88 g, 40%); m.p. 230-232 °C; νmax 
(DCM)/cm-1 2898, 1672, 1632, 1519 & 1342; δH (400 MHz; [CD3]2SO) 2.71 (3H, s, 
CH3) & 7.38 (1H, s, CH); δC (100 MHz; [CD3]2SO) 12.6 (CH3), 98.1 (C), 107.9 (C), 
133.8 (CH), 156.4 (C), 158.8 (C) & 175.2 (C); m/z (FAB) 185.0114 ([M + H+], 
C7H6N2O235Cl requires 185.0117).  
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7-Chloro-5-(4-methoxybenzyl)-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 177 
 
N O
ON
H
Cl
N O
ON
Cl
OMe
 
                         162                                                                      177 
 
To a solution of 7-chloro-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 162 (200 mg, 1.09 
mmol) in acetonitrile (20 mL) was added 4-methoxybenzyl bromide (260 mg, 1.30 
mmol) and potassium carbonate (225 mg, 1.63 mmol) and the mixture stirred for 5 h at 
50 °C.  Water (10 mL) was added to the reaction mixture and extracted with ethyl 
acetate (4 × 30 mL), the organic layers were combined, washed with brine (50 mL), 
dried (MgSO4), filtered and the solvent was removed under reduced pressure. The 
residue was purified by column chromatography, eluting with ethyl acetate : light 
petroleum (1:1, v/v) to leave the title compound 177 as a white solid (271 mg, 82 %); 
m.p. 155-157 °C; νmax (DCM)/cm-1 3053, 1669, 1633, 1588, 1513, 1432 & 1362; δH (400 
MHz; CDCl3) 2.88 (3H, s, CH3), 3.79 (3H, s, OCH3), 4.94 (2H, s, NCH2), 6.89 (2H, d, J 
8.4, Ar-CH), 7.06 (1H, s, NCH) & 7.31 (2H, d, J 8.4, Ar-CH); δC (100 MHz; CDCl3) 
12.9 (CH3), 49.7 (CH2), 55.2 (CH3), 101.3 (C), 108.2 (C), 114.3 (CH), 129.3 (C), 129.7 
(CH), 134.8 (CH), 156.2 (C), 158.3 (C), 159.5 (C) & 175.6 (C); m/z (FAB) 305.0688 
([M + H+] C15H14N2O335Cl requires 305.0690).  
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7-(4-Hydroxyphenyl)-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 172 
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Tetrakis(triphenylphosphine)palladium (12 mg, 0.014 mmol) was added to degassed 1,4-
dioxane (10 mL), followed by addition of 7-iodo-3-methyl-5H-isoxozalo[4,3-c]pyridin-4-
one 170 (100 mg, 0.36 mmol) and the solution was purged with nitrogen for ten minutes 
at 23 °C. Two separate solutions of 4-hydroxyphenylboronic acid (75 mg, 0.54 mmol) in 
ethanol (10 mL) and aqueous sodium carbonate (2M, 0.36 mL, 0.72 mmol)) were 
degassed with nitrogen, and added to the reaction sequentially. The resulting mixture was 
heated at reflux for 18 h under a nitrogen atmosphere, cooled, water (50 mL) added and 
the mixture extracted with ethyl acetate (3 × 50 mL). The combined organic layers were 
washed with brine (50 mL), dried (MgSO4), filtered and the solvent was removed under 
reduced pressure to give a brown oil. This was purified using column chromatography 
with ethyl acetate as eluent to leave the title compound 172 as a white solid (70 mg, 
80%); m.p. 268-269°C (lit.mp.,45 decomposes 250 °C); νmax (DCM)/cm-1 3425, 2359, 
1642, 1436, 1177 & 1118; δH (400 MHz; [CD3]2SO) 2.87 (3H, s, 3-CH3), 6.86 (2H, d, J 
8.4, Ar-CH), 7.29 (1H, d, J 6.0, NHCH), 7.60 (2H, d, J 8.4, Ar-CH) & 11.05 (1H, br, 
NH); δC (100 MHz; [CD3]2SO) 12.4 (CH3), 107.1 (C), 108.1 (C), 115.3 (CH), 124.2 (C), 
128.7 (CH), 131.5 (CH), 156.7 (C), 157.6 (C), 159.0 (C) & 173.7 (C); m/z (EI) 242.0694 
(M+, C13H10N2O3  requires 242.0691), 51 (16), 77 (10), 118 (20). 133 (18), 171 (33), 227 
(46), 242 (100) & 243 (32). 
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3-Methyl-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 174  
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The same procedure was applied as for 7-(4-hydroxyphenyl)-3-methyl-5H-isoxazolo[4,3-
c]pyridin-4-one 172, using the following quantities: 
tetrakis(triphenylphosphine)palladium (4.2 mg, 3.6 ×10-3 mmol), 1.4-dioxane (10 mL), 7-
iodo-3-methyl-5H-isoxozolo[4,3-c]pyridin-4-one 170 (20 mg, 0.072 mmol), 
phenylboronic acid (13 mg, 0.11 mmol) in ethanol (10 mL) and aqueous sodium 
carbonate (2M, 0.02 mL, 0.14 mmol). The residue was purified by column 
chromatography, eluting with ethyl acetate : light petroleum (1:1, v/v) to leave the title 
compound 174 as a white solid (10 mg, 67 %); m.p. 253-254 °C; νmax (DCM)/cm-1 3245, 
2359, 1676, 1629 & 1404; δH (400 MHz; CDCl3) 2.86 (3H, s, 3-CH3), 7.33 (1H, d, J 6.0, 
NHCH), 7.36 (1H, t, J 7.2, Ar-CH), 7.43 (2H, m, Ar-CH), 7.75 (2H, d, J 7.2, Ar-CH) & 
8.72 (1H, br, NH); δC (100 MHz; CDCl3) 13.0 (CH3), 108.6 (C), 112.5 (C), 127.3 (CH), 
128.0 (CH), 128.8 (CH), 129.1 (CH), 133.2 (C), 158.8 (C), 161.7 (C) & 174.2 (C); m/z 
(FAB) 227.0825 ([M + H+], C13H11N2O2 requires 227.0822).  
 
 
 
 
 
 
 
 
 
 
 165
7-(4-Hydroxyphenyl)-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 172 
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The same procedure was applied as for 7-(4-hydroxyphenyl)-3-methyl-5H-isoxazolo[4,3-
c]pyridin-4-one 172, using the following quantities: 
tetrakis(triphenylphosphine)palladium (11 mg, 0.001 mmol), 1,4-dioxane (10 mL), 7-
bromo-3-methyl-5H-isoxozolo[4,3-c]pyridin-4-one 167 (73 mg, 0.32 mmol), 4-
hydroxyphenylboronic acid (65 mg, 0.48 mmol) in ethanol and aqueous sodium 
carbonate (2M, 0.32 mL, 0.64 mmol) to afford a brown oil. This was purified using 
column chromatography, eluting with ethyl acetate : light petroleum (1:1, v/v) to leave 
the title compound 172 as a white solid (25 mg, 36%); m.p. 268-269 °C; identical to a 
sample prepared from the 7-iodoisoxazolopyrdone (see above). 
 
 
3-(2-Hydroxy-2-phenylethyl)-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 182  
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To a solution of n-BuLi (0.6 mL of a 2.5M solution in hexanes, 1.5 mmol) in THF at -78 
ºC was added 3-methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 157 (100 mg, 0.65 
mmol). The resulting solution was stirred for 1 h at -78 ºC followed by addition of 
benzaldehyde (1.0 mL, 1.0 mmol), and stirred for a further 10 minutes. The reaction was 
quenched with water (20 mL) and acidified with 2M hydrochloric acid (20 mL) at -78 ºC. 
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The product was extracted with ethyl acetate (3 × 30 mL), the organic layers were 
combined, washed with brine (50 mL), dried (MgSO4), filtered and the solvent was 
removed under reduced pressure. The residue was purified by column chromatography, 
eluting with ethyl acetate : light petroleum (1:1, v/v) to leave the title compound 182 
(0.12 g, 70%) as a white solid; m.p. 174-175 °C; νmax (DCM)/cm-1 3475, 3215, 3050, 
1672, 1620 1479, 1451, 1341, 1134 & 1052; δH (400 MHz; CDCl3) 3.05 (2H, t, J 6.4, 
NHCH2CH2), 3.50 (2H, m, CHCH2), 3.62 (2H, td, J 2.8 & 6.4 NHCH2CH2), 5.14-5.18 
(1H, m, CH2CH), 6.05 (1H, br, NH), 7.29 (1H, t, J 6.4, Ar-CH), 7.36 (2H, t, J 6.4, Ar-
CH) & 7.41 (2H, d, J 6.4, Ar-CH); δC (100 MHz; CDCl3) 21.2 (CH2), 37.3 (CH2), 40.6 
(CH2), 72.2 (CH), 110.0 (C), 125.5 (CH), 127.8 (CH), 128.5 (CH), 143.7 (C), 160.4 (C), 
163.8 (C) & 172.5 (C). m/z (EI) 258.1001 (M+, C14H14N2O3  requires 258.0999). 
 
 
3-(2-Hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-c]pyridin-4-one 183 
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To a solution of 3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1 (50 mg, 0.33 mmol) in 
THF (20 mL) at -78 ºC was added n-BuLi (0.67 mL of a 2.5M solution in hexanes, 1.7 
mmol) The resulting solution was stirred for 2 h before benzaldehyde (0.68 mL, 6.67 
mmol) was added, and stirred for 2 h at -78 ºC. The mixture was quenched with water (20 
mL) and acidified with 2M hydrochloric acid (20 mL) at -78 °C. The mixture was 
extracted with ethyl acetate (3 × 40 mL), the organic layers were combined, washed with 
brine (50 mL), dried (MgSO4), filtered and the solvent was removed under reduced 
pressure to a yellow oil. The residue was purified by column chromatography, eluting 
with ethyl acetate : light petroleum (1:1, v/v) to leave the title compound 183 (43 mg, 
50%) as a white solid; m.p. 182-184 °C (lit.m.p.,45 181 °C); νmax (DCM)/cm-1 3395, 3131, 
 167
2962, 1675,  1643, 1457, 1217 & 1049; δH (400 MHz; [CD3]2SO) 3.55 (2H, m, CHCH2), 
5.19 (1H, q, J 7.7, CH2CH), 5.74 (1H, d, J 4.9, CHOH), 6.38 (1H, d, J 7.6, NHCHCH), 
7.15 (1H, dd, J 7.6 & 5.7, NHCH), 7.39-7.46 (5H, m, Ar-CH) & 10.15 (1H, br, NH); δC 
(100 MHz; [CD3]2SO) 36.9 (CH2), 70.4 (CH), 92.6 (CH), 108.5 (C), 125.6 (CH), 127.3 
(CH), 128.2 (CH), 134.1 (CH), 144.4 (C), 157.3 (C), 158.9 (C) & 174.8 (C); m/z (ESI) 
257.0924 ([M + H+], C14H13N2O3 requires 257.0921), 150 (100), 77 (94), 51 (70) & 43 
(62)  
 
 
7-Chloro-3-(2-hydroxypropyl)-5H-isoxazolo[4,3-c]pyridin-4-one 185 
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The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 7-chloro-3-methyl-5H-isoxazolo[4,3-
c]pyridin-4-one 162 (100 mg, 0.54 mmol), n-BuLi (2.1 mL of a 2.5M solution in hexanes, 
5.4 mmol) and ethanal (0.61 mL, 10.9 mmol) to yield the title compound 185 as a white 
solid (92 mg, 80 %); νmax (DCM)/cm-1 3420, 2875 & 1653; δH (400 MHz; CDCl3) 1.32 
(3H, d, J 6.0, CH3), 3.41 (2H, m, CHCH2), 4.35 (1H, m, CH2CH), 7.03 (1H, d, J 4.8, 
NHCH) & 8.60 (1H, br, NH); δC (100 MHz; CDCl3) 23.3 (CH3), 37.0 (CH2), 66.3 (CH), 
102.6 (C), 108.9 (C), 130.3 (CH), 156.6 (C), 159.0 (C) & 176.6 (C); m/z (ESI) 229.0376 
([M+H+], C9H10N2O335Cl requires 229.0374) 
 
 
 
 
 
 168
3-(2-Hydroxy-3,3-dimethylhex-5-enyl)-5H-isoxazolo[4,3-c]pyridin-4-one 184 
 
 
 
 
                        1                                                      184                                                                     
          
The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 3-methyl-5H-isoxazolo[4,3-c]pyridin-
4-one 1 (44 mg, 0.29 mmol), n-BuLi (1.2 mL of a 2.5M solution in hexanes, 2.9 mmol) 
and 2,2-dimethylpent-4-enal (0.8 mL, 6 mmol) to yield the title compound 184 as a white 
solid (48 mg, 63 %); m.p. 99-101 °C; νmax (DCM)/cm-1 3415, 3201, 2959, 1677,  1643, 
1467, 1219 & 1059; δH (400 MHz; CDCl3) 1.10 (6H, s, 2×CH3), 2.09 and 2.25 (each 1H, 
dd, J 13.6 & 7.6, CH2=CHCH2), 3.41 (2H, m, CH(OH)CH2), 3.81 (1H, dd, J 10 & 2.4, 
CH2CH(OH)), 5.08-5.13 (2H, m, CH=CH2), 5.89 (1H, m, CH2=CH), 6.54 (1H, d, J 7.6, 
NHCHCH), 6.97 (1H, dd, J 7.6 & 5.6, NHCH) & 8.94 (1H, br, NH); δC (100 MHz; 
CDCl3) 22.2 (CH3), 22.9 (CH3), 30.8 (CH2), 38.4 (C), 43.5 (CH2), 77.3 (CH), 95.7 (CH), 
109.3 (C), 117.8 (CH2), 132.5 (CH), 134.8 (CH), 159.2 (C), 161.5 (C) & 176.7 (C); m/z 
(FAB) 263.1388 ([M + H+], C14H19N2O3 requires 263.1396) 57 (100), 219 (24), 245 
(12.3) & 285 (10). 
 
 
3-(2-Hydroxy-3-methylpentyl)-5H-isoxazolo[4,3-c]pyridin-4-one 186 
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The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
N O
ON
H
N O
ON
H
OH
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c]pyridin-4-one 183 using the following quantities: 3-methyl-5H-isoxazolo[4,3-c]pyridin-
4-one 1 (50 mg, 0.33 mmol) , n-BuLi (3.1 mL of a 1.6M solution in hexanes, 5.0 mmol) 
and 2-methylbutanal (0.54 mL, 5.0 mmol) to leave the title compound 186 in trace 
amounts. δH (400 MHz; CDCl3) 0.86-0.98 (6H, m, 2 × (CH3)), 1.51 (2H, m, CH3CH2), 
2.33-2.41 (1H, m, CH3CH), 3.19-3.28 (2H, m, CH(OH)CH2), 3.92 (1H, br, OH), 4.56 
(1H, m, CH2C(OH)H), 5.91 (1H, d, J 7.6, NHCHCH), 6.98 (1H, m, NHCH) & 10.52 
(1H, br, NH). No further analysis to date.  
 
tert-Butylpropylideneamine 18925  
 
H
O
NH2 H
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                           187                      188                                             189                              
                                                                         
Propanal 187 (16.0 mL, 125 mmol) was added dropwise over 2 h to tert-butylamine 188 
(13.1 mL, 125 mmol) and stirred at 0 °C. After the addition was complete, potassium 
hydroxide pellets (5 g) were added and the resulting solution was allowed to separate 
over 12 h at 0 °C. The yellow upper layer was decanted and distilled over potassium 
hydroxide pellets to yield the tert-butylpropylideneamine 189 (9.3 g, 65%) as a colourless 
oil, which was stored over molecular sieves at 0 °C; bp 103-105 °C  (lit.bp.,25 101-
103 °C); νmax (DCM)/cm-1 3393, 2965, 2873, 1725, 1644, 1627, 1460, 1359, 1306, 1210 
& 1048; δH (400 MHz; CDCl3) 1.05 (3H, t, J 7.6, CH2CH3), 1.15 (9H, s, C[CH3] 3), 2.22 
(2H, qd, J 7.6 & 5.2 CH3CH2) & 7.57 (1H, t, J 5.2, N=CH ); δC (100 MHz; CDCl3) 10.7 
(CH3), 29.7 (CH3), 29.7 (CH2), 56.3 (C) & 160.1 (CH). 
 
 
 
 
 
 
 170
E-2,4-Dimethylhex-2-enal 19125 
 
H
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H
N
 
                   189                         190                                                       191                                                        
 
To freshly distilled tert-butylpropylideneamine 189 (9.3 g, 82 mmol) was added n-BuLi 
(36.2 mL of 2.5M solution in hexanes, 905 mmol) dropwise over 10 minutes in THF (25 
mL) at -78 °C. The solution was stirred for 30 minutes before 2-methylbutanal 190 (9.8 
mL, 905 mmol) was added dropwise over 5 minutes. The solution was allowed to warm 
to 0 °C and stirred for a further 2 h. After this point aqueous citric acid (2M, 100 mL) 
was added and the resulting biphasic mixture was stirred vigorously for a period of 24 h 
at 23 °C. The mixture was extracted with DCM (3 × 75 mL), and the organic layers were 
combined, dried (MgSO4), filtered and the solvent was removed under reduced pressure 
to leave a colourless oil, which was purified by column chromatography using DCM as 
eluent to yield the title compound 191 as a colourless oil (4.5 g, 45 %); lit.bp.,25 63-65 °C 
(17 mmHg);  νmax (DCM)/cm-1 2961, 2928, 2865, 1717, 1638, 1462, 1379, 1215 & 1148; 
δH (400 MHz; CDCl3) 0.79 (3H, t, J 7.6, CH2CH3), 0.99 (3H, d, J 6.7, CHCH3), 1.17-1.19 
(2H, m, CH3CH2), 1.69 (3H, s, CH3), 2.49-2.51 (1H, m, CH2CH), 6.18 (1H, d, J 10.0, 
CH3C=CH) & 9.32 (1H, s, CHO). No further characterization as the aldehyde does not 
store well at -20 ºC and was chromatographed prior to use.  
 
 
3-(2-Hydroxy-3,5-dimethylhept-3-enyl)-5H-isoxazolo[4,3-c]pyridin-4-one 192 
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The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 3-methyl-5H-isoxazolo[4,3-c]pyridin-
4-one 1 (30 mg, 0.20 mmol), THF (20 mL), n-BuLi (0.80 mL of a 2.5M solution in 
hexanes, 2.0 mmol) and E-2,4-dimethylhex-2-enal 191 (0.50 g, 4.0 mmol) to leave the 
title compound 192 as a yellow solid (35 mg, 64 %); m.p. 111-113 °C (lit.m.p.,45 110-115 
°C); νmax (DCM)/cm-1 3332, 3037, 2958, 2872, 1675, 1653, 1587, 1457, 1217 & 1059; δH 
(400 MHz; CDCl3) 0.69-0.76 (3H, m, CH2CH3), 0.82-0.85 (3H, m, CHCH3), 1.02-1.21 
(2H, m, CH3CH2), 1.71 (3H, s, CH3), 2.18-2.26 (1H, m, CH3CH), 3.48-3.60 (2H, m, 
CH(OH)CH2), 3.82 (1H, br, OH), 4.56 (1H, dd, J 5.7 & 11.9, CH2CH), 5.16 (1H, m, 
C=CH), 6.39 (1H, d, J 7.6, NHCHCH), 6.98 (1H, m, NHCH) & 10.13 (1H, br, NH); δC 
(100 MHz; CDCl3) 11.4 (CH3), 12.1 (CH3), 20.4 (CH3), 30.0 (CH2), 33.3 (CH), 34.3 
(CH2), 75.2 (CH), 95.5 (CH), 109.3 (C), 132.9 (CH), 133.3 (CH), 135.3 (C), 158.4 (C), 
161.6 (C) & 174.9 (C); m/z (ESI) 294.1815 ([M + NH4+] C15H24N3O3 requires 294.1812) 
165 (100).  
 
 
3-(2-Hydroxy-2-phenyl-ethyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 195 
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The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 3-methyl-7-phenyl-5H-isoxazolo[4,3-
c]pyridin-4-one 174 (75 mg, 0.28 mmol), n-BuLi (0.56 mL of a 2.5M solution in 
hexanes, 1.4 mmol) and benzaldehyde (0.61 g, 3.3 mmol) to yield the title compound 195 
as a white solid (76 mg, 81 %); m.p. 229-233 °C; νmax (DCM)/cm-1 3424, 2358, 1681, 
1641, 1579 & 1445; δH (400 MHz; [CD3]2SO) 3.56 (2H, d, J 7.7, CH(OH)CH2), 5.19 
(1H, m, CH2CH), 5.85 (1H, m, CHOH), 7.26-7.80 (8H, m, Ar-CH), 7.26-7.80 (1H, m, 
 172
NHCH)  & 7.82 (2H, m, Ar-CH) ; δC (100 MHz; [CD3]2SO) 36.9 (CH2), 70.5 (CH), 
107.9 (C), 108.5 (C), 125.6 (Ar-CH), 126.8 (Ar-CH), 127.2 (Ar-CH), 127.3 (Ar-CH), 
128.2 (Ar-CH), 128.6 (Ar-CH), 132.2 (CH), 133.6 (C), 144.4 (C), 161.0 (C), 161.8 (C) & 
170.6 (C); m/z (ESI) 333.1238 ([M + H+], C20H17N2O3 requires 333.1234).   
 
 
(2-Hydroxy-3-methylpent-3-enyl)-7-(4-hydroxyphenyl)-5H-isoxazolo[4,3-c]pyridin-
4-one 196 
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The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 3-methyl-7-phenyl-5H-isoxazolo[4,3-
c]pyridin-4-one 174 (50 mg, 0.19 mmol), n-BuLi (0.75 ml of a 2.5M solution in hexanes, 
1.9 mmol) and 2-methylbut-2-enal (0.36 mL, 3.8 mmol) to yield the title compound 196 
as a white solid (40 mg, 68 %); m.p. 125-128 °C;  νmax (DCM)/cm-1 3480, 2962, 1673, 
1470 & 1364; δH (400 MHz; CDCl3) 1.62 (3H, d, J 6.8, CHCH3), 1.75 (3H, s, CH3), 3.58 
(2H, m, CH(OH)CH2), 4.59 (1H, m, CH2(OH)CH), 5.61 (1H, q, J 6.8, C=CH), 7.16 (1H, 
d, J 5.6, NHCH), 7.39 (1H, t, J 7.2, Ar-CH), 7.47 (2H, t, J 7.2, Ar-CH), 7.76 (2H, d, J 7.2, 
Ar-CH) & 8.65 (1H, br, NH); δC (100 MHz; CDCl3) 11.5 (CH3), 12.2 (CH3), 34.2 (CH2), 
75.5 (CH), 111.0 (C), 121.3 (CH), 124.0 (C) 127.4 (Ar-CH), 128.2 (Ar-CH), 128.9 (Ar-
CH), 129.2 (CH), 133.5 (C), 136.0 (C), 156.0 (C), 161.1 (C) & 176.3 (C); m/z (ESI) 
311.1394 ([M+H+], C18H19N2O3 requires 311.1390) 
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3-(2-Hydroxy-3,5-dimethylhept-3-enyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 
197 
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The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 3-methyl-7-phenyl-5H-isoxazolo[4,3-
c]pyridin-4-one 174 (100 mg, 0.44 mmol), n-BuLi (1.5 ml of a 2.5M solution in hexanes, 
3.8 mmol) and E-2,4-dimethylhex-2-enal 191 (0.95 g, 7.5 mmol) to yield the title 
compound 197 as a white solid (70 mg, 54 %); m.p. 143-145 °C; νmax (DCM)/cm-1 3432, 
3230, 2955, 2358, 1665, 1650 & 1371; δH (400 MHz; CDCl3) 0.63-0.70 (3H, m, 
CH2CH3), 0.74-0.79 (3H, m, CHCH3), 1.05-1.25 (2H, m, CH3CH2), 1.66 (3H, s, CH3), 
2.11-2.20 (1H, m, CH3CH), 3.47-3.57 (2H, m, CH(OH)CH2), 4.56 (1H, m, CH2(OH)CH), 
5.14 (1H, m, C=CH), 7.10 (1H, d, J 5.6, NHCH), 7.30 (1H, t, J 7.2, Ar-CH), 7.38 (2H, t, 
J 7.2, Ar-CH). 7.66 (2H, t, J 7.2, Ar-CH) & 9.67 (1H, br, NH); δC (100 MHz; CDCl3) 
10.8 (CH3), 11.2 (CH3), 19.4 (CH3), 29.0 (CH2), 32.5 (CH), 33.2 (CH2), 74.5 (CH), 108.2 
(C), 109.7 (C), 126.3 (Ar-CH), 126.9 (Ar-CH), 127.8 (Ar-CH), 128.4 (CH), 132.6 (CH), 
132.9 (C), 133.0 (C), 156.6 (C), 160.1 (C) & 174.3 (C); m/z (ESI) 353.1861 ([M+H+], 
C21H25N2O3 requires 353.1860) 
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3-(2-Hydroxy-3,5-dimethylhept-3-enyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 
198 
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The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 7-(4-hydroxyphenyl)-3-methyl-5H-
isoxazolo[4,3-c]pyridin-4-one 172 (50 mg, 0.21 mmol), n-BuLi (0.83 ml of a 2.5M 
solution in hexanes, 2.1 mmol) and E-2,4-dimethylhex-2-enal 191 (0.52 g, 4.1 mmol) to 
yield the title compound 198 as a white solid (7.6 mg, 10 %); m.p. not determined; νmax 
(DCM)/cm-1 3411, 28522, 1679, 1650 & 1467; δH (400 MHz; CDCl3) 0.74 (3H, m, 
CH2CH3), 0.86 (3H, m, CHCH3), 1.26 (2H, m, CH3CH2), 1.72 (3H, s, CH3), 2.22 (1H, m, 
CH3CH), 3.50 (2H, m, CH(OH)CH2), 4.58 (1H, m, CH2(OH)CH), 5.24 (1H, m, C=CH), 
6.91 (2H, d, J 8.4, Ar-CH), 7.04 (1H, d, J 5.6, NHCH), 7.58 (2H, d, J 8.4, Ar-CH) & 8.59 
(1H, br, NH); δC (100 MHz; CDCl3) 11.8 (CH3), 11.9 (CH3), 29.5 (CH3), 29.7 (CH2), 
30.1 (CH), 34.3 (CH2), 76.7 (CH), 109.1 (C), 109.9 (C), 125.8 (Ar-CH), 128.2 (CH), 
128.7 (Ar-CH) 133.0 (CH), 134.1 (C), 134.9 (C), 156.1 (C), 161.5 (C), 176.4 (C) & 207.1 
(C); m/z (ESI) 369.1809 ([M+H+], C21H25N2O4 requires 369.1811) 
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2-(1-Hydroxyprop-2-enyl)-3,4-dihydro-2H-naphthalen-1-one 20871, 72 
 
O O OH
 
                                    207                                                   208 
 
To a solution of diisopropylamine (4.6 mL, 33 mmol) in THF (50 mL) at -78 °C was 
added n-BuLi (13.2 mL of a 2.5M solution in hexanes, 33.1 mmol). The resulting 
solution was stirred for 1 h at this temperature before α-tetralone 207 (3.9 mL, 30 mmol) 
was added dropwise and stirring continued for a further 1 h. Freshly distilled propenal 
(2.2 mL, 33 mmol) was added to the resulting solution dropwise over 15 mins at -78 °C 
and stirred for a further 30 mins. The mixture was then quenched with water (10 mL) at -
78 °C and neutralised using 5M hydrochloric acid. Colour change was observed at this 
point, from a yellow-green to a blue-green solution. The mixture was extracted with ethyl 
acetate (3 × 30 mL), the organic layers were combined, washed with aqueous 
hydrochloric acid (2M, 30 mL), saturated sodium hydrogen carbonate (50 mL), brine (50 
mL), dried (MgSO4), filtered and the solvent was removed under reduced pressure to a 
green oil. The residue was purified by column chromatography, eluting with ethyl 
acetate : light petroleum (1:7, v/v) to leave the title compound 208 as a colourless oil 
(obtained as a single compound) (5.2 g, 86 %); νmax (DCM)/cm-1 3447, 2930, 1673, 1598 
& 1454; δH (400 MHz; CDCl3) 2.18 (2H, m, COCHCH2), 2.58 (1H, m, COCH), 3.00 (2H, 
m, COCHCH2CH2), 4.27 (1H, s, OH), 4.50 (1H, m, C(OH)CH), 5.23 (1H, d, J 10.4 
CH=CHH), 5.34 (1H, d, J 17.2 CH=CHH),  5.90 (1H, m, CH2=CH), 7.25 (1H, d, J 7.6, 
Ar-CH), 7.31 (1H, t, J 7.6, Ar-CH), 7.49 (1H, t, J 7.6, Ar-CH) & 8.03 (1H, d, J 7.6, Ar-
CH); δC (100 MHz; CDCl3) 25.7 (CH2), 28.8 (CH2), 52.4 (CH), 73.9 (CH), 117.3 (CH2), 
126.7 (Ar-CH), 127.4 (Ar-CH), 128.7 (Ar-CH),132.4 (C), 133.8 (Ar-CH), 137.8 (CH), 
144.3 (C) & 201.6 (C); m/z (ESI) 203.1065 ([M+H+], C13H15O2 requires 203.1067). 
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2-(1-Hydroxyprop-2-enyl)-1,2,3,4-tetrahydronaphthalen-1-ol 20971, 72 
 
O OH OH OH
 
208 209 
 
To a stirred suspension of lithium aluminium hydride (0.61 g, 18 mmol) in THF (40 mL) 
was added the 2-(1-hydroxyprop-2-enyl)-3,4-dihydro-2H-naphthalen-1-one 208 (2.0 g, 
9.9 mmol) in THF (5 ml) over 5 mins at 0 °C and stirred for 30 mins. The resulting 
mixture was quenched with THF : water solution (1:1 v/v, 20 mL). Sodium hydroxide 
solution (15 % w/v, 20 mL) was added and then the mixture was extracted with ethyl 
acetate (3 × 30 mL), the organic layers were combined, dried (MgSO4), filtered and the 
solvent was removed under reduced pressure to a yellow oil. The residue was purified by 
column chromatography, eluting with ethyl acetate : light petroleum (1:4, v/v) to leave 
the title compound 209 as a yellow oil (1.5 g, 75 %); Data for major isomer; νmax 
(DCM)/cm-1 3352, 2925, 1490 & 1431; δH (400 MHz; CDCl3) 1.71 (2H, m, 
C(OH)CHCH2), 1.85 (1H, m, C(OH)CHCH2), 2.75 (2H, m, C(OH)CHCH2CH2), 4.01 
(1H, m, CH(OH)), 4.78 (1H, m, ArCH(OH)),  5.24 (2H, m, CH=CH2),  5.86 (1H, m, 
CH2=CH) & 7.01-753 (4H, m, Ar-CH); δC (100 MHz; CDCl3) 23.6 (CH2), 28.6 (CH2), 
46.7 (CH), 68.5 (CH), 70.9 (CH), 116.2 (CH2), 126.9 (Ar-CH), 127.2 (Ar-CH), 129.2 
(Ar-CH), 129.8 (Ar-CH), 136.4 (C), 137.9 (CH) & 138.6 (C); m/z (ESI) 227.1042 
([M+Na+], C13H16O2Na requires 227.1043) 
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4-Ethenyl-4a,5,6,10b-tetrahydro-4H-naphtho[1,2-d][1,3]dioxin-2-one 21071, 72 
 
OH OH OO
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To a solution of 2-(1-hydroxyprop-2-enyl)-1,2,3,4-tetrahydronaphthalen-1-ol 209 (0.54 g, 
2.7 mmol) and triethylamine (3.10 mL, 22.0 mmol) in dry DCM  
(20 mL) at 0 °C was added dropwise methyl chloroformate (1.35 mL, 17.5 mmol). The 
resulting mixture was stirred for 24 h at 23 °C and then the solvent concentrated under 
reduced pressure. To the resulting mixture, aqueous hydrochloric acid (2M, 50 ml) was 
added and the mixture was extracted with ethyl acetate (3 × 30 ml), the organic layers 
were combined, washed with brine (50 mL), dried (MgSO4), filtered and the solvent was  
removed under reduced pressure to an off-white solid. The residue was purified by 
column chromatography, eluting with ethyl acetate : light petroleum (1:5, v/v) to yield a 
white solid (0.44 g, 74 %) of the title compound 210 as a diastereomeric mixture; m.p. 
150-152°C (lit.mp.,72 152-154 °C); Data for major isomer; νmax (DCM)/cm-1 2879, 1684, 
1660, 1532, 1490 & 1362; δH (400 MHz; CDCl3) 2.06 (2H, m, CH2CH2CH), 2.95 (3H, 
m, CH2CH2CH), 4.71 (1H, m, CH2=CHCH), 5.31 (1H, d, J 10.0, COCH), 5.48 (2H, m, 
CH=CH2), 5.93 (1H, m, CH2=CH) & 7.14-7.61 (4H, m, Ar-CH); m/z (ESI) 248.1283 
([M+NH4+], C14H18NO3 requires 248.1281).   
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2-(Hexa-3,5-dienyl)-benzaldehyde  21171, 72 
 
OO
O
O  
                              210                                                              211 
 
To solution of 4-ethenyl-4a,5,6,10b-tetrahydro-4H-naphtho[1,2-d][1,3]dioxin-2-one 210 
(2.40 g, 10.4 mmol) in dry acetonitrile (20 mL) was added [Pd2(dba)3].CHCl3 (0.54 g, 
0.52 mmol) and stirred for 48 h at 23 °C. The resulting reaction mixture was diluted with 
diethyl ether (10 mL) and filtered through a Celite® pad. The filtrate was washed with 
saturated sodium bicarbonate solution (30 mL), dried (MgSO4), filtered and the solvent 
was removed under reduced pressure to a yellow oil. The residue was purified by column 
chromatography, eluting with ethyl acetate : light petroleum (1:10, v/v) to leave the title 
compound 211 as yellow oil (1.24 g, 65 %); νmax (DCM)/cm-1 3442, 2358, 1696, 1598 & 
1451; δH (400 MHz; CDCl3) 2.42 (2H, m, ArCH2CH2), 3.14 (2H, t, J 7.6, ArCH2CH2), 
4.99 (1H, d, J 10.0, CH=CHH), 5.12 (1H, d, J 16.8, CH=CHH), 5.75 (1H, m, 
CH2CH=CH), 6.01 (1H, m, CH2CH=CH), 6.30 (1H, m, CH2=CH), 7.26 (1H, d, J 7.6, Ar-
CH), 7.38 (1H, t, J 7.6, Ar-CH), 7.49 (1H, t, J 7.6, Ar-CH), 7.84 (1H, d, J 7.6, Ar-CH) & 
10.25 (1H, s, CHO); δC (100 MHz; CDCl3) 32.4 (CH2), 32.8 (CH2), 115.6 (CH2), 126.7 
(Ar-CH), 131.1 (Ar-CH), 131.9 (Ar-CH), 132.2 (Ar-CH), 133.5 (CH), 133.7 (C), 133.8 
(CH), 136.9 (CH), 144.4 (C) & 192.4 (CH); m/z (ESI) 204.1380 ([M+NH4+], C13H18NO 
requires 204.1383) 
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3-[2-(2-Hexa-3,5-dienylphenyl)-2-hydroxyethyl]-6,7-dihydro-5H-isoxazolo[4,3-
c]pyridin-4-one 212  
 
N
H
ON
O N
H
ON
O
OH
 
                     157                                                 212 
 
The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 3-methyl-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 157 (50 mg, 0.33 mmol), n-BuLi (0.66 ml of a 2.5M 
solution in hexanes, 1.6 mmol) and 2-(hexa-3,5-dienyl)benzaldehyde 211 (0.61 g, 3.3 
mmol) to yield the title compound 212 as a white solid (58 mg, 53 %); m.p. 123-125 °C; 
νmax (DCM)/cm-1 3314, 2951, 1666, 1478 & 1334; δH (400 MHz; CDCl3) 2.49 (2H, m, 
ArCH2CH2), 2.89 (2H, t, J 7.6, ArCH2CH2), 3.01 (2H, t, J 6.4, NHCH2CH2), 3.38-3.51 
(2H, m, CH(OH)CH2), 3.62 (2H, t, J 6.4, NHCH2CH2), 4.58 (1H, br, CHOH), 4.99 (1H, 
d, J 10.0 CH=CH2), 5.12 (1H, d, J 16.8 CH=CH2), 5.39 (1H, m, CH2CH(OH),  5.78 (1H, 
m, CH2CH=CH), 6.08 (1H, m, CH2CH=CH), 6.35 (1H, m, CH2=CH), 7.18-7.29 (3H, m, 
Ar-CH) & 7.56 (1H, m, Ar-CH); δC (100 MHz; CDCl3) 21.3 (CH2), 31.8 (CH2), 34.3 
(CH2), 36.7 (CH2), 40.6 (CH2), 68.5 (CH), 109.1 (C), 115.5 (CH2), 125.5 (Ar-CH), 126.7 
(Ar-CH), 127.8 (Ar-CH), 129.5 (Ar-CH), 131.7 (CH), 133.9 (CH), 137.0 (CH), 137.9 
(C), 140.9 (C), 160.5 (C), 163.8 (C) & 172.7 (C); m/z (ESI) 339.1707 ([M+H+], 
C20H23N2O3 requires 339.1703) 
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3-(2-Phenylethenyl)-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 199  
 
N O
ON
H
OH
N O
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H  
182                                     199 
 
To a solution of 3-(2-hydroxy-2-phenylethyl)-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-
one 182 (50 mg, 0.19 mmol) in toluene (30 mL) was added p-toluenesulfonic acid (48 mg, 
0.25 mmol) and the mixture was heated overnight under Dean-Stark conditions. The 
reaction was cooled and water (20 mL) added. The mixture was extracted with ethyl 
acetate (3 × 30 mL), the organic layers were combined, washed with brine (50 mL), dried 
(MgSO4), filtered and the solvent was removed under reduced pressure to leave the title 
compound 199 as a white solid (29 mg, 63 %); m.p. 219-217 °C; νmax (DCM)/cm-1 3078, 
2931, 1674, 1653, 1597, 1473, 1404 & 1334; δH (400 MHz; CDCl3) 3.05 (2H, t, J 6.8, 
NHCH2CH2), 3.64 (2H, dt, J 6.8 & 2.8, NHCH2), 6.04 (1H, br, NH) 7.36-7.43 (3H, m, 
Ar-CH), 7.48 (1H, d, J 16.4, Ph-CH=CH), 7.62-7.64 (2H, m, Ar-CH) & 8.21 (1H, d, J 
16.4, Ph-CH=CH); δC (100 MHz; CDCl3) 21.4 (CH2), 40.6 (CH2), 107.0 (C), 112.1 (CH), 
128.0 (CH), 128.9 (CH), 130.0 (CH), 135.2 (C), 139.3 (CH), 160.9 (C), 163.0 (C) & 
168.6 (C); m/z (EI) 240.0894 (M+, C14H12N2O2 requires 240.0893). 
 
 
3-(2-Phenylethenyl)-5H-isoxazolo[4,3-c]pyridin-4-one 200  
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                    183                                                                    200                                                                    
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The same procedure was applied as for 3-(2-phenylethenyl)-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 199 using the following quantities: 3-(2-hydroxy-2-
phenylethyl)-5H-isoxazolo[4,3-c]pyridin-4-one 183 (30 mg, 0.12 mmol) and p-
toluenesulfonic acid (29 mg, 0.15 mmol) to yield the title compound 200 as a yellow 
solid (18 mg, 65 %); m.p. 217-219 °C (lit.m.p.,45 215 °C); νmax (DCM)/cm-1 3131, 2922, 
1672, 1643, 1569, 1457 & 1217; δH (400 MHz; [CD3]2SO) 6.38 (1H, d, J 7.5, NHCHCH), 
7.15 (1H, d, J 7.5, NHCH), 7.42-7.51 (3H, m, Ar-CH), 7.56 (1H, d, J 16.4, Ph-CH=CH), 
7.75 (2H, m, Ar-CH), 8.21 (1H, d, J 16.4, Ph-CH=CH) & 10.95 (1H, br, NH); δC (100 
MHz; [CD3]2SO) 95.1 (CH), 107.8 (C), 112.6 (CH), 128.2 (CH), 128.9 (CH), 130.3 (CH), 
135.2 (C), 135.9 (CH), 139.9 (CH), 158.3 (C), 159.9 (C) & 171.8 (C); m/z (EI) 238.0741 
(M+, C14H10N2O2 requires 238.0741), 238 (100), 209 (12), 77 (26) & 43 (19).  
 
 
7-Chloro-3-propenyl-5H-isoxazolo[4,3-c]pyridin-4-one 201 
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                         185                                                                        201 
 
The same procedure was applied as for 3-(2-phenylethenyl)-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 199 using the following quantities: 7-chloro-3-(2-hydroxy-
propyl)-5H-isoxazolo[4,3-c]pyridin-4-one 185 (50 mg, 0.23 mmol) and p-toluenesulfonic 
acid (67 mg, 0.53 mmol) to yield the title compound 201 as a white solid (39 mg, 85 %); 
m.p. 224-227 °C; νmax (DCM)/cm-1 2875, 1677 & 1310; δH (400 MHz; CDCl3) 2.06 (3H, 
d, J 6.8, CH3), 6.95 (1H, d, J 16.0, CH=CH), 7.03 (1H, d, J 6.0, NHCH), 7.34 (1H, m, 
CH=CH) & 8.72 (1H, br, NH); δC (100 MHz; CDCl3) 19.2 (CH3), 102.1 (C), 105.8 (C), 
116.5 (CH), 130.2 (CH), 142.2 (CH), 156.8 (C), 158.9 (C) & 171.9 (C); m/z (ESI) 
211.0270 ([M+H+], C9H8N2O2Cl requires 211.0269) 
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7-Phenyl-3-(2-phenylethenyl)-5H-isoxazolo[4,3-c]pyridin-4-one 203 
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The same procedure was applied as for 3-(2-phenylethenyl)-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 199 using the following quantities: 3-(2-hydroxy-2-
phenyl-ethyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 195 (50 mg, 0.15 mmol) and p-
toluenesulfonic acid (42 mg, 0.23 mmol) to yield the title compound  203 as a yellow 
solid (39 mg, 83 %); m.p. 264-266 °C; νmax (DCM)/cm-1 3190, 3054, 2368, 1672, 1643, 
1488 & 1375; δH (400 MHz; [CD3]2SO), 7.34 (1H, m, NHCH), 7.44-7.50 (6H, m, Ar-
CH), 7.66 (1H, d, J 16.8, Ph-CH=CH) 7.77-7.79 (2H, m, Ar-CH), 7.83-7.85 (2H, m, Ar-
CH), 8.14 (1H, d, J 16.8, Ph-CH=CH) & 9.05 (1H, br, NH); δC (100 MHz; [CD3]2SO) 
107.5 (C), 108.0 (C), 112.4 (CH), 127.4 (Ar-CH), 127.7 (Ar-CH), 128.4 (Ar-CH), 129.0 
(Ar-CH), 129.6 (Ar-CH), 130.8 (Ar-CH), 132.9 (CH), 134.0 (C), 135.3 (C), 140.3 (CH), 
158.6 (C), 159.4 (C) & 170.1 (C); m/z (ESI) 315.1132 ([M + H+], C20H15N2O2 requires 
333.1128).   
 
 
3-(3-Methylpenta-1,3-dienyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 204 
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The same procedure was applied as for 3-(2-phenylethenyl)-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 199 using the following quantities: 3-(2-hydroxy-3-
methylpent-3-enyl)-7-(4-hydroxyphenyl)-5H-isoxazolo[4,3-c]pyridin-4-one 196 (40 mg, 
0.13 mmol) and p-toluenesulfonic acid (36 mg, 0.19 mmol) to yield the title compound 
204 as a yellow solid (30g, 81%); m.p. 197-198 °C; νmax (DCM)/cm-1 2923, 1681, 1640, 
1420 & 1350; δH (400 MHz; CDCl3) 1.62 (3H, d, J 7.2, CHCH3), 1.87 (3H, s, CH3), 6.05 
(1H, q, J 7.2, CH3CH), 6.93 (1H, d, J 16.0, CH=CHC(CH3)), 7.09 (1H, d, J 6.0, NHCH), 
7.29 (1H, t, J 7.2, Ar-CH), 7.38 (2H, t, J 7.2, Ar-CH), 7.55 (1H, d, J 16.0, 
CH=CHC(CH3)),  7.68 (2H, d, J 7.2, Ar-CH) & 9.04 (1H, br, NH); δC (100 MHz; CDCl3) 
11.7 (CH3), 14.8 (CH3), 109.5 (C), 109.5 (C), 110.4 (CH), 127.4 (Ar-CH), 127.9 (Ar-CH), 
128.8 (Ar-CH), 129.6 (CH), 133.4 (C), 134.8 (C), 137.2 (CH), 145.8 (CH), 158.0 (C), 
160.2 (C) & 171.6 (C); m/z (ESI) 293.1289 ([M+H+], C18H17N2O2 requires 293.1285) 
 
 
3-(3,5-Dimethylhepta-1,3-dienyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 205 
 
 
N O
ON
H
OH
N O
ON
H  
             197                                                                                        205 
 
The same procedure was applied as for 3-(2-phenylethenyl)-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 199 using the following quantities: 3-(2-hydroxy-3,5-
dimethylhept-3-enyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 197 (60 mg, 0.17 mmol) 
and p-toluenesulfonic acid (49 mg, 0.26 mmol) to yield the title compound 205 as a 
yellow solid (48 mg, 86 %); m.p. 216-219 ºC; νmax (DCM)/cm-1 3061, 2959, 2922, 1673, 
1640, 1562 & 1359; δH (400 MHz; CDCl3) 0.88 (3H, t, J 7.6, CH2CH3), 1.01-1.06 (3H, m, 
CHCH3), 1.31-1.46 (2H, m, CH3CH2), 1.95 (3H, s, CH3), 2.48-2.56 (1H, m, CH3CH), 
5.81 (1H, d, J 9.6, C=CH), 7.03 (1H, d, J 16.0, CH=CHC(CH3)), 7.17 (1H, d, J 6.0, 
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NHCH), 7.34-7.38 (1H, m, Ar-CH), 7.43-7.47 (2H, m, Ar-CH), 7.65 (1H, d, J 16.0, 
CH=CHC(CH3)), 7.75-7.79 (2H, m, Ar-CH) & 9.41 (1H,  br, NH); δC (100 MHz; CDCl3) 
12.0 (CH3), 12.3 (CH3), 20.2 (CH3), 30.0 (CH2), 35.2 (CH), 106.5 (C), 109.7 (CH), 110.4 
(C), 127.4 (Ar-CH), 127.9 (Ar-CH), 129.6 (Ar-C), 130.7 (CH), 132.6 (C), 133.4 (C), 
146.3 (CH), 149.3 (CH), 158.0 (C), 160.4 (C) & 171.6 (C); m/z (FAB) 335.1766 ([M + 
H+], C21H23N2O2 requires 335.1760).   
 
 
3-[2-(2-Hexa-3,5-dienylphenyl)-ethenyl]-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-
one 213 
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 212                                                                                        213 
 
To a solution of 3-[2-(2-hexa-3,5-dienylphenyl)-2-hydroxyethyl]-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 212 (50 mg, 0.15 mmol) in toluene (5 mL) was added p-
toluenesulfonic acid (42 mg, 0.22 mmol) and the mixture was heated for 4 h under Dean-
Stark conditions. The reaction was cooled and water (10 mL) added. The mixture was 
extracted with ethyl acetate (4 × 30 mL), the organic layers were combined, washed with 
brine (50 mL), dried (MgSO4), filtered, the solvent was removed under reduced pressure 
and the residue was purified by column chromatography, eluting with light petroleum : 
ethyl acetate (1:1, v/v) to yield the title compound 213 as a white solid (37 mg, 78 %); 
m.p. 160-164 ºC; νmax (DCM)/cm-1 3019, 2956, 2385, 1671, 1597, 1482 & 1336; δH (400 
MHz; CDCl3) 2.49 (2H, q, J 7.2, ArCH2CH2), 2.90 (2H, t, J 7.2, ArCH2CH2), 3.04 (2H, t, 
J 6.8, NHCH2CH2), 3.64 (2H, t, J 6.8, NHCH2CH2), 4.98 (1H, d, J 10.0, CH=CHH), 5.12 
(1H, d, J 16.8, CH=CHH), 5.76 (1H, m, CH2CH=CH), 6.08 (1H, m, CH2CH=CH), 6.29 
(1H, m, CH2=CH), 7.17-7.32 (3H, m, Ar-CH), 7.38 (1H, d, J 16.4, ArCH=CH), 7.74 (1H, 
m, Ar-CH) & 8.19 (1H, d, J 16.4, ArCH=CH); δC (100 MHz; CDCl3) 21.4 (CH2), 33.2 
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(CH2), 34.4 (CH2), 40.6 (CH2), 106.9 (C), 113.2 (CH), 115.4 (CH2), 126.3 (Ar-CH), 
126.7 (Ar-CH), 129.9 (Ar-CH), 130.1 (Ar-CH), 131.9 (CH), 133.7 (CH), 137.0 (CH), 
137.04 (CH), 141.3 (C), 161.0 (C), 163.3 (C), 168.9 (C) & 175.5 (C); m/z (ESI) 321.1607 
([M+H+], C20H21N2O2 requires 321.1598)                           
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3-Acetyl-4-amino-5-chloro-1H-pyridin-2-one 245 
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                                  162                                                              245 
 
Method A 
A stirred suspension of 5-chloro-3-methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 
162 (50 mg, 0.27 mmol) in methanol (2 mL) and palladium on carbon (5 % w/w, 14 mg, 
0.27 mmol) was treated in the hydrogenation Buchi pressflow gas controller at 2 bar 
pressure for 3 h. The reaction mixture was filtered, the solvent concentrated under 
reduced pressure and the residue was purified by column chromatography, eluting with 
ethyl acetate : methanol (10:1, v/v) to leave the title compound 245 as a white solid (42 
mg, 84 %); m.p. 267-269 °C; νmax (DCM)/cm-1 3346.7, 2888, 1669, 1632, 1508, 1455 & 
1362; δH (400 MHz; [CD3]2SO) 2.50 (3H, s, CH3) & 7.41 (1H, s, NHCH); δC (100 MHz; 
[CD3]2SO) 33.1 (CH3), 104.1 (C), 105.3 (C), 137.3 (CH), 159.1 (C), 164.9 (C) & 202.6 
(C); m/z (FAB) 187.0271 ([M + H+], C7H8N2O235Cl requires 187.0273) 
 
Method B 
Chloro-3-methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 162 (50 mg, 0.27 mmol) 
and molybdenum hexacarbonyl (107 mg, 0.40 mmol) in moist acetonitrile (3 mL) and 
water (0.01 mL) were heated at reflux for 3 h. The reaction mixture was cooled and 
solvent removed under reduced pressure. The residue was purified by column 
chromatography, eluting with ethyl acetate : light petroleum (2:1, v/v) to leave the title 
compound 245 as a white solid (55 mg, 54 %); 
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3-Acetyl-4-amino-5-phenyl-1H-pyridin-2-one 253 
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The same was procedure applied as for 3-acetyl-4-amino-5-chloro-1H-pyridin-2-one 245 
using the following quantities: 3-methyl-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 174 
(150 mg, 0.56 mmol), methanol (2 mL) and palladium on carbon (5 % w/w, 30 mg, 0.56 
mmol) to yield the title compound 253 as a white solid (80 mg, 53 %); m.p. 250-252 °C; 
νmax (DCM)/cm-1 2924, 2812, 1637, 1620, 1518, 1445 & 1261; δH (400 MHz; CDCl3) 
2.69 (3H, s, CH3), 7.31 (1H, d, J 6.0, NHCH); 7.42 (2H, m, Ar-CH), 7.55 (1H, m, Ar-CH) 
& 7.69 (2H, m, Ar-CH); δC (100 MHz; CDCl3) 33.4 (CH3), 104.1 (C), 112.7 (C), 128.5 
(Ar-CH), 129.8 (Ar-CH), 131.9 (Ar-CH), 136.2 (CH), 157.1 (C), 159.5 (C), 165.1 (C) & 
201.9 (C); m/z (ESI) 229.0971 ([M + H+], C13H13N2O2 requires 229.0972) 
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4-Amino-5-phenyl-3-(3-phenylpropionyl)-1H-pyridin-2-one 255 
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                   203                                                                                  255 
 
Method A 
7-Phenyl-3-(2-phenylethenyl)-5H-isoxazolo[4,3-c]pyridin-4-one 203 (100 mg, 0.32 
mmol) and molybdenum hexacarbonyl (92 mg, 0.35 mmol) in moist acetonitrile (5 mL) 
and water (0.1 mL) was heated at reflux for 3 h. The reaction mixture was cooled and 
solvent removed under reduced pressure. The residue was purified by column 
chromatography, eluting with ethyl acetate : light petroleum (2:1, v/v) to leave the title 
compound 255 as a yellow solid (50 mg, 50 %); m.p. 241-243 ºC; νmax (DCM)/cm-1 3445, 
1644, 1558, 1510, 1445 & 1226; δH (400 MHz; [CD3]2CO), 2.98 (2H, t, J 8.0, 
ArCH2CH2), 3.47 (2H, t, J 8.0, ArCH2CH2), 7.14 (2H, m, Ar-CH), 7.31 (1H, m, NHCH) 
& 7.41-7.52 (8H, m, ArCH); δC (100 MHz; [CD3]2CO) 30.9 (CH2), 45.6 (CH2) 102.6 (C), 
111.7 (C), 125.4 (Ar-CH), 128.0 (Ar-CH), 128.1 (Ar-CH) 128.4 (Ar-CH), 129.1 (Ar-CH), 
129.9 (Ar-CH), 134.0 (C), 136.6 (CH), 142.8 (C), 160.0 (C), 162.6 (C) & 202.2 (C); m/z 
(ESI) 319.1445 ([M+H+], C20H19N2O2 requires 319.1441) 
 
Method B 
A stirred suspension of 7-phenyl-3-(2-phenylethenyl)-5H-isoxazolo[4,3-c]pyridin-4-one 
203 (8 mg, 0.3 mmol) in methanol (2 mL) and palladium on carbon (10 % w/w, 14 mg, 
1.3 mmol) was stirred at 23 °C at atmospheric pressure for 5 h. The reaction mixture was 
filtered, the solvent concentrated under reduced pressure to leave the title compound 255 
as a white solid (3 mg, 28 %). Identical to a sample prepared in method A.  
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4-Amino-3-(4-methylhexa-2,4-dienoyl)-5-phenyl-1H-pyridin-2-one 257 
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3-(3-Methylpenta-1,3-dienyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 204 (30 mg, 
0.10 mmol) and molybdenum hexacarbonyl (40 mg, 0.15 mmol) in moist acetonitrile (3 
mL) and water (0.1 mL) was heated at reflux for 3 h. The reaction mixture was cooled 
and solvent removed under reduced pressure. The residue was purified by column 
chromatography, eluting with ethyl acetate : light petroleum (2:1, v/v) to leave the title 
compound 257 as a yellow solid (20 mg, 67 %); m. p. 177-180 °C; νmax (DCM)/cm-1 
3437, 1648, 1510 & 1357; δH (400 MHz; CDCl3) 1.74 (3H, d, J 7.2, CHCH3), 1.79 (3H, s, 
CH3), 5.95 (1H, q, J 7.2, CH3CH), 7.24-7.28 (2H, m, Ar-CH), 7.28-7.31 (1H, m, 
COCH=CH), 7.34-7.43 (1H, m, NHCH), 7.38-7.44 (3H, m, Ar-CH), 7.63 (1H, d, J 15.2, 
COCH=CH), 10.34 (1H,  br, NH) & 10.89 (1H,  br, NH); ); m.p. 177-180 °C; νmax 
(DCM)/cm-1 3437, 1648 & 1357; δC (100 MHz; CDCl3) 11.3 (CH3), 13.1 (CH3), 109.5.0 
(C), 109.5 (C), 110.4 (CH), 127.4 (Ar-CH), 127.9 (Ar-CH), 128.8 (Ar-CH), 129.6 (CH), 
133.4 (C), 134.8 (C), 137.2 (CH), 145.8 (CH), 158.0 (C), 160.2 (C) & 171.6 (C); m/z 
(ESI) 295.1442 ([M + H+], C18H19N2O2 requires 295.1441).  
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4-Amino-3-(4,6-dimethylocta-2,4-dienoyl)-5-phenyl-1H-pyridin-2-one 259 
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3-(3,5-Dimethylhepta-1,3-dienyl)-7-phenyl-5H-isoxazolo[4,3-c]pyridin-4-one 205 (35 
mg, 0.10 mmol) and molybdenum hexacarbonyl (30 mg, 0.12 mmol) in moist acetonitrile 
(3 mL) and water (0.1 mL) was heated at reflux for 3 h. The reaction mixture was cooled 
and solvent removed under reduced pressure. The residue was purified by column 
chromatography, eluting with ethyl acetate : light petroleum (2:1, v/v) to leave the title 
compound 259 as a yellow solid (20 mg, 57 %); m. p. 211-213 °C; νmax (DCM)/cm-1 
3340, 2960, 2920, 1624, 1590 & 1510; δH (400 MHz; CDCl3) 0.77 (3H, t, J 7.2, 
CH2CH3), 0.92 (3H, d, J 6.4 CHCH3), 1.31 (2H, m, CH3CH2), 1.83 (3H, s, CH3), 2.40 
(1H, m, CH3CH), 5.81 (1H, d, J 9.6, C=CH), 7.27 (2H, m, Ar-CH), 7.31 (1H, m, 
COCH=CH), 7.38-7.45 (1H, m, NHCH), 7.38-7.45 (3H, m, Ar-CH), 7.63 (1H, d, J 16, 
COCH=CH), 10.14 (1H,  br, NH) & 10.37 (1H,  br, NH); δC (100 MHz; CDCl3) 11.9 
(CH3), 12.9 (CH3), 20.2 (CH3), 30.3 (CH2), 34.9 (CH), 106.7 (C), 113.4 (C), 126.1 (CH), 
128.8 (CH), 129.6 (Ar-CH), 129.9 (Ar-CH), 132.9 (C), 133.1 (C), 146.6 (CH), 147.9 
(CH), 159.7 (C), 164.0 (C) & 192.6 (C); m/z (ESI) 337.1912 ([M + H+], C21H25N2O2 
requires 337.1911).  
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3-Acetyl-4-hydroxy-1H-pyridin-2-one 252 
 
N O
H
NH2 O
N O
ON
H
N O
H
OH O
 
        1                                                      251                                                      252 
 
The same procedure was applied as for 3-acetyl-4-amino-5-chloro-1H-pyridin-2-one 245 
using the following quantities: 3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1 (10 mg, 
0.07 mmol), methanol (2 mL) and palladium on carbon (5 % w/w, 4 mg, 0.07 mmol) to 
yield the amine which was used in the next step without further purification.  
 
To the amine in water (5 mL) at 0 °C was added sodium nitrite (45 mg, 6.6 mmol) in 
hydrochloric acid (2M, 5 mL) and the mixture stirred for 1 h, and then at 50 °C for 1 h. 
The reaction mixture was then extracted with ethyl acetate (3 × 30 mL), the organic 
layers were combined, washed with brine (50 mL), dried (MgSO4), filtered and the 
solvent was removed under reduced pressure. The residue was purified by column 
chromatography, eluting with ethyl acetate : methanol (10:1, v/v) to leave the title 
compound 252 as a waxy solid (2 mg, 20 %); νmax (DCM)/cm-1 3406, 166.4, 1602 & 
1468 ; δH (400 MHz; CDCl3)  2.74 (3H, s, CH3), 6.03 (1H, d, J 7.2, CH), 7.31 (1H, d J 
7.2, NHCH) & 10.40 (1H, br, NH); δC (100 MHz; CDCl3) 31.4 (CH3), 101.6 (CH), 139.8 
(CH) & 203.5 (C); m/z (ESI) 176.0323 ([M + Na+], C7H7NO3Na  requires 176.0318). 
Data obtained to date.  
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3-Acetyl-4-hydroxy-5-phenyl-1H-pyridin-2-one 254  
 
 
N O
H
NH2 O
N O
H
OH O
 
                                      174                                                            254 
  
To a stirred suspension of 3-acetyl-4-amino-5-phenyl-1H-pyridin-2-one 174 (70 mg, 0.26 
mmol) in water (5 mL) at 0 °C was added sodium nitrite (20 mg, 0.29 mmol) in 
hydrochloric acid (2M, 10 mL) and the mixture stirred for 1 h, and then at 50 °C for 1 h. 
The reaction mixture was then extracted with ethyl acetate (3 × 30 mL), the organic 
layers were combined, washed with brine (50 mL), dried (MgSO4), filtered and the 
solvent was removed under reduced pressure. The residue was purified by column 
chromatography, eluting with ethyl acetate : methanol (10:1, v/v) to leave the title 
compound 254 as a white solid (21 mg, 30 %); m.p. 271-273 °C; νmax (DCM)/cm-1 3005, 
2809, 1630, 1602, 1429 & 1243; δH (400 MHz; [CD3]2SO) 2.42 (3H, s, CH3), 7.28 (1H, t, 
J 7.2, Ar-CH), 7.35 (2H, m, Ar-CH), 7.42 (2H, m, Ar-CH) & 7.62 (1H, s, NHCH); δC 
(100 MHz; [CD3]2SO) 30.9 (CH3), 104.2 (C), 113.7 (C), 127.3 (Ar-CH), 128.0 (Ar-CH), 
130.0 (Ar-CH), 141.8 (CH), 135.5 (C), 159.5 (C), 174.2 (C) & 195.6 (C); m/z (ESI) 
230.0810 ([M + H+], C13H12NO3 requires 230.0814).  
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3-(But-3-enyl)-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 215  
 
N O
ON
H
N O
ON
H  
                             157                                                     215 
                                                                               
The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
c]pyridin-4-one 183 using the following quantities: 3-methyl-6,7-dihydro-5H-
isoxazolo[4,3-c]pyridin-4-one 157 (20 mg, 0.13 mmol), n-BuLi (0.13 mL of a 2.5M 
solution in hexanes, 0.33 mmol) and prop-2-enyl bromide (0.02 mL, 0.2 mmol) to yield 
the title compound 215 as a white solid (5 mg, 20 %); m.p. 107 -109 °C; νmax (DCM)/cm-
1 3128, 3017, 1628, 1616, 1461 & 1419; δH (400 MHz; CDCl3) 2.47 (2H, m, CHCH2), 
2.95 (2H, t, J 6.4 NCH2CH2), 3.13 (2H, t, J 7.2, CHCH2CH2), 3.53 (2H, dt, J 2.8 & 6.4, 
NCH2CH2), 4.96 (1H, dd, J 1.6 & 10, CH=CH2), 5.03 (1H, dd, J 1.6 & 17.2, CH=CH2), 
5.78 (1H, m, CH2=CH) & 5.82 (1H, br, NH); δC (100 MHz; CDCl3) 21.4 (CH2), 25.9 
(CH2), 31.0 (CH2), 40.7 (CH2), 107.6 (C), 116.2 (CH2), 136.1 (CH), 160.5 (C), 163.0 (C) 
& 175.1 (C); m/z (ESI) 193.0971 ([M + H+], C10H13N2O2 requires 193.0972).  
 
 
 
5-(prop-2-enyl)-3-but-3-enyl-5H-isoxazolo[4,3-c]pyridin-4-one  
 
N O
ON
H
N O
ON
H
N O
ON
N O
ON
 
                                                   216                               217                         218    
 
The same procedure was applied as for 3-(2-hydroxy-2-phenylethyl)-5H-isoxazolo[4,3-
 194
c]pyridin-4-one 183 using the following quantities: 3-methyl-5H-isoxazolo[4,3-c]pyridin-
4-one (20 mg, 0.13 mmol), n-BuLi (0.32 mL of a 2.5M solution in hexanes, 0.80 mmol) 
and allyl bromide (0.04 mL, 0.5 mmol). The residue was purified by column 
chromatography, eluting with ethyl acetate : light petroleum (1:1, v/v) to leave the 
following compounds 216, 217 and title compound 218. 
 
216 was obtained as a brown solid (5 mg, 20 %); m.p. 141-143 °C; νmax (DCM)/cm-1 
3181, 3044, 2919, 1682, 1644, 1455 & 1373; δH (400 MHz; CDCl3) 2.52 (2H, m, 
CHCH2), 3.30 (2H, t, J 7.2, CHCH2CH2), 4.96 (1H, dd, J 1.2 & 10, CH=CHH), 5.03 (1H, 
dd, J 1.2 & 16.8, CH=CHH), 5.78 (1H, m, CH2=CH), 6.33 (1H, d, J 7.6, NHCHCH) & 
6.89 (1H, dd, J 7.6 & 5.6, NHCH) & 8.38 (1H, br, NH); δC (100 MHz; CDCl3) 26.7 
(CH2), 31.1 (CH2), 95.0 (CH), 108.9 (C), 116.5 (CH2), 132.6 (CH), 135.8 (CH), 158.2 (C), 
160.3 (C) & 177.1 (C); m/z (ESI) 213.0634 ([M + Na+], C10H10N2O2Na requires 
213.0634). 
 
 217 was obtained  as a brown solid (10 mg, 40 %); m.p. 76-78 °C; νmax (DCM)/cm-1 
2927, 2851, 1671, 1643, 1512 & 1419; δH (400 MHz; CDCl3) 2.79 (3H, s, 3-CH3), 4.41 
(2H, d, J 6.8, NCH2), 5.16 (1H, dd, J 1.2 & 17.2, CH=CH2), 5.19 (1H, dd, J 1.2 & 10, 
CH=CH2), 5.84 (1H, m, CH2=CH), 6.30 (1H, d, J 7.6, NCHCH) & 6.87 (1H, d, J 7.6, 
NCHCH); δC (100 MHz; CDCl3) 12.9 (CH3), 49.0 (CH2), 94.9 (CH), 108.7 (C), 118.3 
(CH2), 132.5 (CH), 137.2 (CH), 158.1 (C), 159.3 (C) & 174.2 (C); m/z (ESI) 213.0634 
([M + Na+], C10H10N2O2Na requires 213.0634). 
 
 
218 was obtained as brown oil (8 mg, 27 %); νmax (DCM)/cm-1 3079, 2925, 2851, 1675, 
1638, 1452 & 1374; δH (400 MHz; CDCl3) 2.52 (2H, m, CH2CH2CH), 3.31 (2H, t, J 7.2, 
CHCH2CH2), 4.41 (2H, d, J 6.8, NCH2), 4.96 (1H, dd, J 1.2 & 10, CH2CH2CH=CHH), 
5.03 (1H, dd, J 1.6 & 16.8, CH2CH2CH=CHH), 5.16 (1H, dd, J 1.2 & 17.2, 
NCH2CH=CH2), 5.19 (1H, dd, J 1.2 & 10, NCH2CH=CH2), 5.74-5.87 (1H, m, CH2=CH), 
5.74-5.87 (1H, m, CH2=CH),  6.32 (1H, d, J 7.6, NCHCH) & 6.89 (1H, d, J 7.6, NCH); 
δC (100 MHz; CDCl3) 26.6 (CH2), 31.1 (CH2), 49.1 (CH2), 94.9 (CH), 108.4 (C), 116.3 
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(CH2), 118.3 (CH2), 132.5 (CH), 135.9 (CH), 137.1 (CH), 158.0 (C), 159.1 (C) & 177.1 
(C). 
 
 
 
3,5-Dimethyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 241 
 
N O
ON
H
N O
ON
Me  
157                                                  241 
 
To a solution of 3-methyl-6,7-dihydro-5H-isoxazolo[4,3-c]pyridin-4-one 157 (50 mg, 
0.33 mmol) in THF at -78 ºC was added n-BuLi (0.18 mL of a 2.5M solution in hexanes, 
0.46 mmol). The resulting solution was stirred for 1 h at -78 ºC followed by addition of 
iodomethane (0.03 mL, 0.5 mmol), and the reaction mixture was stirred for 2 h at -78 ºC. 
The reaction was quenched with water (20 mL) and the mixture was extracted with ethyl 
acetate (4 × 30 mL), the organic layers were combined, washed with brine (50 mL), dried 
(MgSO4), filtered and the solvent was removed under reduced pressure to leave the title 
compound 241 as a yellow oil (33 mg, 60%); νmax (DCM)/cm-1; 3071, 1695, 1629, 1526, 
1425, 1329 & 1312. δH (400 MHz; CDCl3) 2.60 (3H, s, 3-CH3), 2.96 (2H, t, J 6.8, 
NCH2CH2), 3.00 (3H, s, NCH3) & 3.55 (2H, t, J 6.8, NCH2CH2); δC (100 MHz; CDCl3) 
12.0 (CH3), 21.2 (CH2), 33.8 (CH3), 48.6 (CH2), 108.2 (C), 160.3 (C), 161.5 (C) & 171.7 
(C); m/z (ESI) 167.0823 ([M + H+], C8H11N2O2 requires 167.0821), 137 (60) & 154 
(100).  
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3,5-Dimethyl-5H-isoxazolo[4,3-c]pyridin-4-one 228 
 
N O
ON
H
N O
ON
Me  
                                        1                                                   228                                    
                                                 
The same procedure was applied as for 3,5-dimethyl-6,7-dihydro-5H-isoxazolo[4,3-
c]pyridin-4-one 241 using the following quantities: 3-methyl-5H-isoxazolo[4,3-c]pyridin-
4-one (50 mg, 0.33 mmol) 1, n-BuLi (0.19 mL of a 2.5M solution in hexanes, 0.47 mmol) 
and iodomethane (0.03 mL, 0.5 mmol) to leave the title compound 228 as a white solid 
(36 mg, 65 %); m.p. 108-109 °C; νmax (DCM)/cm-1 3061, 2357, 1661, 1447, 1365, 1329, 
1198 & 1039; δH (400 MHz; CDCl3) 2.86 (3H, s, 3-CH3), 3.44 (3H, s, NCH3), 6.34 (1H, 
d, J 8.0, NHCHCH) & 6.95 (1H, d, J 8.0, NHCH); δC (100 MHz; CDCl3) 12.9 (CH3), 
35.3 (CH3), 94.5 (CH), 108.7 (C), 138.4 (CH), 158.2 (C) 159.7 (C) & 173.8 (C); m/z (ESI) 
165.0663 ([M + H+], C8H9N2O2 requires 165.0664) 165 (100).  
 
 
7-Chloro-4-methanesulfonyloxy-3-methylisoxazolo[4,3-c]pyridine 235 
 
N O
ON
H
Cl
N O
ON
Cl
SO2CH3
 
                          162                                                                    235 
 
To a solution of 7-chloro-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 162 (100 mg, 0.54 
mmol) in DCM (50 mL) at 0 °C was added triethylamine (66 mg, 0.65 mmol) and 
methanesulfonyl chloride (68 mg, 0.59 mmol) and the reaction mixture was stirred for 2 h 
at 23 °C. Water (20 mL) was then added to the reaction mixture, which was and extracted 
with ethyl acetate (3 × 30 mL), the organic layers were combined, washed with brine (50 
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mL), dried (MgSO4), filtered and the solvent was removed under reduced pressure. The 
residue was purified by column chromatography, eluting with ethyl acetate : light 
petroleum (1:1, v/v) to leave the title compound 235 as a white solid (102 mg, 72 %); m.p. 
214-216 °C; νmax (DCM)/cm-1 2923, 2853, 1699, 1637, 1463 & 1356; δH (400 MHz; 
[CD3]2SO) 2.89 (3H, s, CH3), 3.62 (3H, s, SCH3) & 7.78 (1H, s, CH); δC (100 MHz; 
CDCl3) 13.2 (CH3), 42.6 (CH3), 104.2 (C), 107.9 (C), 128.7 (CH), 156.1 (C) 157.3 (C) & 
178.0 (C); m/z (ESI) 262.9887 ([M + H+], C8H8N2O4S35Cl requires 262.9892).  
 
 
Attempted preparation of 5-hydroxy-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 222 
 
Method A                                                                                                               
 
N O
ON
H
N OSiMe3
ON
N O
ON
OH  
               1                                              221                                                222 
 
Trimethylsilyl chloride (0.01 mL, 0.4 mmol) was added to a solution of 3-methyl-5H-
isoxazolo[4,3-c]pyridin-4-one 1 (50 mg, 0.33 mmol) in hexamethyldisilazane (1.39 mL, 
6.67 mmol). The resulting mixture was heated at reflux for 24 h. The solvent was 
removed under reduced pressure, and the resulting crude material was used immediately 
in the next step.  
 
m-CPBA (149 mg, 0.67 mmol) was added to a solution of the crude material in freshly 
distilled DCM (50 mL) at 0 °C and stirred for 1 h, after which point the resulting mixture 
was stirred for a further 18 h at 23 °C, water added (20 mL), and the mixture extracted 
with ethyl acetate (3 × 50 mL). The combined organic layers were washed with brine (50 
mL), dried (MgSO4), filtered and the solvent was removed under reduced pressure. The 
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residue was purified by column chromatography, eluting with ethyl acetate : light 
petroleum (1:1, v/v) to only recover the 3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1.  
 
Method B 
 
N O
ON
H
N OMe
ON
N O
ON
OH  
                 1                                            226                                               222 
                                                                                                           
 A solution of 3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1 (50 mg, 0.33 mmol) in 
anhydrous toluene (50 mL) was heated at reflux under Dean-Stark conditions for 1 h. The 
reaction was cooled and dimethyl sulfate (0.07 mL, 0.7 mmol) was added, and the 
resulting reaction mixture was heated at reflux under Dean-Stark conditions for 24 h. The 
mixture was then cooled, water (20 mL) added, and the mixture was extracted with ethyl 
acetate (3 × 50 mL). The combined organic layers were washed with aqueous sodium 
hydrogen carbonate (2 × 50 mL), brine (50 mL), dried (MgSO4), filtered and the solvent 
was removed under reduced pressure, and remaining crude material was used 
immediately in the next step.  
 
m-CPBA (149 mg, 0.67 mmol) was added to a solution of the crude material in freshly 
distilled DCM (50 mL) at 0 °C and stirred for 1 h. The mixture was stirred for a further 
18 h at 23 °C, water added (20 mL), and extracted with ethyl acetate (3 × 50 mL). The 
combined organic layers were washed with brine (50 mL), dried (MgSO4), filtered and 
the solvent was removed under reduced pressure to leave a solid. The residue was 
purified by column chromatography, eluting with ethyl acetate : light petroleum (1:1, v/v) 
to only recover the 3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1.  
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Attempted preparation of 4-methoxy-3-methylisoxazolo[4,3-c]pyridine 226 
 
N O
ON
H
N OMe
ON
 
                                   1                                                          226 
 
Method A 
To a solution of 3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1 (42 mg, 0.28 mmol) in 
acetonitrile (2 mL) was added iodomethane (0.026 mL, 0.42 mmol) and silver carbonate 
(85 mg, 0.31 mmol). The resulting solution was stirred in a microwave (Biotage Initiator 
Eight EXP microwave system) for 10 minutes at 90 °C. The reaction mixture was cooled, 
filtered and the solvent removed under reduced pressure to leave a brown oil. The residue 
was purified by column chromatography, eluting with ethyl acetate : light petroleum (1:1, 
v/v) to only recover the 3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1.  
  
Method B 
To a solution of 3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1 (42 mg, 0.28 mmol) in 
acetonitrile (2 mL) was added iodomethane (0.026 mL, 0.42 mmol) and silver carbonate 
(85 mg, 0.31 mmol). The resulting solution was stirred at reflux for 24 h in the dark. The 
resulting reaction mixture was cooled, filtered and the solvent removed under reduced 
pressure. The residue was purified by column chromatography, eluting with ethyl acetate : 
light petroleum (1:1, v/v) to yield the N-methylpyridone 228 and the recovery of the 3-
methyl-5H-isoxazolo[4,3-c]pyridin-4-one 1. 
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Attempted preparation of 4,7-dichloro-3-methylisoxazolo[4,3-c]pyridine 232 
 
N O
ON
H
Cl
N Cl
ON
Cl
 
                                        162                                                    232 
 
To a solution of 7-chloro-3-methyl-5H-isoxazolo[4,3-c]pyridin-4-one 162 (200 mg, 1.09 
mmol) in dichloroethane (5 mL) at 23 °C was added dimethylformamide (0.5 mL) and 
phosphorus oxychloride (2 mL) and the reaction mixture was heated at reflux for 12 h. To 
the resulting mixture was added saturated sodium hydrogen carbonate solution (20 mL) 
and it was then extracted with ethyl acetate (3 × 30 mL), the organic layers were 
combined, washed with brine (50 mL), dried (MgSO4), filtered and the solvent was 
removed under reduced pressure to only recover the starting material 162.  
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RCFJ32   
 
The data were collected at 150(2)K on a Bruker Apex II CCD diffractometer using MoKα 
radiation (λ = 0.71073Å). The structure was solved by direct methods and refined on F2 using all 
the reflections*. All the non-hydrogen atoms were refined using anisotropic atomic displacement 
parameters and hydrogen atoms were inserted at calculated positions using a riding model. 
Parameters for data collection and refinement are summarised in Table 1.  
 
* G.M. Sheldrick, Acta Cryst. 2008, A64, 112-122. 
 
Notes: 
This is a weak data set (and CIFCHECK will complain about this a bit) but it’s the best I could do 
given the size of the crystals. This results in lower bond length precision than normal. 
In spite of this, and the fact that there is only one electron difference between O and N, the 
refinement for –NH2 is significantly better than that with –OH. This is clear from the ellipsoid 
plots. 
One of the phenyl groups is disordered, it was modelled with equal occupancy of two sites, 
related by rotation and almost perpendicular to each other. 
H-bonding links the structure into 2-dimensional sheets, one molecule thick and perpendicular to 
the a axis. 
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Table 1.  Crystal data and structure refinement for rcfj32. 
Identification code  rcfj32 
Empirical formula  C20 H18 N2 O2 
Formula weight  318.36 
Temperature  150(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 35.47(2) Å α= 90°. 
 b = 4.896(3) Å β= 111.575(7)°. 
 c = 19.665(12) Å γ = 90°. 
Volume 3176(3) Å3 
Z 8 
Density (calculated) 1.332 Mg/m3 
Absorption coefficient 0.087 mm-1 
F(000) 1344 
Crystal size 0.56 x 0.07 x 0.03 mm3 
Crystal description colourless needle 
Theta range for data collection 2.11 to 25.00°. 
Index ranges -42<=h<=42, -5<=k<=5, -23<=l<=23 
Reflections collected 11441 
Independent reflections 2788 [R(int) = 0.1813] 
Completeness to theta = 25.00° 100.0 %  
Absorption correction None 
Max. and min. transmission 0.9974 and 0.9529 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 2788 / 36 / 263 
Goodness-of-fit on F2 0.808 
Final R indices [I>2sigma(I)] R1 = 0.0490, wR2 = 0.0871 
R indices (all data) R1 = 0.1652, wR2 = 0.1122 
Extinction coefficient 0.0019(3) 
Largest diff. peak and hole 0.218 and -0.200 e.Å-3 
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Table 2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 103) 
for rcfj32.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
________________________________________________________________________________ 
 x y z U(eq) 
________________________________________________________________________________ 
C(1) 7395(1) 9563(7) 5664(2) 35(1) 
O(1) 7104(1) 10876(5) 5232(1) 41(1) 
N(1) 7778(1) 10205(6) 5684(1) 35(1) 
C(2) 8122(1) 8998(7) 6151(2) 38(1) 
C(3) 8122(1) 7057(7) 6634(2) 32(1) 
C(4) 7736(1) 6249(7) 6638(2) 34(1) 
N(2) 7728(1) 4236(6) 7108(1) 38(1) 
C(5) 7373(1) 7416(7) 6151(2) 32(1) 
C(6) 6974(1) 6450(7) 6125(2) 31(1) 
O(2) 6954(1) 4960(5) 6620(1) 45(1) 
C(7) 6595(1) 7157(7) 5511(2) 39(1) 
C(8) 6251(1) 5189(8) 5450(2) 48(1) 
C(9) 5854(1) 5762(8) 4842(2) 41(1) 
C(10) 5777(2) 6280(16) 4139(4) 41(2) 
C(11) 5399(3) 6790(20) 3625(5) 52(3) 
C(12) 5061(4) 6760(40) 3808(9) 66(7) 
C(13) 5115(2) 6274(17) 4526(5) 58(3) 
C(14) 5495(2) 5744(16) 5036(4) 51(2) 
C(9') 5854(1) 5762(8) 4842(2) 41(1) 
C(10') 5709(3) 8380(17) 4662(5) 66(3) 
C(11') 5349(2) 8843(18) 4092(5) 59(3) 
C(12') 5136(5) 6750(30) 3654(10) 55(6) 
C(13') 5301(2) 4168(18) 3805(5) 56(2) 
C(14') 5656(2) 3733(16) 4384(4) 45(2) 
C(15) 8508(1) 5802(7) 7108(2) 35(1) 
C(16) 8752(1) 4536(8) 6790(2) 54(1) 
C(17) 9124(1) 3422(10) 7242(3) 77(2) 
C(18) 9242(1) 3495(9) 7978(2) 63(1) 
C(19) 9003(1) 4778(8) 8287(2) 59(1) 
C(20) 8637(1) 5909(8) 7849(2) 44(1) 
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Table 3.   Bond lengths [Å] and angles [°] for rcfj32. 
______________________________________________________________________________ 
(1)-O(1)  1.248(4)        
C(1)-N(1)  1.380(4) 
C(1)-C(5)  1.444(5) 
N(1)-C(2)  1.362(4) 
C(2)-C(3)  1.343(4) 
C(3)-C(4)  1.427(5) 
C(3)-C(15)  1.479(5) 
C(4)-N(2)  1.358(4) 
C(4)-C(5)  1.412(5) 
C(5)-C(6)  1.473(5) 
C(6)-O(2)  1.240(4) 
C(6)-C(7)  1.481(4) 
C(7)-C(8)  1.526(4) 
C(8)-C(9)  1.500(4) 
C(9)-C(10)  1.332(7) 
C(9)-C(14)  1.458(7) 
C(10)-C(11)  1.372(10) 
C(11)-C(12)  1.373(16) 
C(12)-C(13)  1.375(15) 
C(13)-C(14)  1.377(9) 
C(10')-C(11')  1.373(9) 
C(11')-C(12')  1.372(16) 
C(12')-C(13')  1.380(16) 
C(13')-C(14')  1.368(9) 
C(15)-C(20)  1.360(4) 
C(15)-C(16)  1.386(4) 
C(16)-C(17)  1.399(5) 
C(17)-C(18)  1.352(5) 
C(18)-C(19)  1.366(5) 
C(19)-C(20)  1.382(5) 
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O(1)-C(1)-N(1) 117.5(3) 
O(1)-C(1)-C(5) 126.3(4) 
N(1)-C(1)-C(5) 116.2(3) 
C(2)-N(1)-C(1) 123.1(3) 
C(3)-C(2)-N(1) 123.5(4) 
C(2)-C(3)-C(4) 116.7(3) 
C(2)-C(3)-C(15) 119.9(3) 
C(4)-C(3)-C(15) 123.4(3) 
N(2)-C(4)-C(5) 120.8(3) 
N(2)-C(4)-C(3) 117.7(3) 
C(5)-C(4)-C(3) 121.4(3) 
C(4)-C(5)-C(1) 119.0(4) 
C(4)-C(5)-C(6) 121.1(3) 
C(1)-C(5)-C(6) 119.8(4) 
O(2)-C(6)-C(5) 119.7(3) 
O(2)-C(6)-C(7) 118.7(3) 
C(5)-C(6)-C(7) 121.6(3) 
C(6)-C(7)-C(8) 112.1(3) 
C(9)-C(8)-C(7) 115.7(3) 
C(10)-C(9)-C(14) 114.0(5) 
C(10)-C(9)-C(8) 129.6(5) 
C(14)-C(9)-C(8) 116.4(4) 
C(9)-C(10)-C(11) 124.9(7) 
C(10)-C(11)-C(12) 121.1(10) 
C(13)-C(12)-C(11) 117.7(11) 
C(12)-C(13)-C(14) 120.7(9) 
C(13)-C(14)-C(9) 121.6(7) 
C(10')-C(11')-C(12') 121.4(9) 
C(11')-C(12')-C(13') 117.2(11) 
C(14')-C(13')-C(12') 120.7(9) 
C(20)-C(15)-C(16) 118.7(4) 
C(20)-C(15)-C(3) 121.8(3) 
C(16)-C(15)-C(3) 119.4(3) 
C(15)-C(16)-C(17) 119.1(4) 
C(18)-C(17)-C(16) 121.2(4) 
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C(17)-C(18)-C(19) 119.3(4) 
C(18)-C(19)-C(20) 120.1(4) 
C(15)-C(20)-C(19) 121.4(4) 
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Table 4.   Anisotropic displacement parameters (Å2x 103)for rcfj32.  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
______________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
______________________________________________________________________________ 
C(1) 45(3)  34(2) 31(2)  -9(2) 19(2)  -8(2) 
O(1) 44(2)  37(2) 41(2)  13(1) 16(1)  -1(1) 
N(1) 44(2)  30(2) 34(2)  7(2) 19(2)  -7(2) 
C(2) 39(3)  36(2) 40(3)  -3(2) 18(2)  -7(2) 
C(3) 43(3)  29(2) 29(2)  -4(2) 19(2)  -7(2) 
C(4) 56(3)  28(2) 25(2)  -3(2) 23(2)  -5(2) 
N(2) 42(2)  39(2) 36(2)  9(2) 18(2)  -2(2) 
C(5) 41(3)  30(2) 27(2)  1(2) 17(2)  0(2) 
C(6) 48(3)  24(2) 26(2)  -4(2) 18(2)  -3(2) 
O(2) 50(2)  46(2) 45(2)  12(2) 25(1)  -2(1) 
C(7) 44(3)  33(2) 44(3)  2(2) 21(2)  -2(2) 
C(8) 50(3)  36(2) 52(3)  11(2) 13(2)  -2(2) 
C(9) 47(3)  32(3) 38(3)  -2(2) 10(2)  -6(2) 
C(10) 41(6)  39(5) 46(6)  -2(5) 20(5)  -4(4) 
C(11) 60(8)  53(7) 35(6)  -3(5) 9(6)  -8(7) 
C(12) 58(10)  45(11) 75(12)  -27(9) -1(10)  -1(7) 
C(13) 36(6)  70(7) 69(7)  -25(6) 22(5)  1(5) 
C(14) 47(6)  70(6) 40(5)  -6(5) 22(5)  -9(5) 
C(9') 47(3)  32(3) 38(3)  -2(2) 10(2)  -6(2) 
C(10') 68(7)  47(6) 72(7)  9(6) 12(6)  -11(5) 
C(11') 50(6)  45(6) 66(7)  14(5) 2(5)  -5(5) 
C(12') 47(11)  40(11) 70(11)  2(9) 10(10)  -7(10) 
C(13') 40(6)  54(7) 73(7)  -18(6) 20(5)  -2(5) 
C(14') 47(6)  34(5) 59(6)  -7(5) 28(5)  -2(4) 
C(15) 45(3)  28(2) 34(2)  1(2) 17(2)  0(2) 
C(16) 64(3)  47(3) 54(3)  -5(2) 25(2)  6(2) 
C(17) 72(4)  75(4) 81(4)  -7(3) 27(3)  36(3) 
C(18) 69(3)  54(3) 61(3)  8(3) 18(3)  20(3) 
C(19) 67(3)  52(3) 56(3)  1(3) 19(3)  2(3) 
C(20) 42(2)  46(3) 43(3)  3(2) 15(2)  8(2) 
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Table 5.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103) 
for rcfj32. 
________________________________________________________________________________ 
 x  y  z  U(eq) 
________________________________________________________________________________ 
 
H(1) 7801 11453 5379 42 
H(2) 8375 9560 6135 45 
H(2N) 7494 3644 7111 57 
H(1N) 7956 3524 7408 57 
H(7A) 6646 7124 5048 46 
H(7B) 6513 9036 5581 46 
H(8A) 6338 3319 5383 57 
H(8B) 6206 5217 5918 57 
H(10) 6000 6300 3981 49 
H(11) 5371 7159 3135 62 
H(12) 4798 7071 3450 80 
H(13) 4887 6303 4672 69 
H(14) 5524 5358 5526 61 
H(10') 5860 9880 4936 80 
H(11') 5246 10651 3998 71 
H(12') 4885 7069 3264 66 
H(13') 5167 2676 3504 67 
H(14') 5767 1943 4467 54 
H(16) 8669 4425 6273 64 
H(17) 9295 2598 7026 92 
H(18) 9490 2663 8278 76 
H(19) 9088 4893 8804 71 
H(20) 8472 6780 8071 52 
________________________________________________________________________________ 
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Table 6.  Hydrogen bonds for rcfj32 [Å and °]. 
____________________________________________________________________________ 
D-H...A d(D-H) d(H...A) d(D...A) <(DHA) 
____________________________________________________________________________ 
 N(1)-H(1)...O(1)#1 0.88 1.89 2.767(4) 175.4 
 N(2)-H(2N)...O(2) 0.88 1.91 2.578(4) 131.0 
 N(2)-H(1N)...O(2)#2 0.88 2.52 3.137(4) 127.8 
____________________________________________________________________________ 
Symmetry transformations used to generate equivalent atoms:  
#1 -x+3/2,-y+5/2,-z+1    #2 -x+3/2,y-1/2,-z+3/2      
 
 
